FORM 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-12-459621.txt : 20121108 0001193125-12-459621.hdr.sgml : 20121108 20121108115801 ACCESSION NUMBER: 0001193125-12-459621 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121108 DATE AS OF CHANGE: 20121108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GTX INC /DE/ CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 121189055 BUSINESS ADDRESS: STREET 1: 175 TOYOTA PLAZA STREET 2: 7TH FLOOR CITY: MEMPHIS STATE: TN ZIP: 38103 BUSINESS PHONE: 901-523-9700 MAIL ADDRESS: STREET 1: 175 TOYOTA PLAZA STREET 2: 7TH FLOOR CITY: MEMPHIS STATE: TN ZIP: 38103 10-Q 1 d417950d10q.htm FORM 10-Q FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-50549

GTx, Inc.

(Exact name of registrant as specified in its charter)


Delaware		62-1715807
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

175 Toyota Plaza 7^th Floor Memphis, Tennessee		38103
(Address of principal executive offices)		(Zip Code)

(901) 523-9700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 5, 2012, 62,816,924 shares of the registrant’s Common Stock were outstanding.

GTx, INC.

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2012

INDEX


		PAGE
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)

	Condensed Balance Sheets as of September 30, 2012 and December 31, 2011		3

	Condensed Statements of Operations for the Three Months and Nine Months Ended September 30, 2012 and 2011		4

	Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011		5

	Notes to Condensed Financial Statements		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23

Item 4.	Controls and Procedures		23

PART II – OTHER INFORMATION

Item 1A.	Risk Factors		23

Item 5.	Other Information		39

Item 6.	Exhibits		39

PART I: FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

GTx, Inc.

CONDENSED BALANCE SHEETS

(in thousands, except share data)


	September 30,			December 31,
	2012			2011
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	38,731		$	63,745
Short-term investments		8,555			10,695
Accounts receivable, net		1,152			981
FARESTON^® sale proceeds receivable		21,671			—
Inventory		—			161
Prepaid expenses and other current assets		1,233			1,266

Total current assets		71,342			76,848
Property and equipment, net		640			1,096
Intangible and other assets, net		186			240

Total assets	$	72,168		$	78,184

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,214		$	1,219
Accrued expenses and other current liabilities		10,263			4,142

Total current liabilities		11,477			5,361
Other long-term liabilities		786			949
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value: 120,000,000 shares authorized at both September 30, 2012 and December 31, 2011; 62,816,924 and 62,790,223 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively		63			63
Additional paid-in capital		460,073			457,985
Accumulated deficit		(400,231	)		(386,174	)

Total stockholders’ equity		59,905			71,874

Total liabilities and stockholders’ equity	$	72,168		$	78,184

The accompanying notes are an integral part of these financial statements.

GTx, Inc.

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2012			2011			2012			2011
Revenues:
Collaboration revenue	$	—		$	—		$	—		$	8,066
Expenses:
Research and development expenses		9,764			8,181			28,836			23,075
General and administrative expenses		2,999			2,708			7,987			8,886

Total expenses		12,763			10,889			36,823			31,961

Loss from operations		(12,763	)		(10,889	)		(36,823	)		(23,895	)
Other (expense) income, net		(47	)		23			14			332

Loss from operations before income taxes		(12,810	)		(10,866	)		(36,809	)		(23,563	)
Income tax benefit		7,861			591			8,848			398

Net loss from continuing operations		(4,949	)		(10,275	)		(27,961	)		(23,165	)

Income from discontinued operations before income taxes		20,214			1,522			22,752			951
Income tax expense		(7,861	)		(591	)		(8,848	)		(398	)

Net income from discontinued operations		12,353			931			13,904			553

Net income (loss)	$	7,404		$	(9,344	)	$	(14,057	)	$	(22,612	)

Net income (loss) per share—basic and diluted:
Net loss from continuing operations	$	(0.08	)	$	(0.16	)	$	(0.44	)	$	(0.42	)
Net income from discontinued operations		0.20			0.01			0.22			0.01

Net income (loss) per share	$	0.12		$	(0.15	)	$	(0.22	)	$	(0.41	)

Weighted average shares outstanding:
Basic and diluted		62,815,549			62,778,575			62,806,440			55,529,320

The accompanying notes are an integral part of these financial statements.

GTx, Inc.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


	Nine Months Ended
	September 30,
	2012			2011
Cash flows from operating activities:
Net loss	$	(14,057	)	$	(22,612	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of FARESTON^®		(18,831	)		—
Deferred revenue amortization		—			(8,066	)
Impairment of intangible assets		—			1,598
Depreciation and amortization		596			819
Share-based compensation		1,878			3,178
Directors’ deferred compensation		128			141
Changes in assets and liabilities:
Accounts receivable, net		(171	)		(147	)
Inventory		133			(27	)
Prepaid expenses and other assets		34			(476	)
Accounts payable		(12	)		(19	)
Accrued expenses and other liabilities		3,258			1,062

Net cash used in operating activities		(27,044	)		(24,549	)

Cash flows from investing activities:
Purchase of property and equipment		(125	)		(45	)
Purchase of short-term investments, held to maturity		(7,815	)		(12,450	)
Proceeds from maturities of short-term investments, held to maturity		9,955			3,185

Net cash provided by (used in) investing activities		2,015			(9,310	)

Cash flows from financing activities:
Proceeds from issuance of common stock		—			48,982
Payments on capital lease and financed equipment obligations		(67	)		(63	)
Proceeds from exercise of employee stock options		82			55

Net cash provided by financing activities		15			48,974

Net (decrease) increase in cash and cash equivalents		(25,014	)		15,115
Cash and cash equivalents, beginning of period		63,745			58,181

Cash and cash equivalents, end of period	$	38,731		$	73,296

The accompanying notes are an integral part of these financial statements.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

1. Business and Basis of Presentation

Business

GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine^® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

Additionally, the Company is developing Capesaris^® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.

Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON^® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON^® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion.

Basis of Presentation

The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012.

Use of Estimates

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

Discontinued Operations

On September 28, 2012, the Company entered into an asset purchase agreement (the “FARESTON^® Purchase Agreement”) with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON^®. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company has accounted for FARESTON^® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON^® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. The Company has also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations. The Company has set forth the assets and liabilities relating to the FARESTON^® discontinued operations in Note 4, Discontinued Operations. See Note 4, Discontinued Operations, for further discussion.

FARESTON^® Revenue Recognition

Revenue from product sales of FARESTON^®, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON^® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON^® by the Company prior to September 30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, the Company’s accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $528 and $715 have been included in “Other long-term liabilities” in the condensed balance sheets at September 30, 2012 and December 31, 2011, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year. See Note 4, Discontinued Operations, for further discussion.

Collaboration Revenue Recognition

Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company’s former collaboration and license agreements. Revenues from the Company’s prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note 5, Collaboration and License Agreements, for further discussion.

Research and Development Expenses

Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

Cash, Cash Equivalents and Short-term Investments

The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents.

At September 30, 2012 and December 31, 2011, short-term investments consisted of Federal Deposit Insurance Corporation insured certificates of deposit with original maturities of greater than three months and less than one year. As the Company has the positive intent and ability to hold the certificates of deposit until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value. The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time.

Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products.

The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011.

Income Taxes

The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, at September 30, 2012 and December 31, 2011, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income taxes are described more fully in Note 9 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The Company has recognized the tax effect of discontinued operations in the condensed statements of operations in accordance with the intra-period accounting rules. An offsetting tax benefit is recorded in continuing operations in each period.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

Other (Expense) Income, net

Other (expense) income, net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.

Reclassification

Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion.

Subsequent Events

The Company has evaluated all events or transactions that occurred after September 30, 2012 up through the date the condensed financial statements were issued. There were no material recognizable or nonrecognizable subsequent events during the period evaluated.

2. Share-Based Compensation

Share-based payments include stock option grants under the Company’s stock option and equity incentive plans and deferred compensation arrangements for the Company’s non-employee directors. The Company recognizes compensation expense for its share-based payments based on the fair value of the awards over the period during which an employee or non-employee director is required to provide service in exchange for the award. The Company’s share-based compensation plans are described more fully in Note 3 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Research and development expenses	$	335	$	503	$	696	$	1,410
General and administrative expenses		458		623		1,310		1,909

Total share-based compensation	$	793	$	1,126	$	2,006	$	3,319

Share-based compensation expense recorded as general and administrative expense for the three months ended September 30, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $40 and $45, respectively. Share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $128 and $141 was included in share-based compensation expense recorded as general and administrative expenses for the nine months ended September 30, 2012 and 2011, respectively. Share-based compensation expense recorded as research and development expenses for the nine months ended September 30, 2012 was offset by the reversal of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the resignation of an executive officer during the nine months ended September 30, 2012.

The Company uses the Black-Scholes-Merton option pricing valuation model to value stock options. The expected life of options is determined by calculating the average of the vesting term and the contractual term of the options. The expected price volatility is based on the Company’s historical stock price volatility. The risk-free interest rate is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock options. Expected dividend yield is not considered as the Company has not made any dividend payments and has no plans of doing so in the foreseeable future. The amount of share-based compensation expense recognized is reduced ratably over the vesting period by an estimate of the percentage of options granted that are expected to be forfeited or canceled before becoming fully vested.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

The fair value of options granted was estimated using the following assumptions for the periods presented:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Expected price volatility		73.8	%		65.3	%		69.6	%		64.9	%
Risk-free interest rate		1.1	%		2.3	%		1.2	%		2.5	%
Weighted average expected life in years		6.5 years			6.5 years			6.5 years			6.5 years

The following is a summary of stock option transactions for all of the Company’s stock option and equity incentive plans since the Company’s most recent fiscal year end:


	Number of Shares			Weighted Average Exercise Price Per Share
Options outstanding at December 31, 2011		4,945,565		$	9.12
Options granted		1,129,250			3.34
Options forfeited or expired		(669,754	)		8.86
Options exercised		(26,701	)		3.07

Options outstanding at September 30, 2012		5,378,360			7.97

3. Basic and Diluted Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of common shares outstanding during the period. Diluted net loss per share gives effect to the dilutive potential of common stock consisting of stock options.

Weighted average options outstanding to purchase shares of common stock of 5,408,065 and 5,113,943 for the three months ended September 30, 2012 and 2011, respectively, and 5,639,672 and 5,455,700 for the nine months ended September 30, 2012 and 2011, respectively, were excluded from the calculations of diluted loss per share as inclusion of the options would have had an anti-dilutive effect on the net loss per share for the periods.

4. Discontinued Operations

On September 28, 2012, the Company entered into the FARESTON^® Purchase Agreement with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights to FARESTON^® and certain assets related thereto. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company recognized a gain of $18,831 on the sale of FARESTON^® for the three and nine months ended September 30, 2012. The gain represents the gross proceeds received from the sale reduced by a contract termination fee of $1,000 due to Orion (as discussed further in Note 5, Collaboration and License Agreements), a financial advisory fee related to the transaction of $1,712, and other transaction expenses of approximately $128.

The Company has accounted for FARESTON^® as a discontinued operation. The FARESTON^® operating income, along with the gain recognized on the sale of FARESTON^® for the three and nine months ended September 30, 2012, has been reported as “net income from discontinued operations” in the condensed statements of operations. In addition, the assets and liabilities related to FARESTON^® that are included in the condensed balance sheets for the periods presented have been presented below.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

FARESTON^® operating income for each period presented was as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Product sales, net	$	1,826		$	2,029		$	5,294		$	4,903
Cost of product sales		(263	)		(311	)		(782	)		(780	)
Operating expenses		(180	)		(196	)		(591	)		(3,172	)

FARESTON^® operating income	$	1,383		$	1,522		$	3,921		$	951

Under the FARESTON^® Purchase Agreement, the Company remains responsible for and benefits from the collection of accounts receivable and remains liable for future product returns, in each case relating to sales of FARESTON^® made by the Company prior to September 30, 2012. The Company has also recognized liabilities in its condensed balance sheet at September 30, 2012 for the $1,000 termination fee due to Orion and the $1,712 financial advisory fee related to the transaction within “accrued expenses and other current liabilities”. The assets and liabilities related to FARESTON^® discontinued operations included in the condensed balance sheets for the periods presented were as follows:


	September 30,		December 31,
	2012		2011
Accounts receivable, net	$	1,152	$	981
FARESTON^® sale proceeds receivable		21,671		—
Inventory		—		161
Prepaid expenses and other assets		279		178

Total assets		23,102		1,320

Accounts payable		35		116
Accrued expenses and other current liabilities		4,209		919
Other long-term liabilities		528		715

Total liabilities		4,772		1,750

Net assets (liabilities)	$	18,330	$	(430	)

5. Collaboration and License Agreements

Former Orion Corporation License and Supply Agreement

In connection with the Company’s sale of its rights and certain assets related to FARESTON^® to ProStrakan, the Company and Orion agreed to terminate the Amended and Restated License and Supply Agreement, dated January 1, 2005, as amended, between the Company and Orion (the “Orion Supply Agreement”) as well as certain other agreements between the Company and Orion related to the Orion Supply Agreement (collectively, the “Orion Agreements”). Pursuant to the Orion Supply Agreement, the Company obtained an exclusive license from Orion to develop and commercialize toremifene-based products for all human indications worldwide, except breast cancer outside of the United States, and Orion agreed to manufacture and supply all of the Company’s needs for clinical trial and commercial grade material for toremifene-based products developed and marketed in the United States and abroad, including toremifene globally and FARESTON^® in the United States. The termination of the Orion Agreements was effective September 30, 2012. As consideration for Orion’s agreement to terminate the Orion Agreements and to enter into certain agreements with the ProStrakan to effect the FARESTON^® sale, the Company paid Orion $1,000 in October 2012.

GTx, Inc.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

(unaudited)

University of Tennessee Research Foundation License Agreements

The Company and the University of Tennessee Research Foundation (“UTRF”) are parties to a consolidated, amended and restated license agreement (the “SARM License Agreement”) pursuant to which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or controlled by UTRF, including all improvements thereto, and exclusive rights to future SARM technology that may be developed by certain scientists at the University of Tennessee or subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and mid single-digit royalties on sublicense revenues.

Former Ipsen Collaboration and License Agreement

In September 2006, the Company entered into a collaboration and license agreement with Ipsen Biopharm Limited (the “Ipsen Collaboration Agreement”) pursuant to which the Company granted Ipsen exclusive rights in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of Independent States (the “European Territory”) to develop and commercialize toremifene in all indications which the Company has licensed from Orion, which include all indications in humans except the treatment and prevention of breast cancer outside of the United States.

In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company €23,000 as a license fee and expense reimbursement. Under the Ipsen Collaboration Agreement, the Company recorded deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement which was being amortized into revenue on a straight-line basis over the estimated ten year development period for toremifene in the European Territory.

In March 2011, the Company reacquired full rights to its toremifene program following the termination by the Company and Ipsen of the collaboration and license agreement, as amended. During the first quarter of 2011, the Company recognized as collaboration revenue all of the remaining $8,066 unamortized revenue. This amount is included in collaboration revenue in the condensed statement of operations for the nine months ended September 30, 2011.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the condensed financial statements and the notes thereto included in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Forward-Looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include statements about:

•

the anticipated progress of our research, development and clinical programs, including whether our ongoing or planned clinical trials will achieve similar results to clinical trials that we have previously concluded;

•

the timing, scope and anticipated initiation, enrollment and completion of our ongoing and planned clinical trials and any other future clinical trials that we may conduct;

•

the timing of regulatory submissions and the timing, scope and anticipated outcome of related regulatory actions;

•

our ability to establish and maintain potential new collaborative arrangements for the development and commercialization of our product candidates;

•

our ability to obtain and maintain regulatory approvals of our product candidates and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;

•

our ability to market, commercialize and achieve market acceptance for our product candidates or products that we may develop;

•

our ability to generate additional product candidates for clinical testing;

•

our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and

•

our estimates regarding the sufficiency of our cash resources, expenses, capital requirements and needs for additional financing, and our ability to obtain additional financing.

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks, uncertainties and other important factors. We discuss many of these risks in this Quarterly Report on Form 10-Q in greater detail in the section entitled “Risk Factors” under Part II, Item 1A below. Given these risks, uncertainties and other important factors, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q and the documents that we incorporate by reference in and have filed as exhibits to this Quarterly Report on Form 10-Q, completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

Overview

Business Overview

We are a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

Business Highlights

We are developing selective androgen receptor modulators, or SARMs, a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). Our lead SARM product candidate, enobosarm (also known as Ostarine^® or GTx-024), has to date been evaluated in eight completed clinical trials enrolling approximately 600 subjects, including in a Phase Ib and two Phase II efficacy studies. Enobosarm is the generic name given to the compound by the USAN Council and the World Health Organization and is the first compound to receive the SARM stem in its name, recognizing enobosarm as the first in this new class of compounds.

We are enrolling the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. We are conducting these trials in clinical sites in the United States, Europe, and South America. In each of the placebo-controlled, double-blind clinical trials, approximately 300 patients with Stage III or IV non-small cell lung cancer are being randomized to placebo or enobosarm 3 mg at the time they are to begin first line chemotherapy. The trials are evaluating as co-primary endpoints the effect of enobosarm versus placebo on total lean body mass (muscle) assessed by dual x-ray absorptiometry, or DXA, and on physical function assessed by the Stair Climb Test at three months. Durability of effect is being assessed as a secondary endpoint at five months. In October 2012, after a pre-specified safety review in subjects currently enrolled in these two clinical trials, the independent Data Safety Monitoring Board determined that the trials could continue as planned. We currently expect topline data from these pivotal Phase III clinical trials during the second quarter of 2013. We plan either to build a specialized sales and marketing organization to commercialize enobosarm or consider strategic partnerships or collaborations for the development and commercialization of this product candidate.

Additionally, we are developing Capesaris^® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. We believe Capesaris^® has the potential to reduce testosterone without also causing certain estrogen deficiency side effects, such as bone loss, hot flashes and insulin resistance, which are common with current androgen deprivation therapies for prostate cancer. We also believe that Capesaris^® may be effective, in combination with ADT, as a primary treatment of advanced prostate cancer by reducing testosterone to levels lower than what is attainable with ADT alone and potentially reducing the estrogen deficiency side effects caused by the use of ADT.

In May 2012, we announced that the United States Food and Drug Administration, or FDA, had removed its full clinical hold on our Investigational New Drug, or IND, application for Capesaris^®. The full clinical hold was placed on our three then-ongoing Phase II clinical trials evaluating Capesaris^® to treat men with advanced prostate cancer in February 2012 and resulted in the discontinuation of these trials. The full clinical hold followed our reports to the FDA of venous thromboembolic events (blood clots), or VTEs, in subjects treated with Capesaris^® at the doses being studied in those trials (1000 mg and higher per day). Based upon feedback from the FDA in connection with the removal of the full clinical hold, we initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.

Capesaris^® has previously demonstrated the ability to increase the production of a protein called sex hormone binding globulin, or SHBG, in men with advanced prostate cancer and reduce serum prostate specific antigen, or PSA, and free testosterone, which can stimulate prostate cancer growth. The primary endpoint of the current Phase II open-label clinical trial is the proportion of subjects with a ³ 50% decline from baseline in serum prostate specific antigen, or PSA, by day 90. Other key cancer endpoints include serum PSA progression, time to progression and progression free survival in the study subjects. In addition, the clinical study will evaluate the ability of Capesaris^® to treat certain side effects associated with luteinizing hormone releasing hormone agonists such as hot flashes, bone loss, and insulin resistance. The clinical trial requires subjects to continue receiving their ADT treatment, which will allow us to assess the safety and tolerability of Capesaris^® in these subjects, including the incidence of VTEs. The trial design provides for 75 total subjects, with three sequential dosing arms. The first 25 subjects in the Phase II clinical trial are being enrolled in the Capesaris^® 125 mg dosing arm. Assuming that an acceptable incidence of VTEs has been observed when the last subject enrolled in the Capesaris^® 125 mg dose arm has completed one 30 day cycle of therapy, enrollment of the next 25 subjects will commence in the Capesaris^® 250 mg dosing arm. Similarly, the Capesaris^® 500 mg dosing arm will commence enrollment of the final 25 subjects when the last subject enrolled in the 250 mg dose arm has completed one 30 day cycle of therapy, assuming an acceptable incidence of VTEs has been observed in both of the lower dosage arms.

Financial Highlights

Effective September 30, 2012, we sold our rights and certain assets related to FARESTON^® to Strakan International S.á r.l., an affliliate of ProStrakan Group plc, or ProStrakan, for a purchase price of approximately $21.7 million in cash and recognized a gain on the sale of $18.8 million. Through September 30, 2012, we sold FARESTON^® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States.

Our net loss for the nine months ended September 30, 2012 was $14.1 million. Our net loss included a gain of $18.8 million on the sale of our rights and certain assets related to FARESTON^®. We expect to incur significant net losses in 2012 and for the foreseeable future as we continue our clinical development and research and development activities. Currently, we have no ongoing collaborations for the development and commercialization of our product candidates, and, as a result of the sale of our rights and certain assets related to FARESTON^®, we also currently have no source of revenue. Our current product candidates, enobosarm and Capesaris^®, will require significant additional clinical development and financial resources to obtain necessary regulatory approvals in order to develop these product candidates into commercially viable products. Accordingly, we do not expect to obtain FDA approval or any other regulatory approvals to market any of our product candidates in the near future, and it is possible that our product candidates will never receive any regulatory approvals.

At September 30, 2012, we had cash, cash equivalents and short-term investments of $47.3 million compared to $74.4 million at December 31, 2011. In October 2012, we increased our cash and short-term investments when we received net cash proceeds of approximately $19 million related to the sale of our rights and certain assets related to FARESTON^®. As of the date of this Quarterly Report on Form 10-Q, we estimate that our current cash, cash equivalents, and short-term investments, together with interest thereon, will be sufficient to meet our projected operating requirements for at least the next twelve months. We have based this estimate on our current business plan and assumptions that may prove to be wrong. We could utilize our available capital resources sooner than we currently expect, and we could need additional funding sooner than currently anticipated. In any event, to complete the development of and seek regulatory approval for enobosarm and Capesaris^®, we will need to obtain substantial additional funding.

Research and Development

Since our inception in 1997, we have been focused on drug discovery and development programs. Research and development expenses include, but are not limited to, our expenses for personnel and supplies associated with our research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees.

We expect that our research and development expenses for fiscal year 2012 will increase as compared to fiscal year 2011 and to be primarily focused on the following:

•

the continued clinical development of enobosarm;

•

the continued clinical development of Capesaris^®; and

•

the continued preclinical development of other potential product candidates.

There is a risk that any drug discovery and development program may not produce revenue. Moreover, because of the uncertainties inherent in drug discovery and development, including those factors described in Part II, Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q, we may not be able to successfully develop and commercialize any of our product candidates.

Product Candidates

The following table identifies the development phase and status for each of our clinical product candidates:


Product Candidate/ Proposed Indication	Program	Clinical Development Phase	Status
Enobosarm (Ostarine^®; GTx-024)
Prevention and treatment of muscle wasting in patients with non-small cell lung cancer	SARM	Phase III	Enrolling the POWER 1 and POWER 2 pivotal Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Capesaris^® (GTx-758)
Secondary hormonal therapy in men with metastatic castration resistant prostate cancer and primary treatment for advanced prostate cancer used in combination with ADT	Selective ER alpha agonist	Phase II	Initiated a Phase II clinical trial in the third quarter of 2012 for secondary hormonal therapy in men with metastatic castration resistant prostate cancer.

General and Administrative Expenses

Our general and administrative expenses consist primarily of salaries and other related costs for personnel serving executive, finance, legal, human resources, information technology, and investor relations functions. General and administrative expenses also include facility costs, insurance costs, and professional fees for legal, accounting, and public relation services.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments related to revenue recognition, income taxes, intangible assets, long-term service contracts and other contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our financial statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC, we believe that the following accounting policies are most critical to aid you in fully understanding and evaluating our reported financial results.

Discontinued Operations

Effective September 30, 2012, we completed the sale of FARESTON^® for a total cash purchase price of $21.7 million, including payment for purchased inventory. We have accounted for FARESTON^® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON^® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. We have also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations.

Revenue Recognition

Our revenues consisted of product sales of FARESTON^®, which is included in income from discontinued operations before income taxes, and in 2011, also consisted of revenues derived from our former collaboration and license agreements.

Revenue from product sales of FARESTON^® was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. We accounted for rebates to certain governmental agencies as a reduction of product sales. We allow customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although we sold our rights and certain assets related to FARESTON^® effective September 30, 2012, we retain the liability for future product returns relating to sales of FARESTON^® by us prior to September 30, 2012. Therefore, we estimate an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, our accrual for product returns, was $1.2 million and $1.1 million, respectively.

Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with our former collaboration and license agreements and was based on the performance requirements of the specific agreements. We analyzed our agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. Performance obligations typically consisted of significant milestones in the development life cycle of the related product candidates and technology, such as initiation of clinical trials, achievement of specified clinical trial endpoints, filing for approval with regulatory agencies and approvals by regulatory agencies.

Research and Development Expenses

Research and development expenses include, but are not limited to, our expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.

Research and development expenses for the nine months ended September 30, 2011 included an impairment charge of $1.6 million related to the unamortized portion of capitalized license fees paid to Orion Corporation related to our former toremifene 80 mg program.

Share-Based Compensation

We have stock option and equity incentive plans that provide for the purchase of our common stock by certain of our employees and non-employee directors. We recognize compensation expense for our share-based payments based on the fair value of the awards on the grant date and recognize the expense over the period during which an employee or non-employee director is required to provide service in exchange for the award.

The determination of the fair value of share-based payment awards on the date of grant include the expected life of the award, the expected stock price volatility over the expected life of the awards, and risk-free interest rate. We estimate the expected life of options by calculating the average of the vesting term and contractual term of the options. We estimate the expected stock price volatility based on the historical volatility of our common stock. The risk-free interest rate is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock options. Expected dividend yield is not considered as we have not made any dividend payments and have no plans of doing so in the foreseeable future. The amount of share-based compensation expense recognized is reduced ratably over the vesting period by an estimate of the percentage of options granted that are expected to be forfeited or canceled before becoming fully vested. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.

The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
	(in thousands)
Research and development expenses	$	335	$	503	$	696	$	1,410
General and administrative expenses		458		623		1,310		1,909

Total share-based compensation	$	793	$	1,126	$	2,006	$	3,319

Share-based compensation expense recorded in the condensed statement of operations as general and administrative expense for the three months ended September 30, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for our non-employee directors of $40,000 and $45,000, respectively. Share-based compensation expense recorded in the condensed statement of operations as general and administrative expense for the nine months ended September 30, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for our non-employee directors of $128,000 and $141,000, respectively. Share-based compensation expense recorded as research and development expenses for the nine months ended September 30, 2012 was offset by the reversal of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the resignation of an executive officer during the period. At September 30, 2012, the total compensation cost related to non-vested awards not yet recognized was approximately $4.9 million with a weighted average expense recognition period of 2.93 years.

Results of Operations

Three Months Ended September 30, 2012 and 2011

Research and Development Expenses. Research and development expenses increased 19% to $9.8 million for the three months ended September 30, 2012 from $8.2 million for the three months ended September 30, 2011. The increase in research and development expenses during the three months ended September 30, 2012 compared to the prior year comparable quarter was due primarily to a $2.6 million increase in costs related to the continued enrollment of and operations related to the two pivotal Phase III clinical trials for enobosarm. This increase was partially offset by a $1.1 million decrease in research and development expenses due to the discontinuance in February 2012 of the three Phase II clinical trials of Capesaris^® to treat men with advanced prostate cancer that were placed on full clinical hold by the FDA. “Other research and development expenses” in the table below includes the cost of personnel, supplies, and facilities associated with preclinical and discovery research and development activities. The following table identifies the research and development expenses for each of our clinical product candidates, as well as research and development expenses pertaining to our other research and development efforts, for both of the periods presented. Research and development expenses for past periods may not be indicative of future periods.


Product Candidate/		Three Months Ended				Increase/
Proposed Indication	Program	September 30,				(Decrease)
		2012		2011
		(in thousands)
Enobosarm
Prevention and treatment of muscle wasting in patients with non-small cell lung cancer	SARM	$	6,312	$	3,702	$	2,610
Capesaris^®
Secondary hormonal therapy in men with metastatic castration resistant prostate cancer	Selective ER alpha agonist		1,729		2,815		(1,086	)
Other research and development			1,723		1,664		59

Total research and development expenses		$	9,764	$	8,181	$	1,583

General and Administrative Expenses. General and administrative expenses increased during the three months ended September 30, 2012 to $3.0 million from $2.7 million for the three months ended September 30, 2011. This increase was primarily due to an increase in salaries and benefits of $194,000 and increased legal expenses of $71,000.

Discontinued Operations. Income from discontinued operations before income taxes was $20.2 million for the three months ended September 30, 2012 and consisted of FARESTON^® operating income of $1.4 million and the recognition of a gain of $18.8 million on the sale of our rights and certain assets related to FARESTON^®.

The components of FARESTON^® operating income for the three months ended September 30, 2012 and 2011 were as follows:


	Three Months Ended September 30,				Increase/
	Three Months Ended September 30,				(Decrease)
	2012		2011
	(in thousands)
Product sales, net	$	1,826	$	2,029	$	(203	)
Cost of product sales		263		311		(48	)
Operating expenses		180		196		(16	)

FARESTON^® operating income	$	1,383	$	1,522	$	(139	)

During the three months ended September 30, 2012, FARESTON^® gross product sales increased from the same period of 2011 due to an increase in the sales price of FARESTON^® and, to a lesser extent, an increase in sales volume. However, this was offset by an increase in governmental rebates as compared to the prior period.

Nine Months Ended September 30, 2012 and 2011

Collaboration Revenue. Collaboration revenue was $8.1 million for the nine months ended September 30, 2011. As a result of the termination of our license and collaboration agreement with Ipsen Biopharm Limited in March 2011, we recognized as collaboration revenue all of the remaining $8.1 million of unamortized revenue in the three months ended March 31, 2011. We had no collaboration revenue during the nine months ended September 30, 2012.

Research and Development Expenses. Research and development expenses increased by 25% to $28.8 million for the nine months ended September 30, 2012 from $23.1 million for the nine months ended September 30, 2011. The increase in research and development expenses during the nine months ended September 30, 2012 compared to the prior year comparable period was due primarily to a $10.2 million increase in costs related to the continued enrollment of and operations related to the two pivotal Phase III clinical trials for enobosarm. This increase was partially offset by a $2.5 million decrease in research and development expenses due to the discontinuance in February 2012 of the three Phase II clinical trials of Capesaris^® to treat men with advanced prostate cancer that were placed on full clinical hold by the FDA. “Other research and development expenses” in the table below includes the cost of personnel, supplies, and facilities associated with preclinical and discovery research and development activities. The following table identifies the research and development expenses for each of our clinical product candidates, as well as research and development expenses pertaining to our other research and development efforts, for both of the periods presented.


Product Candidate/		Nine Months Ended				Increase/
Proposed Indication	Program	September 30,				(Decrease)
		2012		2011
		(in thousands)
Enobosarm
Prevention and treatment of muscle wasting in patients with non-small cell lung cancer	SARM	$	17,420	$	7,178	$	10,242
Capesaris^®
Secondary hormonal therapy in men with metastatic castration resistant prostate cancer	Selective ER alpha agonist		5,969		8,463		(2,494	)
Other research and development¹			5,447		7,434		(1,987	)

Total research and development expenses		$	28,836	$	23,075	$	5,761

“Other research and development” for the nine months ended September 30, 2011 included research and development expenses of $2.0 million for toremifene 80 mg, which included an impairment charge of $1.6 million, and $434,000 for toremifene 20 mg. We have discontinued our toremifene development programs.

General and Administrative Expenses. General and administrative expenses decreased during the nine months ended September 30, 2012 to $8.0 million from $8.9 million for the nine months ended September 30, 2011. This decrease was primarily due to the discontinuance of our toremifene development programs, which resulted in decreased personnel related costs of $359,000 and decreased legal expenses of $460,000.

Discontinued Operations. Income from discontinued operations before income taxes was $22.8 million for the nine months ended September 30, 2012 and consisted of FARESTON^® operating income of $3.9 million and the recognition of a gain of $18.8 million on the sale of rights and certain assets related to FARESTON^®.

The components of FARESTON^® operating income for the nine months ended September 30, 2012 and 2011 were as follows:


	Nine Months Ended				Increase/
	September 30,				(Decrease)
	2012		2011
	(in thousands)
Product sales, net	$	5,294	$	4,903	$	391
Cost of product sales		782		780		2
Operating expenses		591		3,172		(2,581	)

FARESTON^® operating income	$	3,921	$	951	$	2,970

FARESTON^® gross product sales increased for the nine months ended September 30, 2012 compared to the same period in 2011 due to an increase in the sales price of FARESTON^® and, to a lesser extent, an increase in sales volume, which was partially offset by an increase in governmental rebates as compared to the prior period. FARESTON^® operating expenses decreased for the nine month period ended September 30, 2012 as compared to the same period in 2011 due to a reduction in FARESTON^® marketing and medical education expenses.

Liquidity and Capital Resources

At September 30, 2012, we had cash, cash equivalents and short-term investments of $47.3 million, compared to $74.4 million at December 31, 2011. In October 2012, we increased our cash and short-term investments when we received net cash proceeds of approximately $19 million related to the sale of our rights and certain assets related to FARESTON^®. Net cash used in operating activities was $27.0 million and $24.5 million for the nine months ended September 30, 2012 and 2011, respectively, and resulted primarily from funding our operations for the periods.

Net cash provided by investing activities was $2.0 million for the nine months ended September 30, 2012 and resulted primarily from the maturities of short-term investments of $10.0 million offset by the purchase of short-term investments of $7.8 million. Net cash used in investing activities was $9.3 million for the nine months ended September 30, 2011 due primarily to the purchase of short-term investments of $12.5 million offset by maturities of short-term investments of $3.2 million.

Net cash provided by financing activities of $15,000 for the nine months ended September 30, 2012 reflects proceeds from the exercise of employee stock options partially offset by payments on capital lease and financed equipment obligations. Net cash provided by financing activities was $49.0 million for the nine months ended September 30, 2011 and reflects proceeds from our underwritten public offering of common stock in September 2011 and proceeds from the exercise of employee stock options. These proceeds were reduced by payments on our capital lease and financed equipment obligations.

As of the date of this Quarterly Report on Form 10-Q, we estimate that our current cash, cash equivalents, and short-term investments, together with interest thereon, will be sufficient to meet our projected operating requirements for at least the next twelve months. We have based this estimate on our current business plan and assumptions that may prove to be wrong. We could utilize our available capital resources sooner than we currently expect, and we could need additional funding sooner than currently anticipated. In any event, to complete the development of and seek regulatory approval for enobosarm and Capesaris^®, we will need to obtain substantial additional funding.

Our estimate of the period of time through which our financial resources will be adequate to support our projected operating requirements is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed under Part II, Item 1A “Risk Factors” section of this Quarterly Report on Form 10-Q. Because of the numerous risks and uncertainties associated with the development and potential commercialization of our product candidates and other research and development activities, including risks and uncertainties that could impact the rate of progress of our development and commercialization activities, we are unable to estimate with certainty the amounts of increased capital outlays and operating expenditures associated with our anticipated future clinical trials, other research and development activities, and potential commercialization activities. Our future funding requirements will depend on many factors, including:

•

the scope, rate of progress and cost of our clinical trials and other research and development activities, including our ongoing and any other future clinical trials of enobosarm and Capesaris^®;

•

the terms and timing of any potential future collaborative, licensing and other arrangements that we may establish;

•

the decision to initiate development of new potential medicines from our research and discovery activities;

•

the amount and timing of any license fees, milestone payments and royalty payments from potential future collaborators, if any;

•

future clinical trial results;

•

the cost and timing of regulatory filings and/or approvals to commercialize our product candidates and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;

•

the cost and timing of establishing medical education, sales, marketing and distribution capabilities;

•

the cost of establishing clinical and commercial supplies of our product candidates and any products that we and/or any potential future collaborators may develop;

•

the effect of competing technological and market developments;

•

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, and the cost of defending any other litigation claims; and

•

the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

We do not currently have any commitments for future external funding nor do we currently have any sources of revenue. Until we can generate a sufficient amount of product revenue, which we may never do, we expect to finance future cash needs through public or private equity offerings, debt financings or collaboration and licensing arrangements, or a combination of the above, as well as through interest income earned on the investment of our cash balances and short-term investments. In June 2011, we announced a workforce reduction of approximately 15% in order to reduce our operating expenses relating to our discontinued toremifene development programs. If we are unable to raise additional funds when needed, we may need to further reduce our expenditures, perhaps significantly, to preserve our cash. Cost-cutting measures that we may take in the future may not be sufficient to enable us to meet our cash requirements, and they may negatively affect our business and growth prospects. To the extent we raise additional funds by issuing equity securities, our stockholders may experience dilution, and debt financing, if available, may involve restrictive covenants. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. To the extent we raise additional funds through potential future collaboration and licensing arrangements, it may be necessary to relinquish rights to some of our technologies or product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise additional funds and the terms upon which we are able to raise such funds may be adversely impacted by the outcomes of ongoing and potential future clinical trials of enobosarm and Capesaris^®, uncertainty regarding our financial condition and/or current economic conditions, including the effects of, disruptions to and volatility in the credit and financial markets in the United States, the European Union and other regions of the world, including those resulting from or associated with rising government debt levels. As a result of these and other factors, we cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available when we need them, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs, including our SARM and selective ER alpha agonist programs, or conduct additional workforce or other expense reductions, any of which could have a material adverse effect on our business.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

During the nine months ended September 30, 2012, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2011.

ITEM 4.

CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures.

We have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on the evaluation of these disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting during the third quarter of 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

ITEM 1A.

RISK FACTORS

We have identified the following additional risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. Investors should carefully consider the risks described below before making an investment decision. Our business faces significant risks, and the risks described below may not be the only risks we face. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. If any of these risks occur, our business, results of operations or financial condition could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.

We have marked with an asterisk (*) those risks described below that reflect substantive changes from the risks described under Part I, Item 1A “Risk Factors” included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2012. In addition, the risks described under, and the caption entitled, “Our only marketed product generating revenue is FARESTON^®, which is subject to a number of risks. These risks may cause sales of FARESTON^® to decline.” included under Part 1, Item 1A “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2011 have been removed.

Risks Related to Our Financial Condition and Need for Additional Financing

We have incurred losses since inception, and we anticipate that we will incur continued losses for the foreseeable future.*

As of September 30, 2012, we had an accumulated deficit of $400.2 million. Our net loss for the nine months ended September 30, 2012 was $14.1 million, which included a gain of $18.8 million on the sale of our rights and certain assets related to FARESTON^®. We expect to incur significant net losses for the foreseeable future as we continue our clinical development and research and development activities. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

Our current product candidates, enobosarm (also known as Ostarine^® or GTx-024) and Capesaris^® (GTx-758), will require significant additional clinical development and financial resources to obtain necessary regulatory approvals in order to develop these product candidates into commercially viable products. Accordingly, we do not expect to obtain United States Food and Drug Administration, or FDA, approval or any other regulatory approvals to market any of our product candidates in the near future, and it is possible that our product candidates will never receive any regulatory approvals.

Because of the numerous risks and uncertainties associated with developing and commercializing small molecule drugs, we are unable to predict the extent of any future losses or when we will become profitable, if at all. We have financed our operations and internal growth primarily through public offerings and private placement of our common stock, as well as payments from our former collaborators. We also previously recognized product revenue from the sale of FARESTON^®, the rights to which we sold to a third party in the third quarter of 2012. Currently, we have no ongoing collaborations for the development and commercialization of our product candidates, and as a result of the sale of our rights and certain assets related to FARESTON^®, we also currently have no sources of revenue. If we and/or any potential future collaborators are unable to develop and commercialize any of our product candidates, if development is further delayed or is eliminated, or if sales revenue from any product candidate that receives marketing approval is insufficient, we may never become profitable and we will not be successful.

We will need to raise substantial additional capital and may be unable to raise capital when needed, which would force us to further delay, reduce or eliminate our product development programs or commercialization efforts.*

We will need to raise substantial additional capital to:

•

fund our operations and conduct clinical trials;

•

continue our research and development;

•

seek regulatory approval for our product candidates; and

•

commercialize our product candidates, if any such product candidates receive regulatory approval for commercial sale.

As of the date of this Quarterly Report on Form 10-Q, we estimate that our current cash, cash equivalents, and short-term investments, together with interest thereon, will be sufficient to meet our projected operating requirements for at least the next twelve months. We have based this estimate on our current business plan and assumptions that may prove to be wrong. We could utilize our available capital resources sooner than we currently expect, and we could need additional funding sooner than currently anticipated. In any event, to complete the development of and seek regulatory approvals for enobosarm and Capesaris^®, we will need to obtain substantial additional funding. Our future funding requirements will depend on many factors, including:

•

the scope, rate of progress and cost of our clinical trials and other research and development activities, including our ongoing, planned and any other future clinical trials of enobosarm and Capesaris^®;

•

the terms and timing of any potential future collaborative, licensing and other arrangements that we may establish;

•

the decision to initiate development of new potential medicines from our research and discovery activities;

•

the amount and timing of any licensing fees, milestone payments and royalty payments from potential future collaborators, if any;

•

future clinical trial results;

•

the cost and timing of establishing medical education, sales, marketing and distribution capabilities;

•

the cost of establishing clinical and commercial supplies of our product candidates and any products that we and/or any potential future collaborators may develop;

•

the effect of competing technological and market developments;

•

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, and the cost of defending any other litigation claims; and

•

the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

To the extent we raise additional funds by issuing equity securities, our stockholders may experience dilution, and debt financing, if available, may involve restrictive covenants. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. To the extent we raise additional funds through potential future collaboration and licensing arrangements, it may be necessary to relinquish rights to some of our technologies or product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise additional funds and the terms upon which we are able to raise such funds may be adversely impacted by the outcomes of ongoing and planned clinical trials of enobosarm and Capesaris^®, uncertainty regarding our financial condition and/or current economic conditions, including the effects of, disruptions to and volatility in the credit and financial markets in the United States, the European Union and other regions of the world, including those resulting from or associated with rising government debt levels. As a result of these and other factors, we cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available when we need them, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs, including our SARM and selective ER alpha agonist programs, or conduct additional workforce or other expense reductions, any of which could have a material adverse effect on our business.

Risks Related to Development of Product Candidates

We and any potential future collaborators will not be able to commercialize our product candidates if our preclinical studies do not produce successful results or if our clinical trials do not adequately demonstrate safety and efficacy in humans.*

Significant additional research and development and financial resources will be required to obtain necessary regulatory approvals for our product candidates and to develop them into commercially viable products. Preclinical and clinical testing is expensive, can take many years to complete and has an uncertain outcome. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results. Typically, the failure rate for development candidates is high. If a product candidate fails at any stage of development, we will not have the anticipated revenues from that product candidate to fund our operations, and we will not receive any return on our investment in that product candidate. For example, we announced in May 2010 that toremifene 20 mg failed to meet its primary efficacy endpoint in our Phase III clinical trial of toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, after we had incurred significant development costs. Even if the results of a clinical trial are positive, the efficacy and/or safety results from the trial may be insufficient to support the submission of a new drug application, or NDA, to the FDA, or if submitted, the approval of the NDA by the FDA. For example, we received a Complete Response Letter in October 2009 from the FDA regarding our NDA for toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy, or ADT, notifying us that the FDA would not approve the NDA. We have since discontinued our toremifene development programs.

Significant delays in clinical testing could materially impact our product development costs. We do not know whether planned or other future clinical trials will begin on time, or whether ongoing or planned clinical trials will need to be restructured or will be completed on schedule, if at all. We or any potential future collaborators may experience numerous unforeseen and/or adverse events during, or as a result of, preclinical testing and the clinical trial process that could delay or prevent our or our potential future collaborators’ ability to commercialize our product candidates, including:

•

regulators or institutional review boards may not authorize us or any potential future collaborators to commence a clinical trial or conduct a clinical trial at a prospective trial site, or we may experience substantial delays in obtaining these authorizations;

•

preclinical or clinical trials may produce negative or inconclusive results, which may require us or any potential future collaborators to conduct additional preclinical or clinical testing or to abandon projects that we expect to be promising;

•

even if preclinical or clinical trial results are positive, the FDA or foreign regulatory authorities could nonetheless require us to conduct unanticipated additional clinical trials;

•

registration or enrollment in clinical trials may be slower than we anticipate, resulting in significant delays or study terminations;

•

we or any potential future collaborators may suspend or terminate clinical trials if the participating patients are being exposed to unacceptable health risks;

•

regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; and

•

our product candidates may not have the desired effects or may include undesirable side effects.

If any of these events were to occur and, as a result, we or any potential future collaborators have significant delays in or termination of clinical trials, our costs could increase and our ability to generate revenue could be impaired, which would materially and adversely impact our business, financial condition and growth prospects.

If we or any potential future collaborators observe serious or other adverse events during the time our product candidates are in development or after our products are approved and on the market, we or any potential future collaborators may be required to perform lengthy additional clinical trials, may be required to cease further development of such product candidates, may be denied regulatory approval of such products, may be forced to change the labeling of such products or may be required to withdraw any such products from the market, any of which would hinder or preclude our ability to generate revenues.*

In three Phase II clinical trials of Capesaris^®, which were discontinued earlier in the year, we observed venous thromboembolic events, or blood clots, in subjects treated with Capesaris^® at the doses being studied in the trials (1000 mg and higher per day) and reported those events to the FDA. There were two deaths in subjects treated with Capesaris^® and two deaths in subjects treated with Lupron Depot^®. In February 2012, the FDA placed all of our then ongoing clinical studies of Capesaris^® on full clinical hold and we suspended further enrollment into these studies and notified clinical sites to discontinue treatment of subjects with Capesaris^®. In May 2012, the FDA notified us that it had removed the full clinical hold on Capesaris^®. In the third quarter of 2012, we initiated a Phase II clinical trial to evaluate Capesaris^®, at doses lower than those which were previously being tested in our discontinued Phase II clinical trials, as secondary hormonal therapy in men with metastatic castration resistant prostate cancer. Although our current Phase II clinical trial is evaluating Capesaris^® at doses lower than those which were previously being tested in our discontinued Phase II clinical trials, we cannot be confident that we will not observe an unacceptable incidence of venous thromboembolic events or other adverse events in the current Phase II clinical trial. If an unacceptable incidence of venous thromboembolic events or other adverse events are observed in our current Phase II clinical trial of Capesaris^®, we may be required to abandon our development of Capesaris^®, in which case, we would not receive any return on our investment in that product candidate.

In our Phase II clinical trials for enobosarm for the treatment of muscle wasting in patients with cancer and healthy older males and postmenopausal females, we observed mild elevations of hepatic enzymes, which in certain circumstances may lead to liver failure, in a few patients in both the placebo and enobosarm treated groups. Reductions in high-density lipoproteins have also been observed in subjects treated with enobosarm. Lower levels of high-density lipoproteins could lead to increased risk of adverse cardiovascular events.

If the incidence of serious or other adverse events related to our product candidates increases in number or severity, if a regulatory authority believes that these or other events constitute an adverse effect caused by the drug, or if other effects are identified during clinical trials that we or any potential future collaborators may conduct in the future or after any of our product candidates are approved and marketed:

•

we or any potential future collaborators may be required to conduct additional preclinical or clinical trials, make changes in the labeling of any such approved products, reformulate any such products, or implement changes to or obtain new approvals of our contractors’ manufacturing facilities;

•

regulatory authorities may be unwilling to approve our product candidates or may withdraw approval of our products;

•

we may experience a significant drop in the sales of the affected products;

•

our reputation in the marketplace may suffer; and

•

we may become the target of lawsuits, including class action suits.

Any of these events could prevent approval or harm sales of the affected product candidates or products, or could substantially increase the costs and expenses of commercializing and marketing any such products.

Risks Related to Our Dependence on Third Parties

If we do not establish collaborations for our product candidates or otherwise raise substantial additional capital, we will likely need to alter our development and any commercialization plans.

Our strategy includes selectively partnering or collaborating with leading pharmaceutical and biotechnology companies to assist us in furthering development and potential commercialization of our product candidates. We face significant competition in seeking appropriate collaborators, and collaborations are complex and time consuming to negotiate and document. We may not be successful in entering into new collaborations with third parties on acceptable terms, or at all, including as a result of the collaboration discussions we are pursuing for enobosarm. In addition, we are unable to predict when, if ever, we will enter into any additional collaborative arrangements because of the numerous risks and uncertainties associated with establishing such arrangements. If we are unable to negotiate new collaborations, we may have to curtail the development of a particular product candidate, reduce, delay, or terminate its development or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we will need to raise substantial additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenues.

Any collaborative arrangements that we establish in the future may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. In addition, any future collaboration arrangements may place the development and commercialization of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.

We have in the past established and intend to continue to establish collaborations with third parties to develop and commercialize some of our current and future product candidates, and these collaborations may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. For example, in March 2011, we and Ipsen Biopharm Limited, or Ipsen, mutually agreed to terminate our collaboration for the development and commercialization of our toremifene-based product candidate, and, as a result, we will not receive any additional milestone payments from Ipsen on account of our collaboration with Ipsen. As of the date of this report, we have no ongoing collaborations for the development and commercialization of our product candidates. In the future, we may not be able to locate third-party collaborators to develop and market our product candidates, and we may lack the capital and resources necessary to develop our product candidates alone.

Dependence on collaborative arrangements subjects us to a number of risks, including:

•

we may not be able to control the amount and timing of resources that our potential future collaborators may devote to our product candidates;

•

potential future collaborations may experience financial difficulties or changes in business focus;

•

we may be required to relinquish important rights such as marketing and distribution rights;

•

should a collaborator fail to develop or commercialize one of our compounds or product candidates, we may not receive any future milestone payments and will not receive any royalties for the compound or product candidate;

•

business combinations or significant changes in a collaborator’s business strategy may also adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement;

•

under certain circumstances, a collaborator could move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

•

collaborative arrangements are often terminated or allowed to expire, which could delay the development and may increase the cost of developing our product candidates.

If third parties do not manufacture our product candidates in sufficient quantities, in the required timeframe, at an acceptable cost, and with appropriate quality control, clinical development and commercialization of our product candidates would be delayed.

We do not currently own or operate manufacturing facilities, and we rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our product candidates. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins, if any, and our ability to develop product candidates and commercialize any product candidates on a timely and competitive basis.

We rely on third-party vendors for the manufacture of enobosarm drug substance. If our supply of enobosarm becomes unusable or if the contract manufacturers that we are currently utilizing to meet our supply needs for enobosarm or any future SARM product candidates prove incapable or unwilling to continue to meet our supply needs, we could experience a delay in conducting any additional clinical trials of enobosarm or any future SARM product candidates. In addition, we rely on third-party contractors for the manufacture of Capesaris^® drug substance. We may not be able to maintain or renew our existing or any other third-party manufacturing arrangements on acceptable terms, if at all. If our suppliers fail to meet our requirements for Capesaris^®, enobosarm or any future product candidates for any reason, we would be required to obtain alternate suppliers. Any inability to obtain alternate suppliers, including an inability to obtain approval from the FDA of an alternate supplier, would delay or prevent the clinical development and commercialization of these product candidates.

Use of third-party manufacturers may increase the risk that we will not have adequate supplies of our product candidates or products.*

Reliance on third-party manufacturers entails risks, to which we would not be subject if we manufactured product candidates or products ourselves, including:

•

reliance on the third party for regulatory compliance and quality assurance;

•

the possible breach of the manufacturing agreement by the third party because of factors beyond our control;

•

the possible termination or non-renewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us; and

•

drug product supplies not meeting the requisite requirements for clinical trial use.

If we are not able to obtain adequate supplies of our product candidates, it will be more difficult for us to develop our product candidates and compete effectively. Our product candidates and any products that we and/or our potential future collaborators may develop may compete with other product candidates and products for access to manufacturing facilities.

Our present or future manufacturing partners may not be able to comply with FDA-mandated current Good Manufacturing Practice regulations, other FDA regulatory requirements or similar regulatory requirements outside the United States. Failure of our third-party manufacturers or us to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.

If third parties on whom we rely do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.

We do not have the ability to independently conduct clinical trials for our product candidates, and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. In addition, we rely on third parties to assist with our preclinical development of product candidates. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.

Risks Related to Our Intellectual Property

If we lose our license from the University of Tennessee Research Foundation, or UTRF, we may be unable to continue a substantial part of our business.

We have licensed intellectual property rights and technology from UTRF used in a substantial part of our business. This license agreement, under which we were granted rights to SARM compounds and technologies, may be terminated by UTRF if we are in breach of our obligations under, or fail to perform any terms of, the agreement and fail to cure that breach. If this agreement is terminated, then we may lose our rights to utilize the SARM technology and intellectual property covered by that agreement to market, distribute and sell licensed products, including enobosarm, which may prevent us from continuing a substantial part of our business and may result in a serious adverse effect on our financial condition, results of operations and any prospects for growth.

If some or all of our or our licensors’ patents expire or are invalidated or are found to be unenforceable, or if some or all of our patent applications do not result in issued patents or result in patents with narrow, overbroad, or unenforceable claims, or claims that are not supported in regard to written description or enablement by the specification, or if we are prevented from asserting that the claims of an issued patent cover a product of a third party, we may be subject to competition from third parties with products in the same class of products as our product candidates or products with the same active pharmaceutical ingredients as our product candidates.*

Our commercial success will depend in part on obtaining and maintaining patent and trade secret protection for our product candidates, as well as the methods for treating patients in the product indications using these product candidates. We will be able to protect our product candidates and the methods for treating patients in the product indications using these product candidates from unauthorized use by third parties only to the extent that we or our exclusive licensors own or control such valid and enforceable patents or trade secrets.

Our rights to certain patents and patent applications relating to SARM compounds that we have licensed from UTRF are subject to the terms of UTRF’s inter-institutional agreements with The Ohio State University, or OSU, and our rights to future related improvements in some instances are subject to UTRF’s exercise of exclusive options under its agreements with OSU for such improvements.

Even if our product candidates and the methods for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount of time. Our and our licensors’ ability to obtain patents can be highly uncertain and involve complex and in some cases unsettled legal issues and factual questions. Furthermore, different countries have different procedures for obtaining patents, and patents issued in different countries provide different degrees of protection against the use of a patented invention by others. Therefore, if the issuance to us or our licensors, in a given country, of a patent covering an invention is not followed by the issuance, in other countries, of patents covering the same invention, or if any judicial interpretation of the validity, enforceability, or scope of the claims in, or the written description or enablement in, a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent defense and enforcement. The regulations and procedures to govern administration of the Leahy-Smith Act, and the substantive and procedural changes to patent law associated with the Leahy-Smith Act are being implemented in stages, beginning from September 16, 2011, and continuing through March 16, 2013. For example, the Leahy-Smith Act has introduced procedures making it easier for third-parties to challenge issued patents, as well as to intervene in the prosecution of patent applications. In addition, the Leahy-Smith Act will change the United States from a “first-to-invent” jurisdiction to a “first-inventor-to-file” jurisdiction and will change the definition of what constitutes prior art for an application. Finally, the Leahy-Smith Act contains new statutory provisions that still require the Patent Office to issue new regulations for their implementation and it may take the courts years to interpret the provisions of the new statute. Accordingly, it is too early to determine what effect or impact the Leahy-Smith Act will have on the operation of our business and the protection and enforcement of our intellectual property. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

Even if patents are issued to us or our licensors regarding our product candidates or methods of using them, those patents can be challenged by our competitors who can argue such patents are invalid or unenforceable, lack of utility, lack sufficient written description or enablement, or that the claims of the issued patents should be limited or narrowly construed. Patents also will not protect our product candidates if competitors devise ways of making or using these product candidates without legally infringing our patents. The Federal Food, Drug, and Cosmetic Act and FDA regulations and policies create a regulatory environment that encourages companies to challenge branded drug patents or to create non-infringing versions of a patented product in order to facilitate the approval of abbreviated new drug applications for generic substitutes. These same types of incentives encourage competitors to submit new drug applications that rely on literature and clinical data not prepared for or by the drug sponsor, providing another less burdensome pathway to approval.

We also rely on trade secrets to protect our technology, especially where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time-consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

If we infringe intellectual property rights of third parties, it may increase our costs or prevent us from being able to commercialize our product candidates.

There is a risk that we are infringing the proprietary rights of third parties because numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields that are the focus of our drug discovery, development, and manufacture and process synthesis efforts. Others might have been the first to make the inventions covered by each of our or our licensors’ pending patent applications and issued patents and/or might have been the first to file patent applications for these inventions. In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us or our licensors, which may later result in issued patents that cover the production, manufacture, synthesis, commercialization, formulation or use of our product candidates. In addition, the production, manufacture, synthesis, commercialization, formulation or use of our product candidates may infringe existing patents of which we are not aware. Defending ourselves against third-party claims, including litigation in particular, would be costly and time consuming and would divert management’s attention from our business, which could lead to delays in our development or commercialization efforts. If third parties are successful in their claims, we might have to pay substantial damages or take other actions that are adverse to our business.

As a result of intellectual property infringement claims, or to avoid potential claims, we might:

•

be prohibited from selling or licensing any product that we and/or any potential future collaborators may develop unless the patent holder licenses the patent to us, which the patent holder is not required to do;

•

be required to pay substantial royalties or other amounts, or grant a cross license to our patents to another patent holder; or

•

be required to redesign the formulation of a product candidate so that it does not infringe, which may not be possible or could require substantial funds and time.

Risks Related to Regulatory Approval of Our Product Candidates

If we or any potential future collaborators are not able to obtain required regulatory approvals, we or such collaborators will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.*

Our product candidates and the activities associated with their development and commercialization are subject to comprehensive regulation by the FDA, other regulatory agencies in the United States and by comparable authorities in other countries. Failure to obtain regulatory approval for a product candidate will prevent us or any potential future collaborator from commercializing the product candidate. We have not received regulatory approval to market any of our product candidates in any jurisdiction, and we do not expect to obtain FDA or any other regulatory approvals to market any of our product candidates in the near future, if at all. The process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved.

Changes in the regulatory approval policy during the development period, changes in or the enactment of additional regulations or statutes, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. For example, on July 9, 2012 Congress enacted the Food and Drug Administration Safety and Innovation Act (FDASIA) that, among other things, reauthorizes the Prescription Drug User Fee Act, or PDUFA, for an additional five years. FDASIA incorporates new FDA performance goals that effectively extend by two months the time period in which the FDA is expected to review and approve certain NDAs. Although the FDA has stated that it expects to meet PDUFA’s updated timing goals, it has in the past provided its managers discretion to miss them due to heightened agency workload or understaffing in the review divisions; accordingly, it remains unclear whether and to what extent the FDA will adhere to PDUFA timing goals in the future. If the FDA were to miss a PDUFA timing goal for one of our product candidates, the development and commercialization of the product candidate could be delayed. In addition, the Food and Drug Administration Amendments Act of 2007, or FDAAA, which was enacted in September 2007, expands the FDA’s authority to regulate drugs throughout the product life cycle, including enhanced authority to require post-approval studies and clinical trials. Other proposals have been made to impose additional requirements on drug approvals, further expand post-approval requirements and restrict sales and promotional activities. This legislation, and the additional proposals if enacted, may make it more difficult or burdensome for us or our potential future collaborators to obtain approval of our product candidates. Even if the FDA approves a product candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product, and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. The approval may also impose risk evaluation mitigation strategies, or REMS, on a product if the FDA believes there is a reason to monitor the safety of the drug in the market place. REMS may include requirements for additional training for health care professionals, safety communication efforts and limits on channels of distribution, among other things. The sponsor would be required to evaluate and monitor the various REMS activities and adjust them if need be. The FDA also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.

Furthermore, the approval procedure and the time required to obtain approval varies among countries and can involve additional testing beyond that required by the FDA. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions.

The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. For example, in October 2009, we received a Complete Response Letter from the FDA regarding our NDA for toremifene 80 mg to reduce fractures in men with prostate cancer on ADT notifying us that the FDA would not approve our NDA as a result of certain clinical deficiencies identified in the Complete Response Letter. We have since discontinued our toremifene 80 mg development program, as well as our other toremifene-based products and terminated our license and supply agreement with Orion for toremifene products. While we have met with the FDA to discuss the development program and required endpoints to obtain approval of enobosarm, there can be no assurance that the FDA will ultimately determine that data from our current pivotal Phase III clinical trials of enobosarm will be sufficient for approval of this product candidate. Additionally, there can be no assurance that the FDA will determine that the data from our ongoing clinical trial or future clinical trials of Capesaris^® will be sufficient for approval of this product candidate in any indication. For example, we may observe an unacceptable incidence of adverse events in our ongoing, planned or potential future clinical trials of enobosarm or Capesaris^®, which could require us to abandon the development of the affected product candidate.

In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent regulatory approval of a product candidate. Even if we submit an application to the FDA for marketing approval of a product candidate, it may not result in marketing approval from the FDA.

We do not expect to receive regulatory approval for the commercial sale of any of our product candidates that are in development in the near future, if at all. The inability to obtain FDA approval or approval from comparable authorities in other countries for our product candidates would prevent us or any potential future collaborators from commercializing these product candidates in the United States or other countries. See the section entitled “Business — Government Regulation” under Part 1, Item 1 of our Annual Report on Form 10-K, filed with the SEC on March 2, 2012, for additional information regarding risks associated with marketing approval, as well as risks related to potential post-approval requirements.

Risks Related to Commercialization

The commercial success of any products that we and/or any potential future collaborators may develop will depend upon the market and the degree of market acceptance among physicians, patients, health care payors and the medical community.

Any products that we and/or any potential future collaborators may develop may not gain market acceptance among physicians, patients, health care payors and the medical community. If these products do not achieve an adequate level of acceptance, we may not generate material product revenues or receive royalties to the extent we currently anticipate, and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

•

efficacy and safety results in clinical trials;

•

the prevalence and severity of any side effects;

•

potential advantages over alternative treatments;

•

whether the products we commercialize remain a preferred course of treatment;

•

the ability to offer our product candidates for sale at competitive prices;

•

relative convenience and ease of administration;

•

the strength of marketing and distribution support; and

•

sufficient third-party coverage or reimbursement.

If we are unable to establish sales and marketing capabilities or establish and maintain agreements with third parties to market and sell our product candidates, we may be unable to generate product revenue from such candidates.

We have limited experience as a company in the sales, marketing and distribution of pharmaceutical products. In the event one of our product candidates is approved, we will need to establish sales and marketing capabilities or establish and maintain agreements with third parties to market and sell our product candidates. We may be unable to build our own sales and marketing capabilities, and there are risks involved with entering into arrangements with third parties to perform these services, which could delay the commercialization of any of our product candidates if approved for commercial sale. In addition, to the extent that we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues are likely to be lower than if we market and sell any products that we develop ourselves.

If we and/or any potential future collaborators are unable to obtain reimbursement or experience a reduction in reimbursement from third-party payors for products we sell, our revenues and prospects for profitability will suffer.*

Sales of products developed by us and/or any potential future collaborators are dependent on the availability and extent of reimbursement from third-party payors. Changes in the reimbursement policies of these third-party payors that reduce reimbursements for any products that we and/or any potential future collaborators may develop and sell could negatively impact our future operating and financial results.

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 established comprehensive Medicare coverage and reimbursement of prescription drugs under Medicare Part D. Product candidates currently in development as oral drug products capable of self-administration by patients would likely be covered by Medicare Part D (if covered by Medicare at all). The prescription drug program established by this legislation may have the effect of reducing the prices that we or any potential future collaborators are able to charge for products we and/or any potential future collaborators develop and sell through the program. In March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. This health care reform legislation will increase the number of individuals who receive health insurance coverage and will close a gap in drug coverage under Medicare Part D as established in 2003. However, the legislation also implements cost containment measures that could adversely affect our revenues. These measures include increased drug rebates under Medicaid for brand name prescription drugs and extension of these rebates to Medicaid managed care, each of which would reduce the amount of net reimbursement for any products that we and/or any potential future collaborators may develop and sell. The legislation also extended 340B discounted pricing on outpatient drugs to children’s hospitals, critical access hospitals, and rural health centers, which has reduced the amount of reimbursement received for drugs purchased by these new 340B-covered entities.

Additional provisions of the health care reform legislation may negatively affect our revenues and prospects for profitability in the future. Along with other pharmaceutical manufacturers and importers of brand name prescription drugs, we would be assessed a fee based on our proportionate share of sales of brand name prescription drugs to certain government programs, including Medicare and Medicaid, made in the preceding year if such sales exceed a defined threshold. As part of the health care reform legislation’s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program (commonly known as the “donut hole”), as of January 1, 2011, we would be required to provide a 50% discount on brand name prescription drugs sold to beneficiaries who fall within the donut hole.

The health care reform legislation has been subject to political and judicial challenge. In 2012, the Supreme Court considered the constitutionality of certain provisions of the law. The court upheld as constitutional the mandate for individuals to obtain health insurance but held that the provision allowing the federal government to withhold certain Medicaid funds to states that do not expand state Medicaid programs was unconstitutional. The impact of the court’s ruling remains uncertain. Political and judicial challenges to the law may continue in the wake of the court’s ruling.

Economic pressure on state budgets may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization for use of drugs where supplemental rebates are not provided. Private health insurers and managed care plans are likely to continue challenging the prices charged for medical products and services, and many of these third-party payors may limit reimbursement for newly-approved health care products. In particular, third-party payors may limit the indications for which they will reimburse patients who use any products that we and/or any potential future collaborators may develop or sell. These cost-control initiatives could decrease the price we might establish for products that we or any potential future collaborators may develop or sell, which would result in lower product revenues or royalties payable to us.

Similar cost containment initiatives exist in countries outside of the United States, particularly in the countries of the European Union, where the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take six to twelve months or longer after the receipt of regulatory marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or any potential future collaborators may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our or a potential future collaborators’ commercialization efforts. Third-party payors are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly-approved health care products. In particular, third-party payors may limit the indications for which they will reimburse patients who use any products that we and/or any potential future collaborators may develop or sell. Cost-control initiatives could decrease the price we might establish for products that we or any potential future collaborators may develop or sell, which would result in lower product revenues or royalties payable to us.

Another development that could affect the pricing of drugs would be if the Secretary of Health and Human Services allowed drug reimportation into the United States. The Medicare Prescription Drug, Improvement and Modernization Act of 2003 gives discretion to the Secretary of Health and Human Services to allow drug reimportation into the United States under some circumstances from foreign countries, including from countries where the drugs are sold at a lower price than in the United States. If the circumstances were met and the Secretary exercised the discretion to allow for the direct reimportation of drugs, it could decrease the price we or any potential future collaborators receive for any products that we and/or any potential future collaborators may develop, negatively affecting our revenues and prospects for profitability.

Health care reform measures could hinder or prevent our product candidates’ commercial success.

Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting health care reform, as evidenced by the enactment in the United States of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act in 2010. It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing health care legislation. These changes adopted by governments may adversely impact our business by lowering the price of health care products in the United States and elsewhere.

We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, method of delivery or payment for health care products and services, or sales, marketing and pricing practices could negatively impact our business, operations and financial condition.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any products that we may develop.*

We face an inherent risk of product liability exposure related to our prior commercial sales of FARESTON^® and the testing of our product candidates in human clinical trials, and we will face an even greater risk if we commercially sell any product that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

•

decreased demand for any product candidates or products;

•

injury to our reputation;

•

withdrawal of clinical trial participants;

•

costs to defend the related litigation;

•

substantial monetary awards to trial participants or patients;

•

loss of revenue; and

•

the inability to commercialize any products for which we obtain or hold marketing approvals.

We have product liability insurance that covers our clinical trials and any commercial products up to a $20 million annual aggregate limit. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost, and we may not be able to obtain insurance coverage that will be adequate to satisfy any liability that may arise.

If our competitors are better able to develop and market products than any products that we and/or any potential future collaborators may develop, our commercial opportunity will be reduced or eliminated.*

We face competition from commercial pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we and/or any potential future collaborators may develop. Competition could result in reduced sales and pricing pressure on our product candidates, if approved, which in turn would reduce our ability to generate meaningful revenue and have a negative impact on our results of operations. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.

Various products are currently marketed or used off-label for some of the diseases and conditions that we are targeting in our pipeline, and a number of companies are or may be developing new treatments. These product uses, as well as promotional efforts by competitors and/or clinical trial results of competitive products, could significantly diminish any ability to market and sell any products that we and/or any potential future collaborators may develop.

With respect to our SARM program, there are other SARM product candidates in development that may compete with enobosarm and any future SARM product candidates, if approved for commercial sale, including SARMs in development from Ligand Pharmaceuticals Inc., GlaxoSmithKline, and Bristol-Myers Squibb Company. Pfizer Inc., Eli Lilly & Co. and Amgen have myostatin inhibitors in development that may compete with enobosarm if approved for commercial sale. In addition, Cytokinetics, Inc. is developing a troponin activator with a muscle specific mechanism in Phase II studies, with a focus on neurological muscle diseases (amyotrophic lateral sclerosis and myasthenia gravis) and Novartis AG is developing a human monoclonal antibody for various muscle indications. Moreover, there are other categories of drugs in development, including ghrelin receptor agonists, growth hormone, secretagogues, inflammatory modulators and other agents, that may have some muscle activity. Helsinn Group is developing anamorelin, a ghrelin receptor agonist, in Phase III clinical trials for treatment of cancer cachexia in patients with non-small cell lung cancer. Appetite stimulants such as Megace^® (megestrol acetate) and dronabinol are used off-label for the treatment of weight loss and the treatment of loss of appetite in patients with cancer.

We are developing Capesaris^® for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. There are various products approved or under clinical development to treat men with advanced prostate cancer who have castration resistant prostate cancer which may compete with Capesaris^®. Dendreon Corporation markets and sells Provenge^®, an autologous cellular immunotherapy, for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. Zytiga^®, sold by Johnson & Johnson, has been approved for the treatment of metastatic castration resistant prostate cancer in patients who have received prior chemotherapy. Medivation, Inc. has received approval for Xtandi^®, an oral androgen receptor antagonist, for the treatment of metastatic castration-resistant prostate cancer in men previously treated with docetaxel. Both Medivation, Inc. and Johnson & Johnson continue to develop Xtandi^® and Zytiga^® for men with castration resistant prostate cancer prior to receiving chemotherapy. Millennium: The Takeda Oncology Company is developing TAK-700 for the treatment of men with metastatic castrate resistant prostate cancer prior to chemotherapy and post docetaxel. Capesaris^® is being developed as a treatment for this same patient population prior to the initiation of chemotherapy.

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.

Risks Related to Employees and Growth

If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop or commercialize our product candidates.

Our success depends on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. If we are not able to attract and keep senior management and key scientific personnel, particularly Dr. Mitchell S. Steiner, we may not be able to successfully develop or commercialize our product candidates. All of our employees are at-will employees and can terminate their employment at any time. We do not carry “key person” insurance covering members of senior management, other than $22.5 million of insurance covering Dr. Steiner.

In December 2009, we announced a reduction of approximately 26% of our workforce in order to reduce our operating expenses in connection with the receipt of the Complete Response Letter regarding our NDA for toremifene 80 mg. We also announced a reduction of approximately 15% of our workforce in June 2011 in connection with our decision to discontinue the development of toremifene 80 mg and toremifene 20 mg. These and any future workforce reductions may negatively affect our ability to retain or attract talented employees.

We will need to hire additional employees in order to commercialize our product candidates in the future. Any inability to manage future growth could harm our ability to commercialize our product candidates, increase our costs and adversely impact our ability to compete effectively.

In order to commercialize our product candidates in the future, we may need to hire experienced sales and marketing personnel to sell and market those product candidates we decide to commercialize, and we will need to expand the number of our managerial, operational, financial and other employees to support commercialization. Competition exists for qualified personnel in the biotechnology field.

Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

Risks Related to Our Common Stock

Market volatility may cause our stock price and the value of your investment to decline.*

The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be so in the future. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:

•

delays in the initiation, enrollment or completion of our ongoing and planned clinical trials of enobosarm and Capesaris^®, or negative or inconclusive results reported in any of our ongoing and planned clinical trials of enobosarm and Capesaris^®;

•

reports of unacceptable incidences of adverse events observed in any of our ongoing and planned clinical trials of enobosarm and Capesaris^®;

•

our ability to enter into new collaborative arrangements with respect to our product candidates;

•

the terms and timing of any future collaborative, licensing or other arrangements that we may establish;

•

our ability to raise additional capital to carry through with our clinical development plans and current and future operations and the terms of any related financing arrangements;

•

the timing of achievement of, or failure to achieve, our and any potential future collaborators’ clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;

•

announcement of FDA approval or non-approval of our product candidates or delays in or adverse events during the FDA review process;

•

actions taken by regulatory agencies with respect to our product candidates or products, our clinical trials or our sales and marketing activities, including regulatory actions requiring or leading to restrictions, limitations and/or warnings in the label of an approved product candidate;

•

the commercial success of any product approved by the FDA or its foreign counterparts;

•

introductions or announcements of technological innovations or new products by us, our potential future collaborators, or our competitors, and the timing of these introductions or announcements;

•

market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular;

•

regulatory developments in the United States and foreign countries;

•

changes in the structure or reimbursement policies of health care payment systems;

•

any intellectual property infringement lawsuit involving us;

•

actual or anticipated fluctuations in our results of operations;

•

changes in financial estimates or recommendations by securities analysts;

•

hedging or arbitrage trading activity that may develop regarding our common stock;

•

sales of large blocks of our common stock;

•

sales of our common stock by our executive officers, directors and significant stockholders;

•

changes in accounting principles; and

•

the loss of any of our key scientific or management personnel.

The stock markets in general, and the markets for biotechnology stocks in particular, have experienced significant volatility that has often been unrelated to the operating performance of particular companies. The financial markets continue to face significant uncertainty, resulting in a decline in investor confidence and concerns about the proper functioning of the securities markets, which decline in general investor confidence has resulted in depressed stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These broad market fluctuations may adversely affect the trading price of our common stock.

In the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such litigation brought against us could result in substantial costs, which would hurt our financial condition and results of operations and divert management’s attention and resources, which could result in delays of our clinical trials or commercialization efforts.

Our executive officers, directors and largest stockholders have the ability to control all matters submitted to stockholders for approval.*

As of September 30, 2012, our executive officers, directors and holders of 5% or more of our outstanding common stock beneficially owned approximately 63.3% of our outstanding common stock, and our executive officers and directors alone beneficially owned approximately 38.2% of our outstanding common stock. As a result, these stockholders, acting together, may or will have the ability to control all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of this group of stockholders may not always coincide with our interests or the interests of other stockholders.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:

•

a classified Board of Directors;

•

a prohibition on actions by our stockholders by written consent;

•

the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and

•

limitations on the removal of directors.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Finally, these provisions establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon at stockholder meetings. These provisions would apply even if the offer may be considered beneficial by some stockholders.

If there are substantial sales of our common stock, the market price of our common stock could drop substantially, even if our business is doing well.*

For the 12-month period ended September 30, 2012, the average daily trading volume of our common stock on The NASDAQ Global Market was 316,408 shares. As a result, future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the then-prevailing market price of our common stock. As of September 30, 2012, we had 62,816,924 shares of common stock outstanding.

Moreover, J.R. Hyde, III and Oracle Partners, L.P., two of our largest stockholders, and certain of their affiliates, have rights, subject to some conditions, to require us to file registration statements covering the approximately 10.8 million shares of common stock they hold in the aggregate which are subject to registration rights or to include these shares in registration statements that we may file for ourselves or other stockholders. If any of these large stockholders were to sell large blocks of shares in a short period of time, the market price of our common stock could drop substantially.

ITEM 5.

OTHER INFORMATION

On September 24, 2012, we exercised our option to extend, for a term of two years, the term of that certain sublease agreement, dated October 1, 2009 (the “Lease”), with the University of Tennessee Research Foundation (successor-in-interest to TriStar Enterprises, Inc.) (“Landlord”) for the lease of approximately 53,000 square feet of laboratory and office space located at 3 North Dunlap Street, Memphis, TN (the “Premises”). As a result of exercise of our extension option, the term of the Lease was extended for a period of 24 months expiring on December 31, 2014, unless sooner terminated in accordance with the terms of the Lease. The monthly base rent under the Lease is equal to 98% of the Landlord’s actual operating costs in owning, maintaining, operating and repairing the Premises and the building in which the Premises are located (“the Landlord Operating Costs”). As a result of entering into a Memorandum of Understanding (MOU) with the Landlord concerning the Lease dated April 14, 2011, we agreed to reduce the amount of square feet which we occupy to 31,000 square feet in exchange for a reduction in our monthly base rent to 50% of the Landlord Operating Costs from May 1, 2011 until April 30, 2013. From May 1, 2013 through the end of the extended lease term, we will again lease 53,000 square feet of laboratory and office space at the Premises and our monthly base rent will revert back to 98% of the Landlord Operating Costs unless the parties decide to enter into a new MOU or extend the existing one. Under the terms of the Lease, we are also responsible for maintaining certain insurance policies during the remaining term of the Lease. In the event of a default of certain of our obligations under the Lease, the Landlord would have right to terminate the Lease. The foregoing is only a brief description of the material terms of the Lease and does not purport to be a complete statement of the rights and obligations of the parties under the Lease, and is qualified in its entirety by reference to (i) the Lease that is filed as Exhibit 10.55 to our Annual Report on Form 10-K for the year ended December 31, 2009 and filed with the SEC on March 15, 2010 and (ii) that certain Memorandum of Understanding with the Landlord concerning the Lease dated April 14, 2011 that is filed as an Exhibit 10.59 to our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 and filed with the SEC on August 9, 2011.

ITEM 6.

EXHIBITS

The exhibits listed on the accompanying Exhibit Index are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	GTx, Inc.

Date: November 8, 2012	By:	/s/ Mitchell S. Steiner
		Mitchell S. Steiner, Chief Executive Officer
		and Vice-Chairman of the Board of Directors

Date: November 8, 2012	By:	/s/ Mark E. Mosteller
		Mark E. Mosteller, Vice President
		and Chief Financial Officer

EXHIBIT INDEX


Number		Description
2.1†		Asset Purchase Agreement, dated as of September 28, 2012, by and between the Registrant and Strakan International S.á r.l.⁽¹⁾
3.1		Restated Certificate of Incorporation of GTx, Inc.⁽²⁾
3.2		Certificate of Amendment of Restated Certificate of Incorporation of GTx, Inc.⁽³⁾
3.3		Amended and Restated Bylaws of GTx, Inc.⁽⁴⁾
4.1		Reference is made to Exhibits 3.1, 3.2 and 3.3
4.2		Specimen of Common Stock Certificate⁽⁵⁾
4.3		Amended and Restated Registration Rights Agreement between Registrant and Oracle Partners, L.P. dated August 7, 2003⁽⁵⁾
4.4		Amended and Restated Registration Rights Agreement between Registrant and J. R. Hyde, III dated August 7, 2003⁽⁵⁾
4.5		Consent, Waiver and Amendment between the Registrant and Oracle Partners, L.P., Oracle Investment Management, Inc. and Oracle Institutional Partners, L.P. dated November 29, 2007⁽⁶⁾
4.6		Consent, Waiver and Amendment between Registrant and J. R. Hyde, III and Pittco Associates, L.P. dated December 3, 2007⁽⁶⁾
10.55		Sublease Agreement dated October 1, 2009 between the Registrant and the University of Tennessee Research Foundation⁽⁷⁾
10.59		Memorandum of Understanding dated April 14, 2011 between the Registrant and the University of Tennessee Research Foundation⁽⁸⁾
31.1*		Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
31.2*		Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
32.1*		Certification of Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)⁽⁹⁾
32.2*		Certification of Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)⁽⁹⁾
101.INS*		XBRL Instance Document⁽¹⁰⁾
101.SCH*		XBRL Taxonomy Extension Schema Document⁽¹⁰⁾
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document⁽¹⁰⁾
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document⁽¹⁰⁾
101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document⁽¹⁰⁾

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document⁽¹⁰⁾

†	Confidential treatment has been requested with respect to certain portions of this exhibit. This exhibit omits the information subject to this confidentiality request. Omitted portions have been filed separately with the SEC.

*	Filed herewith.

⁽¹⁾	Filed as the like numbered Exhibit to the Registrant’s Current Report on Form 8-K (File No. 000-50549), filed with the SEC on October 3, 2012, and incorporated herein by reference.

⁽²⁾	Filed as Exhibit 4.1 to the Registrant’s registration statement on Form S-3 (File No. 333-127175), filed with the SEC on August 4, 2005, and incorporated herein by reference.

⁽³⁾	Filed as the like numbered Exhibit to the Registrant’s Current Report on Form 8-K (File No. 000-50549), filed with the SEC on May 6, 2011, and incorporated herein by reference.

⁽⁴⁾	Filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 000-50549), filed with the SEC on July 26, 2007, and incorporated herein by reference.

⁽⁵⁾	Filed as the like numbered Exhibit to the Registrant’s registration statement on Form S-1 (File No. 333-109700), initially filed with the SEC on October 15, 2003, as amended, and incorporated herein by reference.

⁽⁶⁾	Filed as the like numbered Exhibit to the Registrant’s registration statement on Form S-3 (File No. 333-148321), filed with the SEC on December 26, 2007, and incorporated herein by reference.

⁽⁷⁾	Filed as the like numbered Exhibit to the Registrant’s Annual Report on Form 10-K (File No. 000-50549), filed with the SEC on March 15, 2010, and incorporated herein by reference.

⁽⁸⁾	Filed as the like numbered Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-50549), filed with the SEC on August 9, 2011, and incorporated herein by reference.

⁽⁹⁾

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

⁽¹⁰⁾

Pursuant to applicable securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

EX-31.1 2 d417950dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Mitchell S. Steiner, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of GTx, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2012

/s/ Mitchell S. Steiner

Mitchell S. Steiner, M.D., F.A.C.S.

Chief Executive Officer and

Vice-Chairman of the Board of Directors

EX-31.2 3 d417950dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Mark E. Mosteller, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of GTx, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2012

/s/ Mark E. Mosteller

Mark E. Mosteller, CPA

Vice President and Chief Financial Officer

EX-32.1 4 d417950dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U. S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GTx, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mitchell S. Steiner, Chief Executive Officer of the Company certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2012

/s/ Mitchell S. Steiner

Mitchell S. Steiner, M.D., F.A.C.S.

Chief Executive Officer and

Vice-Chairman of the Board of Directors

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 d417950dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U. S. C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GTx, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark E. Mosteller, Chief Financial Officer of the Company certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2012

/s/ Mark E. Mosteller

Mark E. Mosteller, CPA

Vice President and Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 6 gtxi-20120930.xml XBRL INSTANCE DOCUMENT 0001260990 gtxi:IpsenCollaborationAgreementMember 2011-01-01 2011-03-31 0001260990 gtxi:IpsenCollaborationAgreementMember 2006-09-30 0001260990 2011-09-30 0001260990 2010-12-31 0001260990 us-gaap:ResearchAndDevelopmentExpenseMember 2012-07-01 2012-09-30 0001260990 us-gaap:GeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0001260990 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-09-30 0001260990 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0001260990 us-gaap:ResearchAndDevelopmentExpenseMember 2011-07-01 2011-09-30 0001260990 us-gaap:GeneralAndAdministrativeExpenseMember 2011-07-01 2011-09-30 0001260990 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-09-30 0001260990 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-09-30 0001260990 us-gaap:DeferredCompensationShareBasedPaymentsMember 2012-07-01 2012-09-30 0001260990 us-gaap:DeferredCompensationShareBasedPaymentsMember 2012-01-01 2012-09-30 0001260990 us-gaap:DeferredCompensationShareBasedPaymentsMember 2011-07-01 2011-09-30 0001260990 us-gaap:DeferredCompensationShareBasedPaymentsMember 2011-01-01 2011-09-30 0001260990 gtxi:IpsenCollaborationAgreementMember 2006-09-01 2006-09-30 0001260990 2012-07-01 2012-09-30 0001260990 2011-07-01 2011-09-30 0001260990 2011-01-01 2011-09-30 0001260990 2012-09-30 0001260990 2011-12-31 0001260990 2012-11-05 0001260990 2012-01-01 2012-09-30 xbrli:pure iso4217:USD xbrli:shares iso4217:EUR xbrli:shares iso4217:USD

1. Business and Basis of Presentation Business GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. Additionally, the Company is developing Capesaris® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer. Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON ® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion. Basis of Presentation The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012. Use of Estimates The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.   Discontinued Operations On September 28, 2012, the Company entered into an asset purchase agreement (the “FARESTON ® Purchase Agreement”) with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON®. Effective September 30, 2012, the Company completed the sale of FARESTON® pursuant to the FARESTON ® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company has accounted for FARESTON® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. The Company has also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations. The Company has set forth the assets and liabilities relating to the FARESTON ® discontinued operations in Note 4, Discontinued Operations. See Note 4, Discontinued Operations, for further discussion. FARESTON ® Revenue Recognition Revenue from product sales of FARESTON®, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON ® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON ® by the Company prior to September 30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, the Company’s accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $528 and $715 have been included in “Other long-term liabilities” in the condensed balance sheets at September 30, 2012 and December 31, 2011, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year. See Note 4, Discontinued Operations, for further discussion. Collaboration Revenue Recognition Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company’s former collaboration and license agreements. Revenues from the Company’s prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note 5, Collaboration and License Agreements, for further discussion. Research and Development Expenses Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.   Cash, Cash Equivalents and Short-term Investments The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents. At September 30, 2012 and December 31, 2011, short-term investments consisted of Federal Deposit Insurance Corporation insured certificates of deposit with original maturities of greater than three months and less than one year. As the Company has the positive intent and ability to hold the certificates of deposit until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value. The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time. Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products. The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011. Income Taxes The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, at September 30, 2012 and December 31, 2011, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income taxes are described more fully in Note 9 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. The Company has recognized the tax effect of discontinued operations in the condensed statements of operations in accordance with the intra-period accounting rules. An offsetting tax benefit is recorded in continuing operations in each period.   Other (Expense) Income, net Other (expense) income, net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense. Reclassification Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion. Subsequent Events The Company has evaluated all events or transactions that occurred after September 30, 2012 up through the date the condensed financial statements were issued. There were no material recognizable or nonrecognizable subsequent events during the period evaluated.

2. Share-Based Compensation Share-based payments include stock option grants under the Company’s stock option and equity incentive plans and deferred compensation arrangements for the Company’s non-employee directors. The Company recognizes compensation expense for its share-based payments based on the fair value of the awards over the period during which an employee or non-employee director is required to provide service in exchange for the award. The Company’s share-based compensation plans are described more fully in Note 3 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="73%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months  Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Research and development expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">335</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">696</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,410</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> General and administrative expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">458</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,310</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,909</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total share-based compensation </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">793</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,126</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,006</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,319</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Share-based compensation expense recorded as general and administrative expense for the three months ended September 30, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $40 and $45, respectively. Share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $128 and $141 was included in share-based compensation expense recorded as general and administrative expenses for the nine months ended September 30, 2012 and 2011, respectively. Share-based compensation expense recorded as research and development expenses for the nine months ended September 30, 2012 was offset by the reversal of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the resignation of an executive officer during the nine months ended September 30, 2012. The Company uses the Black-Scholes-Merton option pricing valuation model to value stock options. The expected life of options is determined by calculating the average of the vesting term and the contractual term of the options. The expected price volatility is based on the Company’s historical stock price volatility. The risk-free interest rate is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock options. Expected dividend yield is not considered as the Company has not made any dividend payments and has no plans of doing so in the foreseeable future. The amount of share-based compensation expense recognized is reduced ratably over the vesting period by an estimate of the percentage of options granted that are expected to be forfeited or canceled before becoming fully vested.   The fair value of options granted was estimated using the following assumptions for the periods presented:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Expected price volatility </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65.3</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69.6</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.9</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Weighted average expected life in years </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> The following is a summary of stock option transactions for all of the Company’s stock option and equity incentive plans since the Company’s most recent fiscal year end:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price Per Share</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Options outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,945,565</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.12</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Options granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,129,250</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.34</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Options forfeited or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(669,754</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.86</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Options exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(26,701</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.07</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Options outstanding at September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,378,360</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.97</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr>  </table>

3. Basic and Diluted Net Loss Per Share Basic and diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of common shares outstanding during the period. Diluted net loss per share gives effect to the dilutive potential of common stock consisting of stock options. Weighted average options outstanding to purchase shares of common stock of 5,408,065 and 5,113,943 for the three months ended September 30, 2012 and 2011, respectively, and 5,639,672 and 5,455,700 for the nine months ended September 30, 2012 and 2011, respectively, were excluded from the calculations of diluted loss per share as inclusion of the options would have had an anti-dilutive effect on the net loss per share for the periods.

4. Discontinued Operations On September 28, 2012, the Company entered into the FARESTON ® Purchase Agreement with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights to FARESTON® and certain assets related thereto. Effective September 30, 2012, the Company completed the sale of FARESTON® pursuant to the FARESTON ® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company recognized a gain of $18,831 on the sale of FARESTON® for the three and nine months ended September 30, 2012. The gain represents the gross proceeds received from the sale reduced by a contract termination fee of $1,000 due to Orion (as discussed further in Note 5, Collaboration and License Agreements), a financial advisory fee related to the transaction of $1,712, and other transaction expenses of approximately $128. The Company has accounted for FARESTON® as a discontinued operation. The FARESTON ® operating income, along with the gain recognized on the sale of FARESTON ® for the three and nine months ended September 30, 2012, has been reported as “net income from discontinued operations” in the condensed statements of operations. In addition, the assets and liabilities related to FARESTON® that are included in the condensed balance sheets for the periods presented have been presented below.   FARESTON® operating income for each period presented was as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="72%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Product sales, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,826</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,029</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,294</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,903</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Cost of product sales </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(263</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(311</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(782</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(780</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(196</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(591</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,172</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> FARESTON® operating income </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,383</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,522</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,921</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">951</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Under the FARESTON ® Purchase Agreement, the Company remains responsible for and benefits from the collection of accounts receivable and remains liable for future product returns, in each case relating to sales of FARESTON® made by the Company prior to September 30, 2012. The Company has also recognized liabilities in its condensed balance sheet at September 30, 2012 for the $1,000 termination fee due to Orion and the $1,712 financial advisory fee related to the transaction within “accrued expenses and other current liabilities”. The assets and liabilities related to FARESTON ® discontinued operations included in the condensed balance sheets for the periods presented were as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="76%"> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Accounts receivable, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,152</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">981</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> FARESTON® sale proceeds receivable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,671</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Inventory </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">279</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,102</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,320</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Accrued expenses and other current liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,209</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">919</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Other long-term liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,772</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,750</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Net assets (liabilities) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,330</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(430</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

5. Collaboration and License Agreements Former Orion Corporation License and Supply Agreement In connection with the Company’s sale of its rights and certain assets related to FARESTON ® to ProStrakan, the Company and Orion agreed to terminate the Amended and Restated License and Supply Agreement, dated January 1, 2005, as amended, between the Company and Orion (the “Orion Supply Agreement”) as well as certain other agreements between the Company and Orion related to the Orion Supply Agreement (collectively, the “Orion Agreements”). Pursuant to the Orion Supply Agreement, the Company obtained an exclusive license from Orion to develop and commercialize toremifene-based products for all human indications worldwide, except breast cancer outside of the United States, and Orion agreed to manufacture and supply all of the Company’s needs for clinical trial and commercial grade material for toremifene-based products developed and marketed in the United States and abroad, including toremifene globally and FARESTON® in the United States. The termination of the Orion Agreements was effective September 30, 2012. As consideration for Orion’s agreement to terminate the Orion Agreements and to enter into certain agreements with the ProStrakan to effect the FARESTON ® sale, the Company paid Orion $1,000 in October 2012.   University of Tennessee Research Foundation License Agreements The Company and the University of Tennessee Research Foundation (“UTRF”) are parties to a consolidated, amended and restated license agreement (the “SARM License Agreement”) pursuant to which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or controlled by UTRF, including all improvements thereto, and exclusive rights to future SARM technology that may be developed by certain scientists at the University of Tennessee or subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and mid single-digit royalties on sublicense revenues. Former Ipsen Collaboration and License Agreement In September 2006, the Company entered into a collaboration and license agreement with Ipsen Biopharm Limited (the “Ipsen Collaboration Agreement”) pursuant to which the Company granted Ipsen exclusive rights in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of Independent States (the “European Territory”) to develop and commercialize toremifene in all indications which the Company has licensed from Orion, which include all indications in humans except the treatment and prevention of breast cancer outside of the United States. In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company €23,000 as a license fee and expense reimbursement. Under the Ipsen Collaboration Agreement, the Company recorded deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement which was being amortized into revenue on a straight-line basis over the estimated ten year development period for toremifene in the European Territory. In March 2011, the Company reacquired full rights to its toremifene program following the termination by the Company and Ipsen of the collaboration and license agreement, as amended. During the first quarter of 2011, the Company recognized as collaboration revenue all of the remaining $8,066 unamortized revenue. This amount is included in collaboration revenue in the condensed statement of operations for the nine months ended September 30, 2011.

Business GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. Additionally, the Company is developing Capesaris® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer. Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON ® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion.   Basis of Presentation The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012.

Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time. Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products. The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011.

Reclassification Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion.

The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="73%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months  Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Research and development expenses </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">335</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">696</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,410</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> General and administrative expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">458</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,310</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,909</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total share-based compensation </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">793</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,126</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,006</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,319</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

The fair value of options granted was estimated using the following assumptions for the periods presented:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Expected price volatility </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65.3</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69.6</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.9</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Weighted average expected life in years </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5 years</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

FARESTON® operating income for each period presented was as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="72%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Product sales, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,826</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,029</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,294</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,903</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Cost of product sales </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(263</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(311</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(782</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(780</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating expenses </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(196</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(591</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,172</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> FARESTON® operating income </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,383</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,522</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,921</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">951</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   The assets and liabilities related to FARESTON ® discontinued operations included in the condensed balance sheets for the periods presented were as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="76%"> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Accounts receivable, net </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,152</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">981</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> FARESTON® sale proceeds receivable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,671</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Inventory </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Prepaid expenses and other assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">279</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total assets </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,102</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,320</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Accounts payable </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Accrued expenses and other current liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,209</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">919</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Other long-term liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">528</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total liabilities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,772</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,750</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Net assets (liabilities) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,330</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(430</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> false --12-31 Q3 2012 2012-09-30 10-Q 0001260990 62816924 Accelerated Filer GTX INC /DE/ 1114000 1189000 715000 528000 55529320 62778575 62806440 62815549 greater than three months and less than one year 8066000 1000000 P10Y 141000 128000 981000 1152000 178000 279000 1712000 23000000 -430000 18330000 128000 63000 67000 141000 45000 128000 40000

21671000

1219000

1214000

981000

1152000

4142000

10263000

457985000

460073000

3319000

1909000

1410000

1126000

623000

503000

2006000

1310000

696000

793000

458000

335000

5455700

5113943

5639672

5408065

78184000

72168000

76848000

71342000

1320000

23102000

58181000

73296000

63745000

38731000

15115000

-25014000

0.001

120000000

62790223

62816924

62790223

62816924

63000

29330000

819000

596000

18831000

951000

1522000

22752000

20214000

398000

591000

8848000

7861000

116000

35000

919000

4209000

780000

311000

782000

263000

161000

3172000

196000

591000

180000

951000

1522000

3921000

1383000

715000

528000

4903000

2029000

5294000

1826000

-0.41

-0.15

-0.22

0.12

240000

186000

8886000

2708000

7987000

2999000

10695000

8555000

1598000

-23165000

-10275000

-27961000

-4949000

-23563000

-10866000

-36809000

-12810000

-0.42

-0.16

-0.44

-0.08

553000

931000

13904000

12353000

0.01

0.22

0.20

-398000

-591000

-8848000

-7861000

-19000

-12000

147000

171000

1062000

3258000

27000

-133000

476000

-34000

161000

78184000

72168000

5361000

11477000

1750000 4772000

48974000

15000

-9310000

2015000

-24549000

-27044000

-22612000

-9344000

-14057000

7404000

31961000

10889000

36823000

12763000

-23895000

-10889000

-36823000

-12763000

949000

786000

332000

23000

14000

-47000

12450000

7815000

45000

125000

1266000

1233000

21671000

48982000

3185000

9955000

55000

82000

1096000

640000

8066000

23075000

8181000

28836000

9764000

-386174000

-400231000

3178000

1878000

P6Y6M

0.649

0.653

0.696

0.738

0.025

0.023

0.012

0.011

669754

8.86

1129250

4945565

5378360

9.12

7.97

3.07

3.34

71874000

59905000

26701

EX-101.SCH 7 gtxi-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 0504 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 06042 - Disclosure - Discontinued Operations (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06041 - Disclosure - Discontinued Operations (Details 1) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Basic and Diluted Net Loss Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Basic and Diluted Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Collaboration and License Agreements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Business and Basis of Presentation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06023 - Disclosure - Share-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0401 - Disclosure - Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 06022 - Disclosure - Share-Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 06021 - Disclosure - Share-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 0502 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Collaboration and License Agreements link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0110 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 0111 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0120 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 gtxi-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 gtxi-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 gtxi-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Balance Sheets [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Short-term investments Held-to-maturity Securities, Current Accounts receivable, net Accounts Receivable, Net, Current Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current, Total Property and equipment, net Property, Plant and Equipment, Net Intangible and other assets, net Finite-Lived Intangible Assets, Net Total assets Assets, Total LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Total current liabilities Liabilities, Current, Total Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value: 120,000,000 shares authorized at both September 30, 2012 and December 31, 2011; 62,816,924 and 62,790,223 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent, Total Total liabilities and stockholders' equity Liabilities and Equity, Total Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Condensed Statements of Operations [Abstract] Revenues: Revenues [Abstract] Collaboration Revenue Collaboration revenue Collaboration revenue consists of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the company's collaboration and license agreements. Collaboration revenue is recognized based on the performance requirements of the specific agreements. Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Loss from operations Operating Income (Loss) Other (expense) income, net Other Nonoperating Income (Expense) Net income (loss) Net loss Net Income (Loss) Attributable to Parent Net income (loss) per share - basic and diluted: Basic and Diluted Net Loss Per Share [Abstract] Net income (loss) per share Earnings Per Share, Basic and Diluted Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and Diluted Weighted Average Number of Shares Basic and diluted The weighted average number of shares outstanding for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share. Basic weighted average shares outstanding represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Diluted weighted average shares outstanding represents the average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Condensed Statements of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Compensation Director Deferred Compensation Directors' deferred compensation Fees earned by non-employee directors under the company's directors' deferred compensation plan which will be paid out in the form of company common stock. Collaboration revenue Deferred revenue amortization Recognition of Deferred Revenue Impairment of intangible assets Impairment of Intangible Assets, Finite-lived Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of short-term investments, held to maturity Payments to Acquire Held-to-maturity Securities Proceeds from maturities of short-term investments, held to maturity Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Payments on Capital Lease and Financed Equipment Obligations Payments on capital lease and financed equipment obligations Payments on capital lease and financed equipment obligations. Proceeds from exercise of employee stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Business and Basis of Presentation [Abstract] Business and Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Basic and Diluted Net Loss Per Share Earnings Per Share [Text Block] Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Business [Policy Text Block] Business Disclosure of the nature of the business. Basis of Presentation [Policy Text Block] Basis of Presentation Disclosure of the basis of presentation, which describes the underlying basis used to prepare the financial statements. Use of Estimates Use of Estimates, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Cash Cash Equivalents and Short Term Investments [Policy Text Block] Cash, Cash Equivalents and Short-term Investments Disclosure of accounting policy for cash, cash equivalents and short-term investments. Income Taxes Income Tax, Policy [Policy Text Block] Subsequent Events Subsequent Events, Policy [Policy Text Block] Summary of Share-based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Fair Value of Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Stock Option Transactions Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Research and Development Expense [Member] Research and Development Expense [Member] General and Administrative Expense [Member] General and Administrative Expense [Member] Plan Name [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Total share-based compensation Allocated Share-based Compensation Expense Certificates of Deposit Maturity Period Certificates of deposit, original maturities Certificates of deposit, original maturities period. Net deferred tax assets Deferred Tax Assets, Net Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Summary of Share-Based Compensation Expense [Abstract] Summary of Share-Based Compensation Expense Summary of share based compensation expense. Fair Value of Options Granted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Summary of Stock Option Transactions Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Number of Shares, Options forfeited or expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Weighted Average Exercise Price Per Share Options forfeited or expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Number of Shares Options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Shares Options outstanding at December 31, 2011 Number of Shares Options outstanding at September 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Weighted Average Exercise Price Per Share Options outstanding at December 31, 2011 Weighted Average Exercise Price Per Share Options outstanding at September 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Deferred Compensation Arrangements [Member] Deferred Compensation, Share-based Payments [Member] Share Based Compensation (Textual) [Abstract] Share-Based Compensation (Textual) [Abstract] Share based compensation. Share Based Compensation Expense Allocated for Directors Deferred Compensation Arrangements Share-based compensation charge related to deferred compensation arrangements for non-employee directors Share-based compensation expense related to deferred compensation arrangements for the Company's non-employee directors. Earnings Per Share (Textual) [Abstract] Basic and Diluted Net Loss Per Share (Textual) [Abstract] Earnings per share. Weighted average options outstanding to purchase shares of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue Recognition, Multiple-deliverable Arrangements [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Ipsen Collaboration Agreement [Member] Ipsen Collaboration Agreement [Member] Ipsen collaboration agreement. Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Collaboration and License Agreements (Textual) [Abstract] Collaboration and License Agreements (Textual) [Abstract] Collaboration and license agreements. License Fee and Expense Reimbursement License fee and expense reimbursement License and expense reimbursement received under collaborative arrangements. Deferred revenue related to upfront license fee Deferred Revenue Deferred Revenue Amortization Period Development period Deferred revenue amortization period. Share-Based Compensation [Abstract] Weighted Average Exercise Price Per Share Options exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Collaboration and License Agreements [Abstract] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Accrual for Product Returns Accrual for product returns The estimated liability for future product returns of product sold. Net loss from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Net income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss from continuing operations Income (Loss) from Continuing Operations, Per Basic and Diluted Share Net income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Per Basic and Diluted Share Discontinued Operations [Abstract] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Discontinued Operations, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] FARESTON sale proceeds receivable Accounts and Other Receivables, Net, Current Income tax benefit Income Tax Expense (Benefit) Income from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Accrual For Product Returns Included In Other Long Term Liabilities Accrual for product returns included in other long term liabilities Portion of the entity's product returns accrual estimated to be payable after one year. FARESTON operating income Disposal Group, Including Discontinued Operation, Operating Income (Loss) Operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Cost of product sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Product sales, net Disposal Group, Including Discontinued Operation, Revenue Operating Income Related to Discontinued Operations Disposal Group Not Discontinued Operation Income Statement Disclosures [Abstract] Disposal Group Including Discontinued Operation Accounts Receivable Net Accounts receivable, net For the disposal group, including a component of the entity (discontinued operation), the aggregate of amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business. Disposal Group Including Discontinued Operation Prepaid Expenses and Other Assets Prepaid expenses and other assets For the disposal group, including a component of the entity (discontinued operation), the total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of assets, as of the balance sheet date, not otherwise specified. Inventory Disposal Group, Including Discontinued Operation, Inventory Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Accrued expenses and other current liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Other long-term liabilities Disposal Group, Including Discontinued Operation, Other Noncurrent Liabilities Discontinued Operations (Textual) [Abstract] Discontinued Operations (Textual) [Abstract] Collaboration and License Agreements (Additional Textual) [Abstract] Collaboration and License Agreements (Additional Textual) [Abstract] Loss from operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Assets and Liabilities Related to Discontinued Operations Disposal Group, Including Discontinued Operation, Unclassified Balance Sheet Disclosures [Abstract] Total assets Assets of Disposal Group, Including Discontinued Operation Expenses: Operating Expenses [Abstract] General and administrative expenses General and Administrative Expense Total expenses Operating Expenses Business and Basis of Presentation (Textual) [Abstract] Business and Basis of Presentation (Textual) [Abstract] Weighted Average Exercise Price Per Share Options granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Discontinued Operation, Tax Effect of Discontinued Operation Income tax expense Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale of FARESTON Revenue Recognition, Sales of Goods [Policy Text Block] FARESTON Revenue Recognition Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block] Collaboration Revenue Recognition Other Expense Income Net [Policy Text Block] Other (Expense) Income, net Disclosure of the components of Other (Expense) Income, Net. Operating Income Related to Discontinued Operations [Table Text Block] Tabular disclosure of operating income reported in discontinued operations. Operating Income Related to Discontinued Operations Assets Liabilities Related to Discontinued Operations [Table Text Block] Assets and Liabilities Related to Discontinued Operations Tabular disclosure of the assets and liabilities related to discontinued operations. Proceeds from Divestiture of Businesses Proceeds from the sale of FARESTON Net Assets or Liabilities of Disposal Group Including Discontinued Operations Net assets (liabilities) For the disposal group, including a component of the entity (discontinued operation), carrying value of total assets less total liabilities. Contract Termination Fee Related to Discontinued Operations Contract termination fee Contract termination fee related to discontinued operations. Financial Advisory Fee Related to Discontinued Operations Financial advisory fee Financial advisory fee related to discontinued operations. Other transaction expenses Other transaction expenses related to discontinued operations. Other Transaction Expenses Related to Discontinued Operations Aggregate Value Of Liabilities Of Disposal Group Including Discontinued Operation Total liabilities The aggregate value for liabilities of a disposal group, including a component of the entity (discontinued operation), to be sold or that has been disposed of through sale, as of the financial statement date. EX-101.PRE 11 gtxi-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Sep. 30, 2012

Discontinued Operations [Abstract]

Discontinued Operations

4. Discontinued Operations

On September 28, 2012, the Company entered into the FARESTON ^® Purchase Agreement with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights to FARESTON^® and certain assets related thereto. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON ^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company recognized a gain of $18,831 on the sale of FARESTON^® for the three and nine months ended September 30, 2012. The gain represents the gross proceeds received from the sale reduced by a contract termination fee of $1,000 due to Orion (as discussed further in Note 5, Collaboration and License Agreements), a financial advisory fee related to the transaction of $1,712, and other transaction expenses of approximately $128.

The Company has accounted for FARESTON^® as a discontinued operation. The FARESTON ^® operating income, along with the gain recognized on the sale of FARESTON ^® for the three and nine months ended September 30, 2012, has been reported as “net income from discontinued operations” in the condensed statements of operations. In addition, the assets and liabilities related to FARESTON^® that are included in the condensed balance sheets for the periods presented have been presented below.

FARESTON^® operating income for each period presented was as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Product sales, net	$	1,826		$	2,029		$	5,294		$	4,903
Cost of product sales		(263	)		(311	)		(782	)		(780	)
Operating expenses		(180	)		(196	)		(591	)		(3,172	)

FARESTON^® operating income	$	1,383		$	1,522		$	3,921		$	951


	September 30,		December 31,
	2012		2011
Accounts receivable, net	$	1,152	$	981
FARESTON^® sale proceeds receivable		21,671		—
Inventory		—		161
Prepaid expenses and other assets		279		178

Total assets		23,102		1,320

Accounts payable		35		116
Accrued expenses and other current liabilities		4,209		919
Other long-term liabilities		528		715

Total liabilities		4,772		1,750

Net assets (liabilities)	$	18,330	$	(430	)

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43-48

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E-3)C,C=D.%\X,C0P7S1B,3!?.35C85]D.64S M-&9F.&8P830B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D-O;&QA8F]R871I;VY?86YD7TQI M8V5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D)U#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D1I#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D1I#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z M4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H M96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E M;F5D('=I=&@@36EC'1087)T7V4U,F,R-V0X M7S@R-#!?-&(Q,%\Y-6-A7V0Y93,T9F8X9C!A-`T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B]E-3)C,C=D.%\X,C0P7S1B,3!?.35C85]D.64S-&9F M.&8P830O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^1U18($E.0R`O1$4O/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^4V5P(#,P+`T*"0DR,#$R/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^9F%L M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^+2TQ,BTS,3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-3)C,C=D.%\X M,C0P7S1B,3!?.35C85]D.64S-&9F.&8P830-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO934R8S(W9#A?.#(T,%\T8C$P7SDU8V%?9#EE,S1F9CAF M,&$T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E2!A;F0@97%U:7!M96YT+"!N970\+W1D M/@T*("`@("`@("`\=&0@8VQA'!E;G-E M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`L,#`P+#`P,#QS<&%N M/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'!E;G-E'!E;G-E M*2!I;F-O;64L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@ M97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C4I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5R8VES92!O9B!E;7!L;WEE92!S=&]C:R!O<'1I;VYS/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,CQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-3)C,C=D.%\X M,C0P7S1B,3!?.35C85]D.64S-&9F.&8P830-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO934R8S(W9#A?.#(T,%\T8C$P7SDU8V%?9#EE,S1F9CAF M,&$T+U=O'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A M9V=E9"!.;W1E(#$@+2!U'1";&]C:RTM/@T*("`@/"$M+2!X8G)L+&YS M("TM/@T*("`@/"$M+2!X8G)L+&YX("TM/@T*("`@/&9O;G0@3IT:6UEF4],T0R/CQB/C$N($)U6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/@T*("`@1U1X+"!);F,N M("@F(S@R,C`[1U1X)B,X,C(Q.R!O3IT:6UEF4],T0R/E1H92!#;VUP86YY(&ES(&1E=F5L;W!I;F<@ M6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/D%D9&ET:6]N86QL>2P@=&AE($-O;7!A;GD@:7,-"B`@(&1E=F5L;W!I;F<@ M0V%P97-A2P@87,@82!P M2!A;F0@969F:6-A8WD@;V8@=&AR964@;&]W97(@9&]S M97,@;V8-"B`@($-A<&5S87)I6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D5F9F5C=&EV92!397!T96UB M97(F(S$V,#LS,"P@,C`Q,BP@=&AE($-O;7!A;GD@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$;6%R9VEN M+71O<#HQ.'!X.VUA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2P@:6YF;W)M871I;VX@86YD(&9O M;W1N;W1E(&1I3IT:6UEF4],T0R/CQB/CQI/E5S92!O9B!%'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/@T*("`@5&AE('!R M97!A2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871EF4Z,7!X.VUA#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S M='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.C0E.W!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0Q/@T*("`@/'-U<#XF6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q/CQS=7`^)G)E M9SL\+W-U<#X\+V9O;G0^(&%S(&$@9&ES8V]N=&EN=65D(&]P97)A=&EO;BX@ M07,@82!R97-U;'0L(')E=F5N=64L(&-O3IT:6UEF4],T0Q/CQS=7`^)G)E9SL\+W-U<#X\+V9O;G0^(&AA=F4@8F5E;B!E>&-L M=61E9"!F2!H87,@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/CQB/CQI/D9!4D535$]./"]I/CPO M8CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQS=7`^#0H@("`FF5D(&QE2!S;VQD(&ETF4],T0Q M/CQS=7`^#0H@("`F2!R971A:6YS('1H92!L M:6%B:6QI='D@9F]R(&9U='5R92!P3IT:6UEF4],T0Q/@T*("`@/'-U<#XF28C.#(Q-SMS M(&%C8W)U86P@9F]R#0H@("!P28C M.#(Q-SMS('!R;V1U8W0@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/CQB/CQI/D-O;&QA8F]R871I M;VX@4F5V96YU92!296-O9VYI=&EO;B`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@ M("`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`[/"]P/@T*("`@/'`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`@5&AE($-O;7!A;GD@86-C;W5N=',@9F]R M(&1E9F5R&5S(&)Y(')E8V]G;FET:6]N(&]F(&1E9F5R"!A"!C;VYS97%U96YC97,@;V8@979E;G1S('1H870@:&%V92!B965N M(&EN8VQU9&5D(&EN('1H92!F:6YA;F-I86P@"!R871E"!A'0M:6YD96YT.C0E)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/E1H92!#;VUP86YY(&AAF5D('1H92!T87@@969F96-T M(&]F(&1I"!B96YE9FET(&ES(')E8V]R9&5D(&EN(&-O;G1I;G5I;F<@ M;W!E6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN M+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQB/CQI/D]T:&5R M("A%>'!E;G-E*2!);F-O;64L(&YE="`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@ M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/CQB/CQI/E-U8G-E<75E M;G0@179E;G1S(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$ M)VUA2!H87,@979A;'5A=&5D(&%L;"!E M=F5N=',@;W(@=')A;G-A8W1I;VYS('1H870@;V-C=7)R960@869T97(@4V5P M=&5M8F5R)B,Q-C`[,S`L(#(P,3(@=7`@=&AR;W5G:"!T:&4@9&%T92!T:&4@ M8V]N9&5NF%B;&4@;W(@;F]N M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0M:6YD96YT.C0E)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/E-H87)E+6)A6UE;G1S(&EN8VQU9&4@28C.#(Q-SMS('-T;V-K(&]P=&EO;B!A M;F0@97%U:71Y(&EN8V5N=&EV92!P;&%N65E(&1I6UE;G1S(&)A&-H86YG92!F;W(@=&AE(&%W87)D+B!4:&4@ M0V]M<&%N>28C.#(Q-SMS('-H87)E+6)A'0M:6YD96YT.C0E)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/E1H92!F;VQL;W=I;F<@=&%B;&4-"B`@('-U;6UAF4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P M>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O MF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/E1HF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/C(P,3$\ M+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C0U.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]TF4Z M,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@6QE/3-$)V)O M6QE/3-$ M)V)O3IT:6UEF4],T0R/E1O=&%L('-H87)E+6)A3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/C(L,#`V/"]F;VYT/CPO=&0^(`T* M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0M:6YD96YT.C0E M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E-H87)E+6)A'!E;G-E(')E M8V]R9&5D(&%S(&=E;F5R86P@86YD(&%D;6EN:7-T'!E;G-E(')E;&%T960@=&\@9&5F97)R960@8V]M<&5N'!E;G-E(')E;&%T960@ M=&\@9&5F97)R960-"B`@(&-O;7!E;G-A=&EO;B!A65E(&1I'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/@T*("`@5&AE($-O;7!A;GD@ M=7-E'!E8W1E9"!L:69E(&]F(&]P=&EO;G,@:7,@9&5T97)M:6YE9"!B>2!C86QC M=6QA=&EN9R!T:&4@879E'!E8W1E9"!P'!E;G-E(')E8V]G;FEZ960@:7,@2!A M;B!E2!V97-T960N(#PO9F]N=#X\+W`^ M#0H@("`\<"!S='EL93TS1&9O;G0M6QE/3-$ M)VUAF4Z,3)P>#MM87)G:6XM=&]P.C!P M>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D M97(],T0P('-T>6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/CQB/E1HF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8U+C,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W M3IT:6UEF4],T0R/B4F(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C$N,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(N,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/C$N,CPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(N-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@65A3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C8N-28C,38P.WEE87)S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@ M/'`@2!O9B!S=&]C:R!O<'1I;VX-"B`@('1R86YS86-T:6]NF4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L&5R8VES92!0F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@V-CDL-S4T/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/D]P=&EO;G,@97AE6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,N,#<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]TF4Z,7!X/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`S("T@=7,M9V%A M<#I%87)N:6YG#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB M/C,N($)A6QE/3-$)VUA'0M:6YD96YT.C0E M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@5V5I9VAT960@879E2P@86YD(#4L-C,Y+#8W,B!A;F0@-2PT-34L-S`P#0H@("!F;W(@ M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!" M;&]C:R!486=G960@3F]T92`T("T@=7,M9V%A<#I$:7-P;W-A;$=R;W5P3IT:6UEF4],T0R/CQB/C0N($1I'0M:6YD96YT.C0E.W!A9&1I M;F XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basic and Diluted Net Loss Per Share
9 Months Ended

Sep. 30, 2012

Basic and Diluted Net Loss Per Share [Abstract]

Basic and Diluted Net Loss Per Share
3. Basic and Diluted Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders is calculated based on the weighted average number of common shares outstanding during the period. Diluted net loss per share gives effect to the dilutive potential of common stock consisting of stock options.

Weighted average options outstanding to purchase shares of common stock of 5,408,065 and 5,113,943 for the three months ended September 30, 2012 and 2011, respectively, and 5,639,672 and 5,455,700 for the nine months ended September 30, 2012 and 2011, respectively, were excluded from the calculations of diluted loss per share as inclusion of the options would have had an anti-dilutive effect on the net loss per share for the periods.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2012

Dec. 31, 2011

Current assets:

Cash and cash equivalents $ 38,731 $ 63,745

Short-term investments 8,555 10,695

Accounts receivable, net 1,152 981

FARESTON sale proceeds receivable 21,671

Inventory 161

Prepaid expenses and other current assets 1,233 1,266

Total current assets 71,342 76,848

Property and equipment, net 640 1,096

Intangible and other assets, net 186 240

Total assets 72,168 78,184

Current liabilities:

Accounts payable 1,214 1,219

Accrued expenses and other current liabilities 10,263 4,142

Total current liabilities 11,477 5,361

Other long-term liabilities 786 949

Commitments and contingencies

Stockholders' equity:

Common stock, $0.001 par value: 120,000,000 shares authorized at both September 30, 2012 and December 31, 2011; 62,816,924 and 62,790,223 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively 63 63

Additional paid-in capital 460,073 457,985

Accumulated deficit (400,231) (386,174)

Total stockholders' equity 59,905 71,874

Total liabilities and stockholders' equity $ 72,168 $ 78,184

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents investments in debt securities which are categorized as held-to-maturity and that have scheduled maturities within one year of the balance sheet date or the normal operating cycle, whichever is longer; such investments are measured at amortized cost (carrying value). The held-to-maturity category is for those securities that the Entity has the positive intent and ability to hold until maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 5

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 19

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_HeldToMaturitySecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business and Basis of Presentation
9 Months Ended

Sep. 30, 2012

Business and Basis of Presentation [Abstract]

Business and Basis of Presentation
1. Business and Basis of Presentation

Business

GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine^® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

Additionally, the Company is developing Capesaris^® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.

Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON ^® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON^® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion.

Basis of Presentation

The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012.

Use of Estimates

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.

Discontinued Operations

On September 28, 2012, the Company entered into an asset purchase agreement (the “FARESTON ^® Purchase Agreement”) with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON^®. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON ^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company has accounted for FARESTON^® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON^® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. The Company has also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations. The Company has set forth the assets and liabilities relating to the FARESTON^® discontinued operations in Note 4, Discontinued Operations. See Note 4, Discontinued Operations, for further discussion.

FARESTON^® Revenue Recognition

Revenue from product sales of FARESTON^®, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON^® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON ^® by the Company prior to September 30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, the Company’s accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $528 and $715 have been included in “Other long-term liabilities” in the condensed balance sheets at September 30, 2012 and December 31, 2011, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year. See Note 4, Discontinued Operations, for further discussion.

Collaboration Revenue Recognition

Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company’s former collaboration and license agreements. Revenues from the Company’s prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note 5, Collaboration and License Agreements, for further discussion.

Research and Development Expenses

Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.

Cash, Cash Equivalents and Short-term Investments

The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents.

At September 30, 2012 and December 31, 2011, short-term investments consisted of Federal Deposit Insurance Corporation insured certificates of deposit with original maturities of greater than three months and less than one year. As the Company has the positive intent and ability to hold the certificates of deposit until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value. The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time.

Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products.

The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011.

Income Taxes

The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, at September 30, 2012 and December 31, 2011, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income taxes are described more fully in Note 9 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The Company has recognized the tax effect of discontinued operations in the condensed statements of operations in accordance with the intra-period accounting rules. An offsetting tax benefit is recorded in continuing operations in each period.

Other (Expense) Income, net

Other (expense) income, net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.

Reclassification

Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion.

Subsequent Events

The Company has evaluated all events or transactions that occurred after September 30, 2012 up through the date the condensed financial statements were issued. There were no material recognizable or nonrecognizable subsequent events during the period evaluated.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discontinued Operations (Details Textual) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2012

Discontinued Operations (Textual) [Abstract]

Proceeds from the sale of FARESTON $ 21,671

Gain on sale of FARESTON (18,831) (18,831)

Contract termination fee 1,000 1,000

Financial advisory fee 1,712 1,712

Other transaction expenses $ 128 $ 128

X

- Definition

Contract termination fee related to discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_ContractTerminationFeeRelatedToDiscontinuedOperations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: gtxi_DiscontinuedOperationsTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Financial advisory fee related to discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_FinancialAdvisoryFeeRelatedToDiscontinuedOperations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Other transaction expenses related to discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_OtherTransactionExpensesRelatedToDiscontinuedOperations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 20 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation
9 Months Ended

Sep. 30, 2012

Share-Based Compensation [Abstract]

Share-Based Compensation
2. Share-Based Compensation

Share-based payments include stock option grants under the Company’s stock option and equity incentive plans and deferred compensation arrangements for the Company’s non-employee directors. The Company recognizes compensation expense for its share-based payments based on the fair value of the awards over the period during which an employee or non-employee director is required to provide service in exchange for the award. The Company’s share-based compensation plans are described more fully in Note 3 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Research and development expenses
$ 335 $ 503 $ 696 $ 1,410

General and administrative expenses
458 623 1,310 1,909

Total share-based compensation
$ 793 $ 1,126 $ 2,006 $ 3,319

Share-based compensation expense recorded as general and administrative expense for the three months ended September 30, 2012 and 2011 included share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $40 and $45, respectively. Share-based compensation expense related to deferred compensation arrangements for the Company’s non-employee directors of $128 and $141 was included in share-based compensation expense recorded as general and administrative expenses for the nine months ended September 30, 2012 and 2011, respectively. Share-based compensation expense recorded as research and development expenses for the nine months ended September 30, 2012 was offset by the reversal of previously recognized share-based compensation expense for non-vested stock options that were canceled in conjunction with the resignation of an executive officer during the nine months ended September 30, 2012.

The Company uses the Black-Scholes-Merton option pricing valuation model to value stock options. The expected life of options is determined by calculating the average of the vesting term and the contractual term of the options. The expected price volatility is based on the Company’s historical stock price volatility. The risk-free interest rate is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock options. Expected dividend yield is not considered as the Company has not made any dividend payments and has no plans of doing so in the foreseeable future. The amount of share-based compensation expense recognized is reduced ratably over the vesting period by an estimate of the percentage of options granted that are expected to be forfeited or canceled before becoming fully vested.

The fair value of options granted was estimated using the following assumptions for the periods presented:

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Expected price volatility
73.8 % 65.3 % 69.6 % 64.9 %

Risk-free interest rate
1.1 % 2.3 % 1.2 % 2.5 %

Weighted average expected life in years
6.5 years 6.5 years 6.5 years 6.5 years

The following is a summary of stock option transactions for all of the Company’s stock option and equity incentive plans since the Company’s most recent fiscal year end:

Number of Shares Weighted Average
Exercise Price Per
Share

Options outstanding at December 31, 2011
4,945,565 $ 9.12

Options granted
1,129,250 3.34

Options forfeited or expired
(669,754 ) 8.86

Options exercised
(26,701 ) 3.07

Options outstanding at September 30, 2012
5,378,360 7.97

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2012

Dec. 31, 2011

Condensed Balance Sheets [Abstract]

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 120,000,000 120,000,000

Common stock, shares issued 62,816,924 62,790,223

Common stock, shares outstanding 62,816,924 62,790,223

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation (Details 2) (USD $)
9 Months Ended

Sep. 30, 2012

Summary of Stock Option Transactions

Number of Shares Options outstanding at December 31, 2011 4,945,565

Weighted Average Exercise Price Per Share Options outstanding at December 31, 2011 $ 9.12

Number of Shares Options granted 1,129,250

Weighted Average Exercise Price Per Share Options granted $ 3.34

Number of Shares, Options forfeited or expired (669,754)

Weighted Average Exercise Price Per Share Options forfeited or expired $ 8.86

Number of Shares Options exercised (26,701)

Weighted Average Exercise Price Per Share Options exercised $ 3.07

Number of Shares Options outstanding at September 30, 2012 5,378,360

Weighted Average Exercise Price Per Share Options outstanding at September 30, 2012 $ 7.97

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
9 Months Ended

Sep. 30, 2012

Nov. 05, 2012

Document and Entity Information [Abstract]

Entity Registrant Name GTX INC /DE/

Entity Central Index Key 0001260990

Document Type 10-Q

Document Period End Date Sep. 30, 2012

Amendment Flag false

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q3

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 62,816,924

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: gtxi_DocumentAndEntityInformationAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation (Details Textual) (Deferred Compensation Arrangements [Member], USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Deferred Compensation Arrangements [Member]

Share-Based Compensation (Textual) [Abstract]

Share-based compensation charge related to deferred compensation arrangements for non-employee directors $ 40 $ 45 $ 128 $ 141

X

- Definition

Share-based compensation expense related to deferred compensation arrangements for the Company's non-employee directors.

+ References

No definition available.

+ Details

Name: gtxi_ShareBasedCompensationExpenseAllocatedForDirectorsDeferredCompensationArrangements

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: gtxi_ShareBasedCompensationTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Revenues:

Collaboration revenue $ 8,066

Expenses:

Research and development expenses 9,764 8,181 28,836 23,075

General and administrative expenses 2,999 2,708 7,987 8,886

Total expenses 12,763 10,889 36,823 31,961

Loss from operations (12,763) (10,889) (36,823) (23,895)

Other (expense) income, net (47) 23 14 332

Loss from operations before income taxes (12,810) (10,866) (36,809) (23,563)

Income tax benefit 7,861 591 8,848 398

Net loss from continuing operations (4,949) (10,275) (27,961) (23,165)

Income from discontinued operations before income taxes 20,214 1,522 22,752 951

Income tax expense (7,861) (591) (8,848) (398)

Net income from discontinued operations 12,353 931 13,904 553

Net income (loss) $ 7,404 $ (9,344) $ (14,057) $ (22,612)

Net income (loss) per share - basic and diluted:

Net loss from continuing operations $ (0.08) $ (0.16) $ (0.44) $ (0.42)

Net income from discontinued operations $ 0.20 $ 0.01 $ 0.22 $ 0.01

Net income (loss) per share $ 0.12 $ (0.15) $ (0.22) $ (0.41)

Weighted average shares outstanding:

Basic and diluted 62,815,549 62,778,575 62,806,440 55,529,320

X

- Definition

The weighted average number of shares outstanding for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share. Basic weighted average shares outstanding represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Diluted weighted average shares outstanding represents the average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

No definition available.

+ Details

Name: gtxi_BasicAndDilutedWeightedAverageNumberOfShares

Namespace Prefix: gtxi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Collaboration revenue consists of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the company's collaboration and license agreements. Collaboration revenue is recognized based on the performance requirements of the specific agreements.

+ References

No definition available.

+ Details

Name: gtxi_CollaborationRevenue

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Overall income (loss) from a disposal group that is classified as a component of the entity, before income tax, reported as a separate component of income before extraordinary items. Includes the following (before income tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 05

-Paragraph 15

-Article 3

+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Tax effect allocated to a disposal group that is classified as a component of the entity reported as a separate component of income before extraordinary items. Includes the tax effects of the following: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph b(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph b(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of income (loss) derived from discontinued operations during the period, net of related tax effect, per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2012

Share-Based Compensation [Abstract]

Summary of Share-based Compensation Expense
The following table summarizes share-based compensation expense included within the condensed statements of operations for the three and nine months ended September 30, 2012 and 2011:

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Research and development expenses
$ 335 $ 503 $ 696 $ 1,410

General and administrative expenses
458 623 1,310 1,909

Total share-based compensation
$ 793 $ 1,126 $ 2,006 $ 3,319

Fair Value of Options Granted
The fair value of options granted was estimated using the following assumptions for the periods presented:

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Expected price volatility
73.8 % 65.3 % 69.6 % 64.9 %

Risk-free interest rate
1.1 % 2.3 % 1.2 % 2.5 %

Weighted average expected life in years
6.5 years 6.5 years 6.5 years 6.5 years

Summary of Stock Option Transactions
The following is a summary of stock option transactions for all of the Company’s stock option and equity incentive plans since the Company’s most recent fiscal year end:

Number of Shares Weighted Average
Exercise Price Per
Share

Options outstanding at December 31, 2011
4,945,565 $ 9.12

Options granted
1,129,250 3.34

Options forfeited or expired
(669,754 ) 8.86

Options exercised
(26,701 ) 3.07

Options outstanding at September 30, 2012
5,378,360 7.97

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business and Basis of Presentation (Policies)
9 Months Ended

Sep. 30, 2012

Business and Basis of Presentation [Abstract]

Business
Business

GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine^® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

Additionally, the Company is developing Capesaris^® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.

Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON ^® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON^® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion.

Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012.

Use of Estimates
Use of Estimates

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.

Discontinued Operations
Discontinued Operations

On September 28, 2012, the Company entered into an asset purchase agreement (the “FARESTON ^® Purchase Agreement”) with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON^®. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON ^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company has accounted for FARESTON^® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON^® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. The Company has also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations. The Company has set forth the assets and liabilities relating to the FARESTON^® discontinued operations in Note 4, Discontinued Operations. See Note 4, Discontinued Operations, for further discussion.

FARESTON Revenue Recognition
FARESTON^® Revenue Recognition

Revenue from product sales of FARESTON^®, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON^® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON ^® by the Company prior to September 30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, the Company’s accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $528 and $715 have been included in “Other long-term liabilities” in the condensed balance sheets at September 30, 2012 and December 31, 2011, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year. See Note 4, Discontinued Operations, for further discussion.

Collaboration Revenue Recognition
Collaboration Revenue Recognition

Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company’s former collaboration and license agreements. Revenues from the Company’s prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note 5, Collaboration and License Agreements, for further discussion.

Research and Development Expenses
Research and Development Expenses

Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.

Cash, Cash Equivalents and Short-term Investments
Cash, Cash Equivalents and Short-term Investments

The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents.

At September 30, 2012 and December 31, 2011, short-term investments consisted of Federal Deposit Insurance Corporation insured certificates of deposit with original maturities of greater than three months and less than one year. As the Company has the positive intent and ability to hold the certificates of deposit until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value. The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.

Impairment of Long-Lived Assets
Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time.

Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products.

The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011.

Income Taxes
Income Taxes

The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, at September 30, 2012 and December 31, 2011, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income taxes are described more fully in Note 9 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The Company has recognized the tax effect of discontinued operations in the condensed statements of operations in accordance with the intra-period accounting rules. An offsetting tax benefit is recorded in continuing operations in each period.

Other (Expense) Income, net
Other (Expense) Income, net

Other (expense) income, net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.

Reclassification
Reclassification

Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion.

Subsequent Events
Subsequent Events

The Company has evaluated all events or transactions that occurred after September 30, 2012 up through the date the condensed financial statements were issued. There were no material recognizable or nonrecognizable subsequent events during the period evaluated.

X

- Definition

Disclosure of the basis of presentation, which describes the underlying basis used to prepare the financial statements.

+ References

No definition available.

+ Details

Name: gtxi_BasisOfPresentationPolicyTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the nature of the business.

+ References

No definition available.

+ Details

Name: gtxi_BusinessPolicyTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash, cash equivalents and short-term investments.

+ References

No definition available.

+ Details

Name: gtxi_CashCashEquivalentsAndShortTermInvestmentsPolicyTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the components of Other (Expense) Income, Net.

+ References

No definition available.

+ Details

Name: gtxi_OtherExpenseIncomeNetPolicyTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for any discontinued operations. The results of operations of a component of an entity that either has been disposed of or is classified as held for sale is reported in discontinued operations if both: (a) the operations and cash flows of the component have been (or will be) eliminated from the ongoing operations of the entity as a result of the disposal transaction and (b) the entity will not have any significant continuing involvement in the operations of the component after the disposal transaction. If the entity elects to allocate interest expense to a discontinued operation, it may disclose its accounting policy for this election and describe its method of allocation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section S99

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361211&loc=d3e7436-122677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 41, 42, 43, 44

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 03-13

-Paragraph 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2122178

+ Details

Name: us-gaap_DiscontinuedOperationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.

+ References

No definition available.

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 48

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 4

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 6-34, 43, 47, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 6

-Paragraph 5, 6, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition for multiple-deliverable arrangements including, at a minimum (as applicable): (1) the nature of such arrangements, (2) the significant deliverables within the arrangements, (3) the general timing of delivery or performance of service for the deliverables within the arrangements, (4) performance-, cancellation-, termination- or refund-type provisions, (5) a discussion of the significant factors, inputs, assumptions, and methods used to determine selling price (whether vendor-specific objective evidence, third-party evidence, or estimated selling price) for the significant deliverables, (6) whether the significant deliverables in the arrangements qualify as separate units of accounting and the reasons that they do not qualify as separate units of accounting, if applicable, and (7) the general timing of revenue recognition for significant units of accounting. This element is applicable to all multiple-deliverable arrangements, including software arrangements (for example, software products, upgrades or enhancements, postcontract customer support, or services).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=19771336&loc=SL6750900-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=19771336&loc=d3e50766-111635

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-21

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 97-2

-Paragraph 7-14, 35-73

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RevenueRecognitionMultipleElementArrangements

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2197222

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_RevenueRecognitionSalesOfGoods

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reporting subsequent events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 11, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Collaboration and License Agreements (Details Textual)
In Thousands, unless otherwise specified
9 Months Ended 1 Months Ended 3 Months Ended

Sep. 30, 2011

USD ($)

Sep. 30, 2012

USD ($)

Sep. 30, 2006

Ipsen Collaboration Agreement [Member]

EUR (€)

Mar. 31, 2011

Ipsen Collaboration Agreement [Member]

USD ($)

Sep. 30, 2006

Ipsen Collaboration Agreement [Member]

USD ($)

Collaboration and License Agreements (Textual) [Abstract]

License fee and expense reimbursement € 23,000

Deferred revenue related to upfront license fee 29,330

Collaboration revenue 8,066 8,066

Development period 10 years

Collaboration and License Agreements (Additional Textual) [Abstract]

Contract termination fee $ 1,000

X

- Details

Name: gtxi_CollaborationAndLicenseAgreementsAdditionalTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: gtxi_CollaborationAndLicenseAgreementsTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Contract termination fee related to discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_ContractTerminationFeeRelatedToDiscontinuedOperations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Deferred revenue amortization period.

+ References

No definition available.

+ Details

Name: gtxi_DeferredRevenueAmortizationPeriod

Namespace Prefix: gtxi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

License and expense reimbursement received under collaborative arrangements.

+ References

No definition available.

+ Details

Name: gtxi_LicenseFeeAndExpenseReimbursement

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basic and Diluted Net Loss Per Share (Details Textual)
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Basic and Diluted Net Loss Per Share (Textual) [Abstract]

Weighted average options outstanding to purchase shares of common stock 5,408,065 5,113,943 5,639,672 5,455,700

X

- Details

Name: gtxi_EarningsPerShareTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Summary of Share-Based Compensation Expense

Total share-based compensation $ 793 $ 1,126 $ 2,006 $ 3,319

Research and Development Expense [Member]

Summary of Share-Based Compensation Expense

Total share-based compensation 335 503 696 1,410

General and Administrative Expense [Member]

Summary of Share-Based Compensation Expense

Total share-based compensation $ 458 $ 623 $ 1,310 $ 1,909

X

- Details

Name: gtxi_SummaryOfShareBasedCompensationExpenseAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discontinued Operations (Tables)
9 Months Ended

Sep. 30, 2012

Discontinued Operations [Abstract]

Operating Income Related to Discontinued Operations
FARESTON^® operating income for each period presented was as follows:

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Product sales, net
$ 1,826 $ 2,029 $ 5,294 $ 4,903

Cost of product sales
(263 ) (311 ) (782 ) (780 )

Operating expenses
(180 ) (196 ) (591 ) (3,172 )

FARESTON^® operating income
$ 1,383 $ 1,522 $ 3,921 $ 951

Assets and Liabilities Related to Discontinued Operations
The assets and liabilities related to FARESTON^® discontinued operations included in the condensed balance sheets for the periods presented were as follows:

September 30, December 31,

2012 2011

Accounts receivable, net
$ 1,152 $ 981

FARESTON^® sale proceeds receivable
21,671 —

Inventory
— 161

Prepaid expenses and other assets
279 178

Total assets
23,102 1,320

Accounts payable
35 116

Accrued expenses and other current liabilities
4,209 919

Other long-term liabilities
528 715

Total liabilities
4,772 1,750

Net assets (liabilities)
$ 18,330 $ (430 )

X

- Definition

Tabular disclosure of the assets and liabilities related to discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_AssetsLiabilitiesRelatedToDiscontinuedOperationsTableTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of operating income reported in discontinued operations.

+ References

No definition available.

+ Details

Name: gtxi_OperatingIncomeRelatedToDiscontinuedOperationsTableTextBlock

Namespace Prefix: gtxi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business and Basis of Presentation (Details Textual) (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Dec. 31, 2011

Business and Basis of Presentation (Textual) [Abstract]

Proceeds from the sale of FARESTON $ 21,671

Certificates of deposit, original maturities greater than three months and less than one year

Accrual for product returns 1,189 1,114

Accrual for product returns included in other long term liabilities 528 715

Impairment of intangible assets 1,598

Net deferred tax assets $ 0 $ 0

X

- Definition

The estimated liability for future product returns of product sold.

+ References

No definition available.

+ Details

Name: gtxi_AccrualForProductReturns

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Portion of the entity's product returns accrual estimated to be payable after one year.

+ References

No definition available.

+ Details

Name: gtxi_AccrualForProductReturnsIncludedInOtherLongTermLiabilities

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: gtxi_BusinessAndBasisOfPresentationTextualAbstract

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Certificates of deposit, original maturities period.

+ References

No definition available.

+ Details

Name: gtxi_CertificatesOfDepositMaturityPeriod

Namespace Prefix: gtxi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 46

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Compensation (Details 1)
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Fair Value of Options Granted

Expected price volatility 73.80% 65.30% 69.60% 64.90%

Risk-free interest rate 1.10% 2.30% 1.20% 2.50%

Weighted average expected life in years 6 years 6 months 6 years 6 months 6 years 6 months 6 years 6 months

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 34 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discontinued Operations (Details 1) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2012

Dec. 31, 2011

Assets and Liabilities Related to Discontinued Operations

Accounts receivable, net $ 1,152 $ 981

FARESTON sale proceeds receivable 21,671

Inventory 161

Prepaid expenses and other assets 279 178

Total assets 23,102 1,320

Accounts payable 35 116

Accrued expenses and other current liabilities 4,209 919

Other long-term liabilities 528 715

Total liabilities 4,772 1,750

Net assets (liabilities) $ 18,330 $ (430)

X

- Definition

The aggregate value for liabilities of a disposal group, including a component of the entity (discontinued operation), to be sold or that has been disposed of through sale, as of the financial statement date.

+ References

No definition available.

+ Details

Name: gtxi_AggregateValueOfLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), the aggregate of amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.

+ References

No definition available.

+ Details

Name: gtxi_DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNet

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), the total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of assets, as of the balance sheet date, not otherwise specified.

+ References

No definition available.

+ Details

Name: gtxi_DisposalGroupIncludingDiscontinuedOperationPrepaidExpensesAndOtherAssets

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), carrying value of total assets less total liabilities.

+ References

No definition available.

+ Details

Name: gtxi_NetAssetsOrLiabilitiesOfDisposalGroupIncludingDiscontinuedOperations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for assets of a disposal group, including a component of the entity (discontinued operation), to be sold or that has been disposed of through sale, as of the financial statement date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), carrying value of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), carrying value of obligations incurred and payable pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include interest, rent, salaries, and utilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), carrying amount of inventories (net of all valuation allowances and write-downs).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For the disposal group, including a component of the entity (discontinued operation), obligations not otherwise itemized that are due after one year or operating cycle, if longer, from the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationUnclassifiedBalanceSheetDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Cash flows from operating activities:

Net loss $ (14,057) $ (22,612)

Adjustments to reconcile net loss to net cash used in operating activities:

Gain on sale of FARESTON (18,831)

Deferred revenue amortization (8,066)

Impairment of intangible assets 1,598

Depreciation and amortization 596 819

Share-based compensation 1,878 3,178

Directors' deferred compensation 128 141

Changes in assets and liabilities:

Accounts receivable, net (171) (147)

Inventory 133 (27)

Prepaid expenses and other assets 34 (476)

Accounts payable (12) (19)

Accrued expenses and other liabilities 3,258 1,062

Net cash used in operating activities (27,044) (24,549)

Cash flows from investing activities:

Purchase of property and equipment (125) (45)

Purchase of short-term investments, held to maturity (7,815) (12,450)

Proceeds from maturities of short-term investments, held to maturity 9,955 3,185

Net cash provided by (used in) investing activities 2,015 (9,310)

Cash flows from financing activities:

Proceeds from issuance of common stock 48,982

Payments on capital lease and financed equipment obligations (67) (63)

Proceeds from exercise of employee stock options 82 55

Net cash provided by financing activities 15 48,974

Net (decrease) increase in cash and cash equivalents (25,014) 15,115

Cash and cash equivalents, beginning of period 63,745 58,181

Cash and cash equivalents, end of period $ 38,731 $ 73,296

X

- Definition

Fees earned by non-employee directors under the company's directors' deferred compensation plan which will be paid out in the form of company common stock.

+ References

No definition available.

+ Details

Name: gtxi_DirectorDeferredCompensation

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Payments on capital lease and financed equipment obligations.

+ References

No definition available.

+ Details

Name: gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations

Namespace Prefix: gtxi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 46

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow from purchases of held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

+ Details

Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 36 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Collaboration and License Agreements
9 Months Ended

Sep. 30, 2012

Collaboration and License Agreements [Abstract]

Collaboration and License Agreements
5. Collaboration and License Agreements

Former Orion Corporation License and Supply Agreement

In connection with the Company’s sale of its rights and certain assets related to FARESTON ^® to ProStrakan, the Company and Orion agreed to terminate the Amended and Restated License and Supply Agreement, dated January 1, 2005, as amended, between the Company and Orion (the “Orion Supply Agreement”) as well as certain other agreements between the Company and Orion related to the Orion Supply Agreement (collectively, the “Orion Agreements”). Pursuant to the Orion Supply Agreement, the Company obtained an exclusive license from Orion to develop and commercialize toremifene-based products for all human indications worldwide, except breast cancer outside of the United States, and Orion agreed to manufacture and supply all of the Company’s needs for clinical trial and commercial grade material for toremifene-based products developed and marketed in the United States and abroad, including toremifene globally and FARESTON^® in the United States. The termination of the Orion Agreements was effective September 30, 2012. As consideration for Orion’s agreement to terminate the Orion Agreements and to enter into certain agreements with the ProStrakan to effect the FARESTON^® sale, the Company paid Orion $1,000 in October 2012.

University of Tennessee Research Foundation License Agreements

The Company and the University of Tennessee Research Foundation (“UTRF”) are parties to a consolidated, amended and restated license agreement (the “SARM License Agreement”) pursuant to which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or controlled by UTRF, including all improvements thereto, and exclusive rights to future SARM technology that may be developed by certain scientists at the University of Tennessee or subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and mid single-digit royalties on sublicense revenues.

Former Ipsen Collaboration and License Agreement

In September 2006, the Company entered into a collaboration and license agreement with Ipsen Biopharm Limited (the “Ipsen Collaboration Agreement”) pursuant to which the Company granted Ipsen exclusive rights in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of Independent States (the “European Territory”) to develop and commercialize toremifene in all indications which the Company has licensed from Orion, which include all indications in humans except the treatment and prevention of breast cancer outside of the United States.

In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company €23,000 as a license fee and expense reimbursement. Under the Ipsen Collaboration Agreement, the Company recorded deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement which was being amortized into revenue on a straight-line basis over the estimated ten year development period for toremifene in the European Territory.

In March 2011, the Company reacquired full rights to its toremifene program following the termination by the Company and Ipsen of the collaboration and license agreement, as amended. During the first quarter of 2011, the Company recognized as collaboration revenue all of the remaining $8,066 unamortized revenue. This amount is included in collaboration revenue in the condensed statement of operations for the nine months ended September 30, 2011.

X

- Definition

The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-1

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SalesRevenueServicesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 24 133 1 false 4 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://gtxinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Balance Sheets Sheet http://gtxinc.com/role/BalanceSheets Condensed Balance Sheets false false R3.htm 0111 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://gtxinc.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 0120 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://gtxinc.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) false false R5.htm 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://gtxinc.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) false false R6.htm 0201 - Disclosure - Business and Basis of Presentation Sheet http://gtxinc.com/role/BusinessAndBasisOfPresentation Business and Basis of Presentation false false R7.htm 0202 - Disclosure - Share-Based Compensation Sheet http://gtxinc.com/role/ShareBasedCompensations Share-Based Compensation false false R8.htm 0203 - Disclosure - Basic and Diluted Net Loss Per Share Sheet http://gtxinc.com/role/BasicAndDilutedNetLossPerShare Basic and Diluted Net Loss Per Share false false R9.htm 0204 - Disclosure - Discontinued Operations Sheet http://gtxinc.com/role/DiscontinuedOperations Discontinued Operations false false R10.htm 0205 - Disclosure - Collaboration and License Agreements Sheet http://gtxinc.com/role/CollaborationAndLicenseAgreement Collaboration and License Agreements false false R11.htm 0401 - Disclosure - Business and Basis of Presentation (Policies) Sheet http://gtxinc.com/role/BusinessAndBasisOfPresentationPolicies Business and Basis of Presentation (Policies) false false R12.htm 0502 - Disclosure - Share-Based Compensation (Tables) Sheet http://gtxinc.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) false false R13.htm 0504 - Disclosure - Discontinued Operations (Tables) Sheet http://gtxinc.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) false false R14.htm 0601 - Disclosure - Business and Basis of Presentation (Details Textual) Sheet http://gtxinc.com/role/BusinessAndBasisOfPresentationDetailsTextual Business and Basis of Presentation (Details Textual) false false R15.htm 0602 - Disclosure - Share-Based Compensation (Details) Sheet http://gtxinc.com/role/ShareBasedCompensationDetails Share-Based Compensation (Details) false false R16.htm 06021 - Disclosure - Share-Based Compensation (Details 1) Sheet http://gtxinc.com/role/ShareBasedCompensationDetails1 Share-Based Compensation (Details 1) false false R17.htm 06022 - Disclosure - Share-Based Compensation (Details 2) Sheet http://gtxinc.com/role/ShareBasedCompensationDetails2 Share-Based Compensation (Details 2) false false R18.htm 06023 - Disclosure - Share-Based Compensation (Details Textual) Sheet http://gtxinc.com/role/ShareBasedCompensationDetailsTextual Share-Based Compensation (Details Textual) false false R19.htm 0603 - Disclosure - Basic and Diluted Net Loss Per Share (Details Textual) Sheet http://gtxinc.com/role/BasicAndDilutedNetLossPerShareDetailsTextual Basic and Diluted Net Loss Per Share (Details Textual) false false R20.htm 0604 - Disclosure - Discontinued Operations (Details) Sheet http://gtxinc.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) false false R21.htm 06041 - Disclosure - Discontinued Operations (Details 1) Sheet http://gtxinc.com/role/DiscontinuedOperationsDetails1 Discontinued Operations (Details 1) false false R22.htm 06042 - Disclosure - Discontinued Operations (Details Textual) Sheet http://gtxinc.com/role/DiscontinuedOperationsDetailsTextual Discontinued Operations (Details Textual) false false R23.htm 0605 - Disclosure - Collaboration and License Agreements (Details Textual) Sheet http://gtxinc.com/role/CollaborationAndLicenseAgreementsDetailsTextual Collaboration and License Agreements (Details Textual) false false All Reports Book All Reports Process Flow-Through: 0110 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0111 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: 0120 - Statement - Condensed Statements of Operations (Unaudited) Process Flow-Through: 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) gtxi-20120930.xml gtxi-20120930.xsd gtxi-20120930_cal.xml gtxi-20120930_def.xml gtxi-20120930_lab.xml gtxi-20120930_pre.xml true true XML 38 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Discontinued Operations (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Operating Income Related to Discontinued Operations

Product sales, net $ 1,826 $ 2,029 $ 5,294 $ 4,903

Cost of product sales (263) (311) (782) (780)

Operating expenses (180) (196) (591) (3,172)

FARESTON operating income $ 1,383 $ 1,522 $ 3,921 $ 951

X

- Definition

Amount of costs of goods sold attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of operating expenses attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of operating income or loss attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of sales or other form of revenues attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 47

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 39 0001193125-12-459621-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-459621-xbrl.zip M4$L#!!0````(`$1?:$&&VX=*5UP``%<.!``1`!P`9W1X:2TR,#$R,#DS,"YX M;6Q55`D``Y_DFU"?Y)M0=7@+``$$)0X```0Y`0``[%U;<]RVDG[?JOT/.-IL MRJZ:NWS3Q3XE2TI6>VQ+*\FUV2<5AL3,("8)!B"EF?SZ[6X`)#@76;+DL93H M)=&0N'6C+U\W&O3N/Z=IPBZ%-E)E;S?ZG=X&$UFD8IF-WVZ4ILU-).7&/]_] M^[_M_J/=9K^]/_W`?A69T+P0,;N2Q82>?>3Z"]M7^4S+\:1@S_:?L^&,G9ZR M`Y5E(DG$C+7;?I#WW$!?E=G1!IV^>S<=ZH3!>C+S=F-2%/EVMWMU==7!QQVE MQ]U!K[?9E9DI>!:)#=MR.Y'9EVN:X^LAS.>;3Q?:7VU2Z_[6UE:7WOJFXV(J MJY;X(XLZD4IAW/Z@M[79\^VD42\&_=?7K=FV\!V`K6/.\ZK#B)LA-78O:(9V MK]_>[%?+AO'D+;B";^.Z0]CX5=>^K)H:N8P?T++?_>WCA[-H(E+>GI\@%G.C M&Q%UQNJR"R_"]<.^,K:+;-TV--*I&#%B\W8QR\7;#2/3/,%AZ=E$B]';#61V MV[.Y,S7Q!NO:@5!\]E56B&G!SD14@-1:X8%WD7LNX[<;YS"0^`@/)N8PBT5\ ML=D'$84A^Q='N1'9Q;Y*$CY4(,8PQ,7>&)JG(BLN/HIT*+1=-HP)CV0Q<[_@ MMXSQR4@*S8@P".[,=MB MFB19T=<+>[ M=)YZ9=WFTG:[#2[LYD)+%0>$%%P7!V`/WB%_<=][?1BC>EHU%%D<--L$\<"A MXZ#1;C<8?+?K=G1Q>]_S!(5QSQR/+C9[9R)'N7[:V?O>6:OTQ3OD;KNWU=Y$ M@MVS.V]8O__=]^+F]*%`WAM]_0,1P9"]AT1?KPTF&17NV^A;M*=N$P<7I\(( MKJ/)Q5X67QR(2Y&HG!3N<)J#=(M'HGCHY^(R`>4[!(>D9D*<"7TI(W$VX5H0 M9-E7*5)D-2])5$1_'8].1:3&F?Q3Q"?$S'UE"O-^=BIRI8L/,A-6A_U,GF'` MKX!=CEMK,-'@FE_?P$0/O$9\FXF^1F(L?DQ(8/;B5&;2%&C/+L63S*R0&<6;(RC]/*K$%HKHFT#\1(:`V/ M0I9>$*97][8^^;QO=/;#CP`(?7#_)0(_?J,;)1!W*A$(Z>N]_*0N M'][^H8B^_%;Z_IMGJ`<49X%T@B2T'P2%:PI(_M%N?\YD577GB^Y*?(;L.2FU MJ'B1"F[@]SLJ6]S.X<_=KG]FQ\9^"'AW`Y81)C8KV+YLP:L8OW(="\P,1\!JS,.$\-I"-285^HJQS-C[1$5? MV#D?CT7,/JE"5&T\1CS68Y[)/PD![JO,J$3&]`/@O@1[<@)TP!SV46G`:QIS M($RD94Z@,8OWHDB5H";9^$0A4!3F'"37SNS$^!0K2U/_^_ MDT,V*=*$G7Q^_^%HGVVTN]W_W=SO=@_.#]AO_W7^\0/K=WKL'!"MD3@_3[K= MPT\;;$D5[?EI=XIC];&S^[-=!#T[<1%O`$-^'A<[M`5N(2MYUV=MMA:^+5D3 MRE4K,\N6:U]-YU^-@/?,%+,$K!_^W1[Q5":S[0("!<,R<<6T2GFVP8S\$YH, M-K`W=ASZ/[KU7SC`0Q^]ZGVC*7(_?LHU;'>[4/EV?Y!/=]SOH2H*E6[W\FFU M]+O1W.\P+PB,9S$C06%JQ$)182N633_RKQ+PZCNN'_^0^$=%!2U*7L/LNZQZ MAZ'E:,L,G?+VB_^\&Q4T_Z_GTQ8[RJ(.>_8S3_.=_W@S&/1VX&GUJ[_#E&;% M1+"@`69">#8+&CUO,\T"#%U!<;/MW7_5VQF\ M:+'^UM9K$H*)X/$?)>`%H:$#6!V(LO.)-"UV+C)DLA`M!F+"V5"J'+Q*RB-1 M%C+B"N/Y8F4I="SUKPOCJTHSFA'[CB2/+$V2\40I/R M)&&I2D14)L#'D>-#H04OJ"LTBA!EZI;[/S-ECL<_\A)X`(QHT>@*>L$K!#.E M82FM#=>:Q61V38=]BX@LU\QY&=G)>8S79\(F=Y.;X(Z`%K1[@U>/.\P M6C5#0>I1P0W8KUN78V'M(*"DYN$AP9[#9A6*Y!DXY>2,18FEIHD2P*V[0 MY1%A(.XY""#F$^TP3JYJ,<).9:+,%V!V`2.[WKA`-QZ\-(%TA1R-)EIE,F+` MU$CE(I,<6#L6L$T):4LP`I`YM],BTRI)<)CB"LB1EPKG/YEP(]C1T1%P068D MV84&DJ'])4]*7C1WTBN1XP:J&M!F=334JR9O%OF2`>BW"AH)^$]2(G7$J\>E M37MQ[+!7`G:I:'"<%ASHUS[/!3!1FC7)_#.4^-+MAV"3!!*KF=$UT3I%,E&FC7/9[C%L/E>ZNWQ MN,(1`1-@@`PBH^"/0E0V%P2G5>L8\H^C6\BUA(V$O!WMSFPE1 MBD05\UI.CF0B=RW:^J;(0/P$<@GVCBZQ6H`,M!<<&`?N1N`;9[9!,'[9.ST\.S_^],U; M6['MYOL+TY[!7GT!XW`$0:VVR@-;?-:AWIQ'92%VF.XD'3(A'*0T036P&%_Y MWK]J5>8L3Z(&-J@;A`"!E/FG0;_UZG7?*Q/(S`3=%0PSGMR2PW=FW"UM*AA' MD,Y>]5@*7I4/P:6;ED4X.SM4M09Z,L0GIO"&S/TDZ`J MT$[EO#2(#Q3\:'F3@TDS&/0,E0EPYQD8"HKC`8!7P9P+JXVF M#FVL.1^5F@`)PNK2X#';-WK>-VN)T%:'EH\C7$,PQB,7X"`:*#,.H`YW$TTL MUI"!L(`#RS",860NZ5P:K,0(_70E`P@F7(@#LW![#@KZ"3"*Q[^7)#W0[1D, MB_:7P.4(/#\$6@EQ`9Q\J34^#]H_AX5'$)VAK2=_RT9<:L1Y-;MAF""T[+_> M,<&*06X)";70[I=)0;NE*O&S]@\4G8W`M=EH3/!HPFR2V$]D?3DR2L>H$LZ5 M5XDE1`?ZFYADS=*UC)IP<'!#(;)`)(%W*I4% MMJK@44..KY=>BD*,\/S_FJR;B2K!J`\QI.$.UF6_EUE4PSI:@-./RC40X,-E9Q`00ZB-9[ANQ&N<(=$`!%:**TF" M*'."2(6@I*AF*R:\($ZD?(8,%M,!LUA MRK]0T.@8BZ(+D+9,VFT.G^/?US+*Y/:LABTNC]$;I:!.VQMNPN"2W M67_B"Q;+($MVIM2B.YJ-MY"ETB.4%ZV^[4L?BW= M7RGO#<6\MPXE70%6UZNK]Q\O'B_/D[]9%L8@ZK$N'32+N^"0Y:6.*(_`?1$; MQ![-+/Z/B!E/_+*JVKI&<$0- M]Y"28P]"[%R04E`2F^**2F/`ST7$*)=F"#/HN:WVI=Z^`ZH>)K.5GA%Y( M53"T\FJD%^37UJT80<0AI@Z,^R@#@D\@+'=IMX@[;.%@2N7;B:@``BT&G?4< M(>!?SM$[@_+FJ0L)#QY]\3Q/I,"XI-"*NT.V(%AWJE4CEI44+:R/&'";-?9Q M-I=4L,"?C)/Q1G4%9Q8I0S<%R_$QV7)<%@K7O5B/0,"L(?FZE*W::Q"#VV?/ M'G+6[?Z!S")B"S=P&4);TZ8N+@R"=+)_S-WL7'^&\/[93VOR=)%ES+6*2U!< M!`-F_6C`YT^D":VI2^0#7'&K7*5Q0P%*('S3@D\QW+OB:";\;5R68"$.C.O3 M;Y0I=$%2[.BF\7V8Y9Z!;2TUVJEK^#4WU=4$O`*L#O"-H7-0++',+'A`I%G? M,P'_)`W,#_A,%@##VXZQ)";#)6+L"1%R1-&PQ06.ATA. M@P]SF)`I"!3EG2?P)7HFI3=D7)H MQ!^EJ%&C&ZD!U1,^%(F@^%JZ'`?&[P!K$HB-\2SH!QZH?8.?$;<_)00^P_H- M/?-N<^8\18')#[\#3KH;_O3^;,`W0/+AK$%(M?U?`T>:3,!<"!RDDE#D-292 M"*(WJ:=E#OT'?T<`I+`@R5DD:X[8!/14:3IVG^<=Y7(J2^+?.D09XY5^.2Q) M#"$NP"\-U\:NRI;B(?XTPK`517%17@S>VP^O^RQ5(.<@X'!-V212X M.+1M(=`+"P[G,3IL&=WF8&8B""/>C4DA4>ZTE5+^[@C)N-HM[4W?*J8NB(=C M,`^\;\S5N5?YXG'4W\IK$N*"9N=-2M"PC MJDX#.U5F,6U\F0.4P#(6=U6X!8(?H61CZ9!!@93IL-3&!6S64]LOS)!H-LI5 M47!MGKL275@SR!P*EI\!'9J*9/U9]%4RC+E^$*.H09.-P>P*J_1A#8Q,?9*W M7"W0DM]D1'8%UCS$4Y5I)@T4FLX^4?'=.4(5T%(ZRT*)R+(A6&8#FV0\F>'0 MX:Q4,0A&!OZ4"!CI!*^%YZI5=:8I0-_IW%%- M)=@]-9[5S^:JHM'8CVTEO*W<]-HKNR'S4+1IF%5U) MT_95;+:@#;.Z5?[3!5WPJSI6F?FBAE(OA)$UP$;4&N;GKG56@:B`S2%CB8>_ MA3O'T0$`@,VIUUM?VEBR3F1`2>7']*4N6XB/A<=@O&)*::-1;5DX)I9D$]V1 M$57?HGF=W<3;^EF:KHKJ?U>*N6,:72;QB_4+=5.AY;,'U'124R-.FY?VO9:4 MZX0NL$$,PD<-"_];G@?OLPE`>AMW'&67PJ?.'Y%) M#C62\&:,V9:)'$^2&8@YT&N/HCQI)">V]#Q!M0/;1:)<%8F[C#^H,"7-;+A" MAV&B9M[WO%!QQ\L3=XL#32T0(=<:2/X7$6.A"XQ#]8D@.=X,[S?NN%'JC1B" M*27K3-D-I"0Q9V(TQ%O<2E.19X*LZ=MPSC00('J?8J!6+ M*"]MO9R[;.230K"[$TR!46B]8I$(X*K%V0LI5'Q7H\<-;3S:7QZV+GH@D M=A:>^C=!!-+U3+O%V7E=4Y8$S;UIAB7I;NMJE21Y1LIN4VJR)+8!J( M)0![--@4\LDL+S'0\_B>ZA=A6J:KBJ>F"!C`30G7+A/YD%'N$6R&U+X4_0,F M5\6'&_YPW=;[!G0,JT4:?(D!VQFZ*RQ98@5PBM.]#8L@',5 MGT&0DPM)H=)R^K:`G8HDAJ*XPN6M6)*MKX=9AO[NWHKI+&`0 M&;<'K-##@FR@UIZH-Z_:-'))]7)` M6/7AL!1^Q`J8A44JB?PBDID%3I@9I4TQ*.65`YE+OR]R]DHF"76V-YK(T*`'WH:XCC MTEY7LZ<$6]>ZNN475>[YZA41?]WUJX?L?L(L0`#N"0G#3CDE0'.SNI#QFO+1 ML.[7M5Z6C)28=FR[A&UP;4B75#&TAP9O!#)CJT]0K\'-CZS"5'C/WD#"%=*] MT\:DP77/OV5NTU9//'.'2<^=DED5?D0NTY$A/!DR(,/A;AN3@*'`&QQT'I%% M,WO)@]N*M#%5/9$G@*A6T%=N7(8%=#JK_%=."65%-J;Q*"B2=00%Z1"G"Q7=UTC:;GU6:`#6%E?7MLG2D(+O M\4'0^S4^=N4N@>4K\GQ]L2EPV]3_M_?US8TB2=Y?A?#N/M$3(L[WK:/K?G=O>O#HQ*$C<(M(#L]G[Z)S.K@`(A"2$0DLQ%W$Y+%E2^5.5+ M5>:O%CR,`74'(*V;B%@H=,U$^M;P,DM;,.).\:C-,V4I9:H;]NT M@X>A#!.WH8&K`I.#5=+)D[@HR_"3@XAPAQ^7$!Y'AB02^P'Q$5V8!R.$Z!B, M\[,0B;!DPK:)XT(8*B216\:(9"X"03;/+:AV<,Q!&"E9#PLK**OXP4]N(IG0 M^`EVD]J06$KP+I2P+=G5#Y?LDBB*8(T<<[([<7%C@N>0X`5YG+D?:7"^6)JK;H:T$4_^:2RGL7/GL?_D,HVK`A97NOV&P2 M7"CTX9<+DQ`*+M:XL4[E"IZ+38(@!6"+_II M0Y$R-<+"J8L?"B4DRI\Z]']%78F:C#3I$JB8%WX#4OR9[D*B'WO*%05WF49^ M4TQ:FXS/775X8]5ZS1$'D?K6*"?4ZO[$'-F\>(N61*MW.F*<]S;M0/V"5QO! M-S/^30F^OAF?=BV)I`[W=M>G=.FT[X,[?EU-^Y2G*;910=[Y)]-D;#*Y6,L- M9,/)Q#*]-8&9Z'NUW>FP>7(OXI)_67&3W*H,%RD1'L<2V9'O/Q=:/>(CX6_L M-[ZN]W)1X+@OGK'XY8+_]Z)4&1REA3IIK?8Z>J/5L]-J?]1OM'IV6E5;7;5S M`GHME`?7'%7\RKO+>#/'>&[A'4H>!V4_\[ABS_"\O.G=[0U/8'(WZBWJD[0F MTCAC]:HM_22<4Z/@P@H>=48GH.!-T4=F@?KZG0Z9X%U/.@L_M!H`B?TMJOC( MWMS:5(%P/,,V$S#-G*L6(X;3?');#@_TGT5ZXKG5QV2^B;GJSDVU"%(&[M+/+L_:'!8TKB-)!M) M-I)\=J9XG:JK8U7$JQ9)1V*!`O7[?#K2+J]].4E.82W0A^)H70:U?#.%+6KK@"% MY1#C+CHN!A46ZY>#D.\LR9C$[`W-EM_QSPP#C8P0I['CM4?S%R* MJ]4GEHE`$,7@"XM>FWX`$T4$R)W"2P%`KWRP#?./RV_FS+69?_D;\P(4#&]J M#E%V8_2IN3MF-BY%WAHLMT"+5N0(I,M6JM,YRTI( METUQ%M-OX8-XEO_'Y02-=`)'.,4JQT'[O?T-'L)[X9;>JT!">R&`"3+UA&H3 M@UP[03QC$Q+ETU[-"B.7S;'PN)0X("V!*>>Q4,(H M4(%->ISUL/T\G!ZB#?WIE9:R!.TO>M2Q#ES,JG`F4G=_B(::1I9[ M(D8FS!(7LD0&1=QQ^`0DSCE\*[:/KK_!Z2]'::3.0\']7KO^HL5&P56V5;?KKW)K%%RA@KOM^LO=*5G19#F$UM\@O50=9L.N[3-I34G>S&/YBB$NY7FE>ERI@)A(35R[-TG>@[S/%5@^?K'V+7,7]WF8 M27?86SY678<7(IU,X>>@?\:%GZIV/,5^IT9O4[!T^`JW9;)>S9W$_Z8F*>Z` MZJ@Q>,MJ"1/KF)UKGF'3+T2YX&NPS\`!P_=7($&RXOW.;&CV79G6J0W6V-NKU6KU__1N%1&L&].*H;8674 M5NO?WZ_UP%FOVHZ)GK7&2E5\4-52M5%+ZS4@P&>L9+VM=T]`OP<]K:K<@"5Z MEMF/!=ZLW5BS:B?ZNWY_U!KTZI_L/S76K#(E#]O#^NLYSSOX8B+G;PQ6U09+ MZ[<&G?IK_1I[567TU1G4KN`]HZ]31^,\3Z3VXQ%^>0^=1\G:FMW8#4AEC:>M MU@KW6OI@V-+[S4;'&2MYT!XUKK:!QFV<;4%G6[2FZJ]72_]R:AB+]Y\LW[1= M?^FQN\E'"5#P@6/&?G3]P*_9QZ-'`U&N)7PX8%-?KGX+\.Y[*B7 MZ(J_@YN^U#OT[XN_"7%\NOOX^*_[&V46S&WE_O75U?_T#]>77UZ M_*3\\^^/OWU1('A0'K%FRT*N#?OJZN;KA7(Q"X+%^ZNKEY>7]HO>=KWIU>/# MU0]\EXH/BW]>!M*3[7$POEA_:KW*MZY<*EMY3KTOLPINN+XZJ[!-M$7)@=Y6 M0/.62;5IGRQ[B1ND7UF@?'%]'XL+.&@NGV)K2@JVHRWVJZ_CB[D8"RX-;3DM>M!2Y";,Y=AQ?IS5P;3!>AL(:XJXAI*0.AOJ0:'XAG MAVIIL`8P?!L5T"1"30DNER,WMB-99U`YM9[A>0BGF1D@E?@8,47E@BYBGUH< M+5BF/T1&Q8%2E8O^D!QP@@O7-^Q?/7>Y\&\)M!P&1]\( M1%K.DHWO@`$NR=ACGJMCZDJ.:5_1U.V_NFA)8UJ5F-A#N*R?19VS_),]-RJ< M+`NA#;F%:"50J:E$D8#$,\"/[Z>`;', M`[>MW)!11?.:[0R(P55U(QZXS<2;%%BSA"E]8/YD71[1E*-.#*`)[Y@T#7\6 MAPH:L%1]ZD2! MZ2N%(L1TB$:/2//1'00*1_GG*/83QE6AMCJ=#D3%%(3?>?BG=Q"FC,&2+WW4 MP63IX7+!7F)R6;T6S1$+6?V('2)/KF=$/35?0,6./!_\GT@X]',(UI0)$."8 M�XV?+!]WR*(TE+D\A\<7]/8+2`:Y#',4EBN0?1#>!X#49"Q#/#X)QMU_I MJI0J@^[R'4]ZJN-=!H9IXL4$J`^878>VI-B*-99]NQOZ=CY1ZS`]@@3L%'/` M'C.8&;8+GZ*K*,3JB*38>-M&9`\,19LN,Z!IV0D M]/B[)V:[+ULRK+1E26Q;'_8RC=)-5.7J7!7MRH(GE3$#8EAQK4JL'KS8R?!% M,ZE_,GV9QWPAQR!OF^*Z/L-5KC#E MV/7T%E=V_9CXS64$;^XR@CH MKRC]K3F8P")H/'%:R$'%F<831],:\D[KUS^?FS;;"A6L9V&:-0H^'P4/AO6# M;C4*KE3!]7=GYE#PIICC=+8T[J)*@["LK`E!*I[?ZFG,[T;!A14\JG_OJE%P MA0KNC9H8\ZP5K+?4P4E$F1N#D%/'$&C@>HZ)H4:.C1R/B:%CD^,I[D$?ME6! MF$R7MI]INEGWR8W:TH?U[W2?7XQ:OUY[6OV1::/7LO6JMT9:_4EEH]>R]3KJ MG8)6SSJ-;*#HCHRC1I*-)!M)[IA.1I\/?=%M^1W5O\.KO7)P7*3\D[-:!,#%R;A)NUT_3TOB'!-SV]1W`$>KV:LC6=O56>7ZF]YOSJ_/0Z&I[Z M.<>Q&J@::C0(-S2%NTM;BN=I$X^F[I1C19_`.FHTO!CI M1'VW(=IZ8]*:"=_8NFI"_?XIN+)3#`GO/;8PK''6$1,_/FJL6L6!VJ!!,3IC M]:J#X0FH=V,D=NI%>^?9(]+(L?I>F]-)0A[IXJC&8Q_$8^LMM=-L/)^QAM66 MKM4/K-&X[3-T-XTFS.0ZLVXWCL!&]YHMZB35NN'1GHK9QS7 MO!H];R%Z8]XHAV!W9++SQ]A([>AJK=;A)W=-. M82>\46]!0@;J*43;S8[)R67ZC1R;@X[T04?CM@^8;`R.`+^T<=P5'G8,>LUA M1^-R&M==]["%7/>Q.NJO"+'!`2C>2>[ZIS/UUW4W3:G#EJZ?@AEO%+O;^.^Z M1Z#6MPX??Z[(8(TDJW+1T><=,=;^>K7T+Z>&L7C_R?(7KF_8OWKN77U#_WCU=6GQT_* M/__^^-L7!>(2Y1%ALRQDVK"OKFZ^7B@7LR!8O+^Z>GEY:;_H;=>;7CT^7/W` M=ZGXL/CG92`]V1X'XXOU>`2KDN@IETH!*:1&R(3.&ZY'F"KLAFT!#=%K*Q*U M`JKLBV7B*6Z,6N?S>?@4F?0-\5D6"_T*.HN0I9`= M9.W;XV-MXI`?YU>"P'C#/[FEO+$ M@A?&G#6$O<.O0Z%KG9_YM^E1HQ^H/_^$+W]A-I9F1YH0W57QXML\:`HV,'M, MY5V('OG,[%/&;X@6(B4*"GN,O`A[_BL M0&`I?L-9X[X<0C9`6DW;/Y@00R-R/D1O-`OC"?/-<8M`:+((3[# M=RM3VWT")EY)`/CK`T-^9E'-$2IE5$TA8JX4R36]P-)ADPF?VVL@.XDSCA)Z M38B?J'WA'E#0]-*$UJ+EMVIF5B@@>$]7(6@G8`;^&1E5B3<`<)877,#< M?&8>1(>O.`\?&;A<\)>,"`-7PPS/G"F?W:4S3L86 M!+*X)_+?2>[E]\>'STFOAW#$AD=PL[`(#%J2N#^*GJP5NEN!9RP<>>@WXI69 M=K??KA]^6Y5\8N"%Y,9>9I:9")?(E(`9)JS8V&%%SB0,FW!A@\UG/RR?T))I MW("9,\>UW2GRY+Z@VW,]D@0F.AYZWS'B&J,L9#N,;[+F8-B?Q3Q![\\"E[N@ MF`HQ-M`MX)R3HR)@LA&`)WB%<$%R#S!B:(Q\TX(!@&8?L8TWZ10LHK]\\MF_ ME_``>#@A>K)R2+^R)%CM\,6A((A;"ZT@3$3X)ECR9&K%#.+\NIM9+K?U$AEM M)0;LSM9FTEA9(.HG2/3#`&AA<`&#["":LZ,Y@Y#8`7,()7C"T+_;[@M,>6=J ML\NQ-;4"6`:OADT3$I:OPX(8`#MRNN1JP3IF/T?;B_@\D\ M5.*73IMN%SYS\N2"IV3'(#N*X@$,YOO)V4,.FZ(F88/2S*^:')J^7%8?+'3;PTE*^NMZ+`:'_K%.`-R;;%P6A M&-'Z(2M9:U\RN/S/%!?*6A`ZUOM=['C%0!$3Y3B]8TQX,&H)($%XS)H_P3RG M%\NV?@L%R3L3D!N0_)A-8+JQ<6AED9L_:R,\YDKGQ/SURP7,%>I$R*0P29V8 M2Q@1/#'RTW,7XI7_A.8B&A3D"TKQ#%R(EY#@,052-?1+SYPW8AQB&&O.*0)" M7B%@"I<$C<61ZE,IW\JBCE;74<^VWR@81,C9M-X,\]]+"Q4V6=HVGP]13&/1 M?R+6P>6"Q9L+H'Y*5U/98.J&"-0CU[*8TSF,N;RSTU8^+;UPG(GEP;+_]Q(" M5%SWDTQNHBLE<..H@.213D/:0+YNM[91K\L.BPH#/2.]\=>(GZW8A^]GU!/_M.1RAJ^'9\ MYOT'\*`8[_(7G>&YQ)["4BZ537+*<7)QD&W_D+Q3BDMI_%\??X!O=&0Z_F)F8;YM9^<1O&N!'/<)]?'[.8=7J.D_.&X+SR7`7=W!RX& MG"4[T/8PL`"KXK*C=7]JTZZ`3_M'!KW=M`V?`MFQMYQ*NZP+L&U@U'"SW0W# M>I[CX!12YDMP30S#.VGC`F+BG<0.)XI,78,=ZIBKW M>[I;[/;V-G6R`+]_-NPEO\HKUF1T+U*D MV$ODCF1U6JOI>CP67C4\$8LES@\&X_7UT5@P$*+E'VC.O\,9/^@-T;:#1?1` MM2!V2-4]UQK#AWB]0VJ16N^&#:89PER8;CX$N:AVG^&D-#Q^Q#-SO3GMR^&L M-A:OJ&)0?CCK,9L1(28D,@'N24`\3F%E9'-I`R%:8R@_2OX6'J0YWJLTG^B, M;OR,CXW3KU&6?AC9SI_"P)Z(B(S8F,$KG_E?!+5MY0.=A2T7_*JU\9,!,4]T M2][G3]3+QY0\;VVZ3"3%@ MEMJX#'":2D>05#VF+&PS$1O$/TCLY.%B_C-'C@\7$\R9&;HK>,UTMJ.$#WS, M_$[:8#`MG.GL)Z7?4>;@53'C"7Q^3FPLZ#1FG!UU2NLEN3^(?A*6"OS.71A+ M'^,#%SZTUAQO?P-#02DO!.!1,B,7[REQ]5Z!2085B]]'WZR,4_? ME,9M2,A+2K8KR4ZU9"J/.VYWDWM^T2/)K,GJL^469?5;159W:6*V)JA$)J88[![-Y!;L[\%-;C^0_P5$H$[QVE<;`BX?#?>_X M@E9K];0BGL@87<)X"]P0@-@0WFYC]96)8>^ZVB<'3M+4U..;IW^)FB=B[_AWYV[8'EA^Q([2"/#VR*J365PEW^LTV+T\/P M!2/B]`@3UPUP<9+9YONBOM"-_9K8Z:SPJ$&F!\W]+)U7:&JZ< MS'?P@A$>F:&H_7`'BE=4\#,=W#Q(7R:<5;AWS6L('AAN*^'V63@3_CN*#.@D MAV^B9UYO*?;0A2<'B87K(PHM*&%`LG?9EM>(!V`P6K@6S2!^UOG,XF,'/AJ6 MAI`D1'D(GGB9@13A8!KGX<&'CRE/R!42O):M375@8KKO MX7>?W4UNQ"&?WP0;0DQ23T120D<36P!9N%ABU9U06$'C/_(-/?`,D9_>8F>Y M8477A'5?)?A8C]&YKB^%)+Q:^@\6'7R+*F3?7\X7PK-BN9H15;^*Z`1-+9ZI MSCD0*G"3?4E]*SI6X(Y4$TLT$9O]LWVHNQM+-+@Y+EIEK#BLI@LTL+R+KF* MP%?&\4$R?XC$2I$.!@@!^I3P)>'^:VBH37*!8PO$XH4^U_4E,>8ZCTVNMVF;6QV8UN3YV5+3S*]N027PR(?I-!ZS0[(J?=IW64?O@ZS]L:298EB MQQ'K`TW:G%Y?_US'1N1]2%9V52.Y%VF[<7.5H]38A:MF@B<-/G5'<>=A39WP M5%EZYY;^F\/LX>XDM;82;4KSIJ.\VZ:8>]G4Z<,/(7A'WX'W41>I5K#CF'9B MYR*@DU':;(A6#,0TIB@/I+UK^5AV8;Q&3X./B4V%T10)U M8/'30=M8-I/13@MU-QDBFFB%\4D+IHU/>]=3UQW[M/?>BD(/-\I-HPB&U@7O M$3LT<_$V!-4XCZ6M!\M#QA;B+,0]X%R);HWIEZ M\BB?)@_64QB+A6U1W5_@N8:HW)!V\,32RJCJ2W.T0A$8*\& MD'&*RH/72&:5,W130$ZX49,=@\N3JZZNMW6ZAFFP^Y',08]R=HKI*HO\NY5& M_KUTY/_`[=@#K[E%3K]A;\[=Y%>R9TW(S\4FA?R;)59X]Z7\N'@U`9#M05;` M?R`;L4J8(H2J2%(]];1$]*]ROLC1BF:WN/OML`%`U,.3*'T7Q080_0HJUQGP M)P8VE84_#8P?N%.$/1Q2O;Z-Q<+PWO"(ATZCHOX,SC>]/]RA$=^!JUYZZ/8V MR"LUU,L,&V<8ALO4K<6>+5`ECT4Q<8E+Y7D/)?:^!E9@8W,L>,]Q*]H9XR$L MOGYB_>!',V,F^B&>;%'L*B`>N*]]%<08OHL_>:7--P\['1+=O8E(UF-/M%T`#[UN;/+&4@];DUZ$4MR87FP0X-&<]2;;BVN/YO=C[V-F,ZBH M^T+_-:$^#?"&B,J"YB5L?Q8[GHB!$3="^ZUD^[,OXD&![8(&,-&XA>:1'\1& M!A)H!LN&YBL<`<,FUZ3:^\W0=!..09&C9S<.O_VX)BG;^&*\D.>-R@O$#'+4 M'@4`9.>91U5T"T=[\#Q@-;D8)#*3&#J&_4J]PBD@E+E8-@KCZT9. M"7P.G,"#?(:Y!%ETBB68C8@IJ%9?8+'0CEO7_7(NF(F,>+^^:4_F7P.HQK44L1WEJR,TRZ>DACK1CU^_S6@6>PX1,24[8>$G^LR?YSSQHEY4YTPU6LC+?VJ_4MPY6 M?2N?%]?.^%,$V[XT0(?H/&H0G8)C[I5;$?C1Q]DKR!1J]R$!T@GY$TH!^B`CO1ECPI$4\TG0S8/:Y5I"^75P60-N[FE M-\<0E_#V%E:618UP?@`.A2JOW!^6R3''HN]2#:@834QYTS%OD@L[KXT)EI;[ M*P'$OR$QPIT)VJ0B_Q3_(N&W,59).M=(S#SWQ+/.Z%10[!W!IZC8X#6L_\5[ M:5.[8?$^`2;?\JG5QFA(FBH*(8KS\K=`5#=X4H0)RHGIC?OC,^A$`2RIT]-[ M!MYYSS/V>()W'--!+WKM%L\J6<896PA_@XV.Z+]?\X1SX2C)6(A:+==.E2_$"?._+0V?"JCLEV.L1+,$*H>$)[3%6\UKY4YX$&E M#GB8:(3Z:/@S_/\;"%2?(7.'P`)8_C9SO>`1XLA;YYF)$^:F;BY;G&%_5&%) M'DLA'1+?4O!_%8D'#H.-7/`=-HF/4_+:LM$.T7Q]969-9X16"?SR&IZ0-3(E MO!'<1LL,[HU#/88MVZ)4`JP\'0_QC3FJ(F*Q\(X7=VO/;6$_GA"RU!*["9\9 M(B;;\![J]H*9$WKJCPG$&3IDXKBGS!-A"9?T6#Q)RG`]"P2RHHTIMMI2.HOP MR+)J*`@@W>"?XEW2:W\%&Y#OSZ+Q>.;=1P+Z(SS^`.W.\+"'-I'7$(FV(2*. MPT-0*U,L':EC"C%(^*F5P:.X&;,%8CA_/O$@D0)N5N#:&@'%+%%W$G8?_Q!A M"/7A(>X`2P8J\9SG=/'Y^@5=FZ(E!^/BB%\4[ERDN$&"HLT&\/@^KV$'?WO) M_2V>0!+2C+OT3#I6)7*3/69+$!HB.KI/Z--IV\ER%DO<;`KW&*@;#(95O*@M M(#D%?`BM;<,39V[;NXP*6^K*//ZP4H\_2J?@9B/)J6/><,5B#Q=$E,*)S[& M_#B]\,!CSQ9[\?FIHLUS$GZ:3[W!,>-8K,$0M)/0D2@6P&/:*<]+,"D6-0&6 M9R[G"(XBLC)Q8DJ'@RT%>)IQ(^?PWBGJ#0H_MI0(IENT:S*9!A#^*IWD3)#8 MI8\GP([\``%.6:M%)_$9HSCGE]JOT=3'GI2$3&OCHL99P)^3:P(\@TR1)J@C!KG.Y,8SC\+K_QT1]CFC: M0H4?;P#V(9$GRP7C";F,(9'UPQM/XI-<&?IT2(`D:90\?C;,SQ%0E!E:E8H/ MR(^2R^KK=YH*/?/[0A5BK,V&G*%J$0TBV^7\5>EXWS3 M6%@!`5,G=YT$`K*;<<.4#)V3N$H$>V!$@U\"D'C#(=B*=`46KH"&E<&+L2B# MB(J/@,1+-E^@(%U=D^B>6+^16?#N'KZ_M>X2F^-=S?%$DJ?HBY'$X\VU'[BF MBI^W7AP(G[>"R*6RV'E4+0)P9R5XIE+11^-'$P&OD9@<`J\1UO'$L;SP]Q$+ M?T\I8(U:^5-UN=PJ1$CW5-",E9&I(P7Y!^OZ;B*HCPC[@X<0^`BZ1BJG-7GH M(")@\OC917OD:[+0!7`4XX?P>:)@.L3YMQ"!-YBYXU8NBE-;$HFR#-XB3[74 M\NUX&23Q#GX8Y2F$D5HS'(]1F6/P.DQX@N]0X`4W'*8@@?J2.*N)R1&G>!Y+ ME'1B?8Y'T;LBD%E=A]=%TPZ:1<6"6!PNPG>+P-_G6,MN6W\P^Y7'ZGCR2$KQ M<99',4NJ?F)5LB^6;=/#'%R'8IL46-&>-9-X88YTHI/!)(\K\7>9%/(:'(@+ MN,#^PSRWK=Q*=?QB.OBF9SW!;T@V>)'`:]2U-=H8765#892,`D3,;T(".N:( M1]Y"E?))2KY`4V(1H+E9WSZWH6E1[C85O\XZ[+/P6.]2'(A*P"3>DAH+KM'@ M36#.\")U7-<064[X@HE2#(YQ@A02!%IB4`EY+%_TM,;I58>@T`U MU^(DE+/ZE05-,+1&=.'Q8!ZI'H_4E856ZS3RA&$FRPD`U+8D/D M]GS?`SP#`D50@8=COG(L"8-W*DVI&X9AQ#:Q7D$&'$G#C"R7(%)1ZKX MOR0+ECI6S3Y%DT?@I,LW$V"-;MR!+_K6L"&-_W3[Z4>>B5B=I:H6Y%75TMG: M/5;UWI/M?F#AL1NO>[J.NN<_49"PX(TVC>'BDI2RN%V%>#3979K:4[)>'T4G M(:]+%^%-"/L5YU@>DPZ3L0V3([7%X=&ZV$L&:\W1.D3B*+U]:->959UAJA;_ M45T!@/P6-:3>/,='S4T8M49\DC7*);FC,4$QM0HG]Y1L4#K)"V^T&//KC*-C M3RE@$IM`KLG+9<4YU*:=@N4"ZW:B[NIQ>&-&$J`G,QVG30#+]Y>B+A<^T5<. M%=(PNH@C3$RIML2E`"KQE=09+AB2SI.$V8WXSF74MLP)/WK;O(0 M;0UP2_\1"Z[/T,;E$ZQLR:J2:1[K=Z`](NE"3F2?EV\OYS`R_!`QO(%3<M"GU^L<3#[Y6*D_>5">:)F`OI:$,6_N:2VQH7/WH?_$(HV M;$A\WRLVFP07"GWXY<(D.,F+-3.>YK?R=P1<3\VRP,./2OQY'-(VT/^2Q6TP M7GG@6=#`Q10QE_?Y`_^H(?>-DQN7N:U,_M7%D&(G:5EEG)?D2`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`K+T)WYWUSO&EN"F*E>X0$&FN,"1RBN\O]?#($;]ANQ_ME(W`!-F[Z MYU+SL4C_7+_;],\UY)XAN9MRKZ/(N<^O":OIGSM9U6WNGSMVS;W%M5Y_VTG3 M[_/F^GW>N.";&?_F9GS._:*WT.%V$V*(X^UK3'EV\0)?O,-N579G46MP-"6. M`[U=?PGZ7X[22)V'@ON]=OUE)8V"JVQ\:]=?A]`HN$(%=]OU%R3D4'"A3+GN MSGK+_^-R@EA[B>M:FZBCXJ*XMGH*,[K1;]'BN";F.&O]JFVMT>\9ZU=KUP]\ MLF?$<3I['_]@J##$'']FGC&5+E2SK0D&)G3O5M.+7W68#7,^HF6-Q(^N"KC1 M=J/M1MN-MAMMG[JVJRP>+J,(=-^*X6T7%>5ZR>IU1!D\RA71,H_79F`]6\'K MFZX2UK=4">\FO*.\L,/R%4/]9>[BYB+#1Y2)Y9N&'=VG>S+5QH/^&5<; MJ]KQ5)B>&KU-E=SARRJ7R2))=Q+_F^PYCWKJ*&QYRVH)=W-B=J[YM@[]0M2X MWOQ@GFGY3+FG;=@>UE]$?-[!%Q,Y?V.PJC986K\UZ-1?8-K8JRJCK\Z@ M=@7O&7V=.DC?>0(X'X_PRWOH/.HDU^S&9N-%*%%+=>-I*[/"O98^&+;T?K/1 M<<9*'K1'C:MM$#,;9UO0V593R+=;G=:^Q7OZ7L5[W11F*/[B_=V"X66#SO36 M,=TY>V`V(C8^NI\L'ROR+&?)QN(W;Q;9,Q2<;;X]W7`B^(:RW\Y2):@1Z;\@4HOHS74^@G%#>4'!;M@>BH[(\9YDQ`?\;( MGX@BJAB^J"?T3Z8T[YB!0`=Y*]76E;H=$?9C0VY#[G[[T2=>7]<`@3:J*PX$ MJG"%*<>NI[>XLNO'XFM`$-\<".(;%WPSX]_\-.$YPV9^ M"WX5K`KM+(YLZBZN5EO#YA;*,]2KUNIH]8,#-GHM_V15&]5?<=GHM8(&ID[] MT'BU%EI6%DS@#7?8QK^0@XHSC2>.ICK@G=:O?SXWE985*EC/:FMM%'P^"AX, MZ^^[;!1!SJ5(-*PT0QM/QFQ"D\OFMGL;\;A1<6,&C^O>N&@57 MJ.#>J(DQSUK!>DL=G$24N3$(.?4R\J9CZY@8:N38R/&8&#HV.9[B'G3EM>T) MOT5,IDO;SS3=K/OD1FWIP_IWNL\O1JU?KSVM_LBTT6O9>M5;(ZW^I++1:]EZ M'?5.0:MGG48VWCSSOWY>_=BUVX'3_=2;]/5[F6:,>_ M]GT6^%\LX\FRK)Q9)7"5,O<].-%;-S^4L23B M#-O`*WK\&4-^$`,`?\`A`'P9`X!YK`$!*!D$H+\G",#P>/J^3XS<0CNIY]9A M5C#C2W6.'5F;\CF*./-ZE=HDW*R=IBWV#0F^:8L]@E/$:]-TET[@TW61UC/R MU#3'5GD$I/::(Z#ST^MH>.I'!<=JH&HH<\!N/FSM`\L]E@WCF=K$HRG=U-16 M?W`*ZZC1\%Z$##55DVG:C;KC-:&G$_7=.L_P+M=[;4Q:,^$;6U=-J-\_!5=V MBB'AO<<6AC6.NA[IM,@-9LP3QT>-5:LX4!LT0$!GK%YU,#P!]6Z,Q$Z][NT\ MVRP:.5;?KG(Z2EFMG[!*:2\^#<>0* M\\:N53OSNRVMTVP:GK&"1^HIJ/<40[`[LEFVZTPO`^;-&ZMUN$G=TTYA)[Q1 M;T%"!NHI1-O-CLG)9?J-')N#CO1!1^.V#YAL#(X``K1QW!4>=@QZS6%'XW(: MUUWWL(5<][$ZZJ\L"`$HWDGN^J@UK>. MP'ZNX%J-)*MRT='G8C!E^R%4[0M4%F&,C1F0,F?.&/X_^&P;TWR(81/#]ME? MKU:>CE_ZD9\:?@9F#/M?S/"`T$_`8+[W7UZJVJ6N\A'6O2H>[)-K+N?13^X) M-NHS?.?G&^U_=#[0VM>L&PF)V6$<_-^LD:+7K([#B=A)=OB_EYT1?)$<*_&J MU9$>7Q\^^6@1\8#H)P)8;]P&'&KOV[R?=.[ZO[3(,J M2\?B?^=/7RAC9EISF.&_7-Q^_7SQM[XV5/LCK9L@:<.8:?H^6S;S/H+0IZZ7 M4P[7ILEL7/JPH.EQ>>S$^]*#/;"IY2/(7O#5F.=4Z*^/_U1NOWY4KC[=7,D# M)=\E@Q)BM8!A?W8]<5'\`PN6GN.OE;:N?F(FHIA(TO[]VR=9U)7++[^\ILH/:V4[J= MC(IYR2?VGC8LF9%\;#(:]0:\F MPM=9IZU4#SO];O?HQ)V'<+77ZX[V(_PC\P)K8IG@#6"=?6(+U[>"WPQ8*&"_ MNBT\!_Z68;.[X1,$R+M]+_?+GSF?$](Z_LUS`.&(=WW MWPCK[^)O]VKG7X+LK,P/7"Y^!@`DK"^G'9:A<[:JQ/#<-5H2F[;8H MBR+9>>6FR(<58]B_>NYRP1T;!)"9^@]KRQ\BA!W<@-TS>!@-$U+D/!@6XF\C40?E,Y\BM<&H4CX_@_EU3,NP MK\?/E@_YU`%"V0=FS9^6GD]FO#Q'$/-T\_O# MBIKTA'_;2I;$`JPOKI4[3PKA(9;(K^R]5]-E5Y>H+X.B@S&8<\X-]0HYI*5% M5P)`3`-_"U==U0M)=K@%:9"XN#=><6KZ=\Y'8V$%AOV%&3Y.8+Y$V?CFWTMK M@3^Y>[*M:08/!4.9OAZS48B(4IDH%/OT!^6Q0#D.I$/)H$GH\]JV74PVQI\A MMA(QEI\59%U[,!>F9&QR*NE[^)KO\GN^$SG?B9[O(6NK-G%;A%H^4X>3V/HM MA;)%UNV=A\36S3&M]#DFF\!3EMCZ?932YUBG>HDM_A]E$&'[&684/ M+EB<:^T=(JO]`;D];US>2EK.+$531YF4)8?9CY2\P8(X6BA"2B(; M+$DV8>J=9ZPRJ-HQ<2Y$%K:02@%E29+JJMT5FK)'VIN@O)MYFHC9=J5H/!97 M7]U#+>LNH-1L->DK:M@Y9'9#[Y=?N=SD#?C\C0.&\TX65$Y[J> MMF&YAJZ.W.^_,@?2%_L[F/?OU^.YY=`A;6`]L^_B1?EBAU'GR!A[8#XS/'-& MG'UBS\QV*4_8C2T*NP_/5JZ#MTR+J_6/B]ZR)EA?TX^,L5(F6*]3"UN%\G+< MWCNF-:Z59KST>E;Y>L9*F5O]T7'9@BW3:S`ZKA5>VO3J]H9'QE@ITTO7>_NS MY036&(L40*;?F(D'_1#NWOS@13F?/7>.KU@&](:[R8WA.98S]>^91X-MU>;Y#@J`SJJF:X8(T.YUA5]5%7/S&.BQ3W<';[^J@_T$Z,W8)5 M06)*=X:=?J]:CDLY@QX,U6%J3T4Z7LT[5DY/HZG]8VT;>Z>QN[VT]7>MDD+<3#14RD7/;%"+(+"'OP<5'PY^!>\;_ MX!G7LV'CEO!U\-'PO%=XQ?\:=JK>+4OXG2WI!ZRZY,YAKF%+I31?9CO0M50X M>WA*\TWHOC[H]HY#IEMFK3XL>Q?+@)OR2YVG\]7 MY0^U;D)F#"6V:.\-[\[[%F!"0;,N#$%V9>?F_MM*6-1I=SJJI(7MHY9(9K8H M*B:3QX?7RV#F>M9_V'@G*:X)+JGR+.F[-XQ8`FGYX]Y22;OU_64Y$NMC!:*F MZ1NHXH/M25%^0<7M:/M1E*=+KEQ!K?3([4=;J2++0UM)L<:Z.9[EJ7,/GB]\ MV&GP5+G_MK%W+R3-BLI'8:'B&BJR27PT?O#HO82:^(RQY=?O0T`^)>U(P,*# MITG6\&^;446*,Y:;,TIIL4F=@N89=T]*"T5LO53*48#.K$3O5\-ROKB^C]LM M87Y(F>+J3S^PB>LQ"`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`%(_]NIS>HD/=MT5*W MDYOU=%-9*#9NL=H; MCR/EE=>/M#]%N5%IBE,$?W23PBSU&C=ME;*U(Q:FKG#QO7X(ZHHE"-U:!;>U MTG50F+SPWMA']]K\]]+RV+JJ\U*VM;5N+YFRY!Z^#*H+PI&D$I:R2(8('/03 MO-Z#A0FNG?A*\%+R\"TTKQV\%**+K3&M))KYCFWF3FUI=_JF:HMSC%DBD;E+ MG#M/1+"7]7KV[.,>QZ.A'V&R5U-_FXYK+6 MXCM;*6"BK<.NIU(8"S`2I)37Z)8"P[9!Q57:8%U-W8U;`EW5,EIH6HU&O0.R M2>J^6U"YS,T/YIF67TZOU08F,L?AEG9YU1VDBO'ZP, MLG+"SZ>ZA_-3]GJR'1E?1=/)T:#?K8JSP(`%,@[!'*Y-ARX*9H(5'YLW5 MG/+]VWW_7_W?4D170E`MC&_P!6?.^;HY?.9L;W`EM7*^8@=6Q_FPRSC_ZX+! MQ7WZUP>_H;DM-T99@MI MU']#0LH5P6;*::`/ST5.#Y;_QV>00X@;4)YEZFB]BH2417.=(BINE3I:55;I MV&14T")U9)2^LQ90<6L$\^ST9"1V;C^[WH31`0SND(/ULT1;*.3Y=.'SCI-H MW?6D_=&@URU!2GG)/K"4_L&LZ0S=@>EA$9E,%. MN9+]%7X8E#S95%4;:;VMFPI%B2Q7`-*MO%^7N#^_TQ[9&@ET1]U>KU^&^U]' M96U"R'\ERCTQ6>?$4!NW1X-AEY6\9 M-7SWP;R5WN[L(K12Z2]9=DG37[W@]%V"I/*(3TFM_/Y2=9@ZMMG6L5E^#VEO M-.KT=J39\,__C]0 M2P,$%`````@`1%]H0<%T&$M5#```^9T``!4`'`!G='AI+3(P,3(P.3,P7V-A M;"YX;6Q55`D``Y_DFU"?Y)M0=7@+``$$)0X```0Y`0``[5U+<]LX$KYOU?X' MKN>2'&198;AH_C?-Y?\<"9XM2%P\1@Z;R9OG8>- MCY+,`HA\/[#.'84+T[.@Q#%>?AL/G MY^?C]0,)CC%9#,2] M2'$U*KG1QX\?A^)35I3"3U3(WV#/#8672G$YVA+\KX$L-N#_&HS&@]/1\9KZ M1\P'CO.9X`#<@KDC`'P*-RMP=D3A70)$_9G@Y8II%]]%R[%I!5N"=.\^!&!O7%*Z)7"7('1A0$?[PGN1 M;Q?@N";`<>OU=H8#Z$$3HDWUM.O1>[`.(S>HZ=>MEI:]6Q5T-6VMMYBT*O[* M"ML-EII1TD1X,!8]YHA+&$0LW_H=A#>8TAD@XHL-`J)$OF6`E>.WDK;:X"\A M]3!+=5`$_.D*$-.^5"?7$B#C:"P1;Q>>06=:)M\N0.,H--/2$EC3O*E8.@'G MN8$7!>*C&P8E!9+9`9`/?`F3:]US;)"HA2'7<'+B#!Q9?O=7%_E.+.P4C2S* MVXB`#^+N'@$(:7GSI"B<)JG.U\]8JX3"1Q!"CX=$!2Q*R5K`[E@G'W>2T_EN MHU32_Q5*-09HXM+'+P%^KH0G)Z2$HX[QPFA61T42OJ,1#^`M#O;[!+-Z@OB4 M12+HJ.)I6Y\$+`8LP%ZJ0,#G#S!)>R!!*"8)YBY]$#,%$1TL7'(_;A`!!71#N:U).^%P3M+6N<237\!^345(?J(F*3&D MT3)NJ`:0!824GQ.\5+HV^3Y<"3PF/B!G1ZP'C"C#A%?\^WBS\`SX;)KXI`O. M_@T"_QY_<\.(L%;[#GC\)QNDZ0.M5,).GDIA)PR-;6/HW/-PQ$+J%GB`A1?K M_%G.7-`.%!:WDYMBS`DQI[81&#Y,-@RL@HCTQW8Z/HTQX>;F8L/15C-)9LK'CVJFY]BHM;1D$QV(217VUCY`M$S,@;^`3\:Q2Z:`%9 MQQ4;J.:D3,`R5LK@)KS\TS9>;J#[`(.2+%95J,OL;N9N>-Y3GM=E"W86-'HW M9].Z+.0D<#[:%C@,+XF`;Q0_!67M9D2'6@Y03VQC90,0!`TMY M-Q%NBBNW1L0&C@JMD8P5467=4%6DJ3N(?\?(T]:@HL*]H:?("$F3=>,IHSI4 M6&L..:F(ETN,!!KM_&&N2&?Q4QXQ>;`R3NP;R?D^C*',V&CT&DW<%0S=8,<" M5<=H(&0Q/2;P)6'6C1%O^?HE`OZ52Q!$"\JZ^VC)_0O\2S"''E2UPR9"%A-F M`E\29C:$M+W/4960%EHW&)-C`#F)]3+%2[73V!5E[9O#JVB`G.`^_K6P"U@1 MB/G:Q0Z7GX>9I=&]UTM+%HGEPNE8OW#ZHL'!<^=%A_/F.W(CUJH"_ZT]RZG, M_]>(60_X[B-%JYCYO)OU!?G]7UC(3>*=(*R)R].3J3]BX41IIX(<+,,<$Q`69-S11TYCV3F*FM;JU&W.-N4BNJ/:A MG6*`DP7'"X!8YJS+RK2E+8J'HLXRW[@H;"E=7!W80UR1T9F(!/1J'1*760>1 M2S;7S)UBRHI),D\S?(MK%`(":#'Y+7UC;P.H)7_(I>CCL=W]E1C;,"-P;#0W M@5N;U"G=U&^!@.6!4+M2I6:/"_P@MZ39W7U,T^@U`RIEJ9^&:)7Q;2<'^9W7 M_#]_I@Y@W8(G@'*3Z@7E.ALH%$09]W(!9*.5SA,N>D-/UQJ53W M:4EQ;LZ`9S`GQ]9JCWBUFCMM=`QIWG<$K#6Z'UU)>9-<)UXJZ>MWE%0RM1\- MY+8#2-(CW>RGHIRMG58!Y/+DP(H1Z"V@@#F#GX"Y9/UM@,6VS<2,J[471/R6 MF7/OKP@2OHUP1K`'*)W@W`@S7LNKH:W3"JL-SI=ERAJF]:/QCJ\,"IB%Y_X2 M(DA#[I(GS3C06,I>7HU-Z$<#J\PL^-S8?`X\EEXH/Z\RR5RNRZ+QX"&FE,L= M4AXYFFZ@G97A_'%=N3!\:KHPS%4X0H>U"\,<(FM_GR"#<+'Y3GE[O&T(SCU6 MM<5F#?6JL;%P%U5\WU7O#E8%*Y(@^]F,!48+Q9TTMF!%@`>%$]CO`1"^93W( MDK\F9FF*33NF/4ZDN"5-MJ-05[2)G.E.TR>W,D::8R+UFN M[+'"EV`.""GTO4'YGE%@8)%DPKJCT[?`PPLD-MJRU"?!KIZ+C@=/1<5[QENY M09(V_<&!05?S<\N5"PG/Y:;S[)G`^+A@P(\+*B@TENPAF\:V26*MV^G/4B8" M6$M^">*?URA_)8.*5".Q/C)J9)BD4[_INK-ZFL,O;WI0CUM*RK\*!E,62>KT M9U#MH2ZY#4)V$\I;(8PX-5/T*L@V,U5.LNN'$_9$0>8P=:76>"OS*KC-625I MM.X\K!)[Y@"V*9$YL=?"9MG7P*_>.DFO_L1P9_3RC0'`%VN4"7*&6.2[ ML76B[0X".IU7(;X)K7T,B2;LEL%B=OCZ%?3G2L=*+UAWK9/&B"\0N81@2P/Z0"\?:, M4,%W&2K?C6P,=/DCD%G8[[.P4RH$]D2)\_(26O/`M2]$9O&.LWB%Y"!^U56U M;:9MC/+5HS30]^9`G3>QBK>'0OSRYE4:\X>3<2Z(]:`3+<[HT+C'"MP5G"UQ MCUO`;?K,9!K_NWW:#N>-5'=H_V\?(%STY]5[!1O6AACJ*?MYXR1Z0^%#U/'7;DUEECU_G M4H_<^*JD M5C<>"JG+S_=Q0S]NNGBME]HW4!?VO_Y^U-XUE]KCH\;F*5^H536`]77VF?F& M7"!;`?OOZ38U=/O0;OU$<$=5GT.EGN5MWZA3O\5(O^%+LT>/:K4<);K['!8- MNZ+M?$(3)^>+!0$+-P3BB:_I?-_$2A4GS>E^/3EGPXYY?=,0Q:<'FU#873`U M7=GV[)UTQQ)?30Y3>G:Q(9W_CR3]H4C[KQ`TGAY,[KY/GDMM-*J*=/_TT57D MG+W3I4YG5K6+Z.]R^Q=*YU&DM,C`Q,C`Y,S!?9&5F+GAM M;%54"0`#G^2;4)_DFU!U>`L``00E#@``!#D!``#M7%%OXC@0?C_I_H./?=D^ MA`"]GJ[</?O_[RX3?+ M^G;5O44N=\8>,!\Y`K`/+NI-4;>+.IPQH!2FZ!$/!B!"J:A>J^I_C?J??Z%K M/IH*,ACZZ/WU66R699DUKK!4,M6\8+%&M3[[AA+VHZE_]-3W2*%FLCGI">KZ MKM@B3 M/F8.F%FQ&5'IYW:())2O/V<8/ED:;P#5+R\O[>!;-522I@R`W7('^\$.O;H" M6CE"?[+"899^9-4;UGF].I%N19D8H9F1!:?0A3X*4#3]Z0A:%4F\$=7H@V=# M`?U69>!/B!)3;]0NSVM:R+N'(180[-\U]T;`9`"Z`SXF5%:0%OQ?]V:NA!;` MG*K#/5M_9;\RWYQ$2S19NXM<=2"T!X(`!V' M,BOXS`*C>F#AI%5EA2>&H:E=\"+0<*A$"&?<`\LE"H!FC0HR"T45F4LAS+?5 M4-N,L1,%Y(UZOI3E<@^3C)"79^\1+_3QF/H;`PZGYXXXL(SE@=<#D1%M?&K> M2#&EV?`%$PPJ=>BA?T,/1AWH$T9T:*+WMX0!NO'!D\CGBS%GP9$8ZN/.)ZCA M/V(ZJ0`&YH(;:J67WI1^C5SB:Q&U/VH-9*$.D0[EZ.*=SW/ZE-YE.`!Q!/BO:2=6Y3:@[<^WX7'#Y@Y">X7T$0KL9)7S[B MWL)5%)<"#9*E/->RC\5V5],NC+CPM6^W)T3NR8S+R\8MNHBBMHC;5H5LB-%$ M[X8'TDQ&7W`O=V\Q^/D^[:\9B?0TX+Q.@%#H[N`H24J*:T,RX2P MW*-%=Z/00IV.R>L2[9C78H59KPL2%/L-U7VB`T]`^4A?)3Y-M#)P9]*P1%.D MFEF87O\``X&I`M=V/45*TM?WIB=(HUG*N7D>1,O7C'V<0JO()'H@Y14!+X^A MG.P:OU\D&35?/HF:,E4$G:!=4L:?L4PC9>*2?%53@,MK67DM>V/9BHZ?H+Z0 M:YH2625/[@EJ*ODQSI*M\KQ>&?=:4-.LXM34<0UNJ^*+,2P>J,\%6A2=F@@9_9H[-F')E"<8[:GLM=S_T$^^/XP] M#XOI?3\9E#G1VSU]Q#O^"_TVDE`8LQL#@[L6Z(HM3#OY*'+`M8R*'2V9]N@Y2EJZ+3OK)T=82EJ]S*(&'S\M3J(!O=:F\/I@$Y?QEAB?G.,U,? M,L*.AP)/Z>;[E6+V!7OKJ#X^Y+0:?7'=WUI3[KC"?$M7W2,5V,XR+],KO_,18<(<)14F93-1'.F]&IMM\KQ M=CYR,]E;;)$<%S.6A82""@F%M"$.XWY]^`V#S'_(^)(++EY204PBPLQ%1B9: M"#T@6NC"$[`QF"-"8[Y33D5&%#I`R1,(G6]'_6+=77)38851C?;C^WX$T1IV M7#'V(%H#V^UBE!A6:'F`38"3#]V=.^\^WU"*^*+:NR^SN]G(SDL#B+ACZ2"+DM).*+\VO=:O8ZU%9K7\PY?<-O6]^0TJQCX== M2S]Y[CSMM"W-SE/1T8@&Z3=+TZKZF MJ%-GE[$[_&:MSZ"+'Z8@V@7B]<9"PBPFEP&GF%3XFR?&/5YYN60^JL"#:^Z_ M]_UTX-=/V9UOO!#=]KCPR<_`2V=5]R3?2#&IX%1Y-P=EVD!XV29XXVJO#""C MY_F1Z;D^UHS2OQ^)TFD#V*A]<6"MKY//LU.79[RZIL3[V5)$M/4E[EY0K=461F!EF.>0$Y,B: M_>L?&@!)<`B0X"<@IRJ7E25TH[N);C0:C>X__MOS-D)/F*1A$O_IU>G;]Z\0 MCOTD"./UGU[MTQ,O]0$_Z1H$"4_3O_T M:I-ENT_OWGW__OWM\R.)WB9D32'?__PN'_B*C_STG(:5T=]_SL>>OON/+]?W M_@9OO9,P3C,O]DLH0*."._WX\>,[]E\V!*_4 M5$2$O`/X=S%>P[>$&3["#*=_@!G^4?SZVGO$T2L$(W^]N](R]+&"2P"]XU1& M\*]K2DV%3OR8#.'>%20" MZ))4Z?2(GZ.F/[:P+4:\\Q.Z&G?92<0ER\%7)-EV(DR0D70`^EOT&!US5&&' MX#39$Q]W^HXR%UWERRFB>DDAP4CA^.37^U?_FH,B+PX0!T82-/J6P__7'_G\ MX[(4B.G99%.RACEK80G]]I@A$\40W#!.4NR_72=/[P(<,G,+/S"E.7E_*@S. M/])?_8W3?8?7(9`;9U^]+3YB53]L7J5H(Q=T0#=FMB7?3$!M&8A%78Y%,'C> MCW]&EQ_QHBMJN9__'1^T#-7&V?K\&H*KW_]HD(4%H*1`MP+$8,1&(SI\KC60 M&Z('BE;!2O7/\W]Q%7GYAY;_-NOWK4^LM^\P9NYO>8M)F-`M*3BGGEL#_4?C M['U=)<''G[DRR,KW5E"@__!\,'5;`@3#YUH#2SIY``1<1MY:P.LWU@Q<^W;%F,0#)I;JR_#U/>B_\0>N:2_21O6:6VD/I5(0VTN"YJ5+2N#+$!S+HV MSO:$5):RW@G0#YU_9;21G2\,W;A9UT4S$;5E(897[,7<3@$_9%R&$29G=-IU M0O3'O*-1M@YY2F*K1[S*$`L'/,7\NN,=&XKRL3.?[Y/M-HGOL\3_[7[C43'< M[#,(A<-]@/[PV@AD[>1OP,I1&*`!PD9,H)4<;8"`02(&ND`<&$G00]?4RDL? M&2O[]&3M>3N^L'"4I?EOCE>8^/7?[C.ZK&'CNUE=AK$7^R'=+9,T;`B\=P.= M=[7U80O67!>XV59>=Z+J^U<2!SB&V[W/7@07:'3Q89RE#='W^=;>,DTI*2VK M['B0G?6D)E5>.=41DZR1)TP>DQ1?-RP5%17UD_#]_<7#_22W+DW+V(PV-LBA MY2D\0*-56AMK<[%J"*^OV:.!=I>NDABM6^XQF$^6EK(9K7SL`N4TN["TS[QT MLXP#^,_%_^S#)R^BE*7+[,PCY$#]D;]XT?[XV-D1UL[2[\28K`I&@+94HP-Q M=56A0.R>VHAG(,B*&P9QK_C*/@(?GB97M"3V[WV(?_AC@W]AJY MM$+9,8>&S,B&L`7$E@DT(JNVY.XW"IK>DQY`^YU$.X5R0"FNJ)&)*>X#)4?#<'6(G46O(E-> MY/+?;2WJ.@VUA5`,F7W5=B&.K4U[2_*6X)T7!A?/.X@#4M_M)MM@4CG`:I@T M@K2S@#LP):]K`S!;R]V8M-I"$Y`(<]"4N=@)0"._$B:974N&\R1`&4L,&!U% M4QR)#IJ$B9R(!K9&`2=9_UF2>9%Q[$^S)AX`B>TE;4+HT1)=($:YS1T@V6&2 M'6XIE>RU`SUY[^`@I'=2FD%LV?QV-JK&7C_>GI5OHTEA"CD(?VN2C[?CK`\@ M?X$8$'\,5')AU36Z#.,PP]?A$PZNXHQ2'=*C!-=>O6JT`=E1#C-69/5HAK"E M("94*5SM?*3D^WC""MO0DUY<<*`3!H4DEO+MQ*JJ<"(:-T6[_HW>L;'IT32Z M,E9=F!;?Q;++_(#BVW\>;@=I9L5_;D16T* M:\N"=Z.OM@"OKY:?KZZO'JXN[M'RZSFZ?[@Y^_<_WUR?7]S=_X0N_M^O5P__ M.;O*#.6I!"_\'^K0N9`(()%FENC2!&!=F0Q27O2C'5"8;LDO40DX?P9,9ZHE M`+=R8?+KA%OO`%<)9E=8QX/M7EZI25==6U5'VKZP4E&CO^[9\='6KJBZ42M& MNQ"I]'VRQT%=8_7\ZL9;6^;-#!RM=/5@BXN]B2#5"H+Q3?%\R?+;T(9>[*CL MOTM^C_$^YXZ?8^;?V#G_&J^/:EC?YLHV)EFUE*T?F=GUF$395[JB&E=V$X"= M%=[.@KS2]:-M6?HVBFH+B5]I1DF\YCEJ-E=_3^(KNE#"6$QM3[;;D.?Y0:)J M$F=AO,:Q3PG4<-X(82F-O9V)2O*Z?KBUE/4VDA1/U0H(GOHLP\R?Z#R8_K,F M^N=\X-DQ>.I>N+1;@-2]D&CG@*$,\!.[],T.\X=X!I(MHIS++"/AXSZ#PS#* M$GHN=B;R([WG;GSP5!MF;U-0D7N\$\AC;)K_.AU*FYG$*.7OXO_I_=OW[T_1 MSB/H"8`^H=,/[Q?OW[/_H92_FO?VV28AX>_T2.EEZ)$>C-$]%1S>/E)OY.?W M"\3J$X,!/L>^^.TI^^WI_T5_^+#X/Z=_6'S\\,]L!/WGOWQ\O_CPX><<>YBF M<%AE1^[R>3[,9#K)`E$\.^QGX1..YL],[29X49"`C5R@*\:\Q4!5$+`W[5YT MZX7!57SF[4)ZII)8TL4D#``MA:Z,6:K$L%JAK`6S#"FKAX$*0`29G2=AC'P. M.W\$:P0>`!)1'@3LHE+APYX&W>',"V,<7'@$GD&F2]_?;_<1E``_QZO0#W5. MGPF@'0TR9TG6H'8H6QID2IDJD)H/1`$?.;OJ]"8^!T0Y)'HM\R.`W[AT3#+V MBMTY%ID=A^P$A'5T:`+"J>((Y,`):/C)QWJ@N"V9I6<.C`/7(HWL=,FALGYE MTD"51E^DT#$[ESBA/STY4N=+65<C'=&%*O&->L"'.J,#,CEFZS]4!DWG7_LFE%?6O?UX;X?:QF8@CBQ_35UC MD_'.*$)[:6.E-B3ZFL;SJX0Q#T=ZX41AYJO83[:X*/W;(^UY>5;H]!G99I6&-PG@L/M MXYZD8E=<)0128C!=S+S\:T"GB)(=;Z`+>3(B>QC^M@VI5F=)C`OL\$P^\<.R MNWFV`>JV.R\^_)32GV3J`45.C+_0X9/N`I]>1;[VWS+3M#5/(YURDNSFQ4ST?=)I`]I'(VR M0>J=6*;+.#@O%ZDH0G;Q[$=[.!,L?;8>@JOXEB0^3E.@72OZ`1AM.6&#A5#U MUWJCL^?:#219X61I[%_^R,^"=S@ICQ+.HHC?ZP(MRO%""I7`C`"UQ000<7*+ MU_P@>)VD.G.J'&GIQ92>Z,I3J?HP.U?<6D+J=\#T3PB814EQI)[_390QN<5( MQ(>BUS#8YG*&UUE?DSBILB!T4<=O"Y#%9X&MK-2>!FHAK#X/;*%*\\KNM=@G MWE"#"3!VRIH-8$"&*E1$`%K4DJ\X:S7W1V/LZ("24'G)5P;8,>X*$FJK@8X1 M2QB]CE06\J5I_KF.2LM06C]<#LJUT:^K'VZ ML;:VFF9ZVK42XA_\2@^=0&`$`AUP<@FC?8:#^6/9'?GY7%!\SBF&XIF(N91% M_I,3\>YCOACA<"3C9!M*HP;EAL)HF&G2FR,0._N8$5%==,BZNIAQ4#S-*'1D M@6J:9$]7_HK#]892L*3VSUOCKWMX=GFSJEWUMVPSW='8T::^[,KJU16'K>VJ M'YVU!9RC01['HTA*F7_K&ILW@0=Q1'`?46\GOBCVO6&;G.9^],B<-'*HNISJ M!F_A/K4/@\4]:Q?@>>]?NU-FX%FU+DPKM[:CLAJHM[YY;G)'X.1A@]'W8]L8 M%Y^I;B79G:VX!@V3@'DRV/,WXD@0QO3_8*Q/P;YO<%P_(M#APIDH3Q+P/W9W MZE$?R=M"F4P&0O`N(8RT%'DHI5#T_$KE0"?*\#:_D5UY/LYO7U=A3"]ZG_`(DP%#\*V1]:[-> MGVJW)[L$2D72(;X7^?"J%OY6_PAOD7#I:I,H4%.YP,4]7'LKZ>*\UJ@3`LHV M)-FO-Q2AO)2HBRSN@/B')&F&7I=]>Q^]B-VY2V2\X;?Z'@S$G##EJ,`[Y.M# MS/6(J7!$*D-`?P6%/.(#92O8^SQ'[S5(+U_+11+K!D?LPV0$>^F>'-[`Q_4( M">D2\++NW^@M^ON_R\UE#[GKIR!H'X>9MFH)6WV@=?E*D]=&KJ@7M_>`J+)4 M`"MZ?7'[ZYM%L3J/,R3H$A>-EF%V_CD4E,72![&8(5%D:=ZLH/OP991\;TN* M;`:Q]>2[G8WJXV_]^-DS;-N),4ZS91VD&0(GPCC0LI12=$N2)VIH@L^'7U.X M,R\N!9=%EE/+FNN#R-J%1$^6CVXM.F*Q=43M2ZFZ"_J*+5WY>AOVI@+%_*?4 MT=B#,!AC,4>%'@_H]:]\`WJ#RGOR$J,3*KP,_GLOVH-#%5/*P16U-^E#U5?=J'G%6JV9-.Z>]FEMS\*6H=E5,"_XOR2>#U`-V M+0J_A9^!HL+%=,.2H?GE+__P2S>8Y'%4@.YL>I^C/ M$88?EG&PW,*)^G=55*,;J!WSU84MV029P-DR(^:TU=:U#,I.F9X$,[MRC\3( M`A7`C*=E`T\S'E3%?1T.SI(MI$] MU&FGI&X%!0C*81K7Q"SW-0.X2'^"/WX(6$:`=G0A]WX3^!GT/HP@]8E9]%Z+$>6@6GKFQ M>P..M;CV@)((5I^TL8=YP,7-*A>F^BVN&8BMQU3M;%1?2^G'VWL.U4:3C9>P M'SG],5[#T]"1Z2\,8_Y4U*K#VX,!"024N^!'\Y)ZQK(FU,J$A-\"'/=&YQW0 M(VB`KI&$,;2ELB?=F*N403$#M64#.I%76XTE-+LO+'O;6VJ!/B8W)3S*FZ=S M%"<,A]4"0G!_C<\Q_Z\4T!)5Z]MK"ADCL%9FJ".+1Y6'#*&M:5U'"NO[\(;^ M"[-K>*YJHD*"Q<;1@WG*$:#7.0IX%2>%2`4:)^*C=6[S!L%TA\;A$[S5,1:4 M"M05Q=.SU:QR=;AQEAD'[`TV]TZ-A6.&S!7UZ<)ZLUZ98')'XQK5S;G. MB](`T[Q$P5+)M`NNXJUWZ.4G%G"N:*F&(3,/40"Y92TJ?0'!JJV*2F.X896 MF7&D5RS&Z+6>*Q4O8R>9*&Y(:N3JI%@%P1V5+8[B[*JFD/;BKITI;`> M::%$;<#A2U9H)V"9&XMSP-GU7GV+,FK^:(:>21XLZ^&<< M!0_)%R_;DS`[W&,?_JOW93O`.Z*!;0PV*J`.V!G]:R:P4?W234*R$WC1+C9( M\5B'/?FG2WDKD-I7R*Y,*O014)QDR4G.%"JQ6%1&*/>-@_22KF#!':6'A64Y M!]3XG'E1E-ZLNJKI&)@M*?!X0JFH]G"TMOSBT4A7W'MPS-Q-WA:XW38/,XFC MQ+U`$G:VDS/\("4G[8KY26/P4<7]L_&P,[%3$2LM??J(U4X^(N[S(Z+J0.SP M>7B\<[!S.GG)RW<-CU\U(G)*1PU8-M#5!BR.Q:]:*6V-7ZUR#"[&K[JSUZ*W M!4+GXE>2XW$E"GW=K*16NP8.BP;.OJO=R)#.D58"N>`F-Q#6XO7)%=SD]W]6 MW=S^[%Q)[,@=GD=\[9P?MV]BD6U^#?>XU`GGBHS+^-G-8Q2N>?^B(Z:'(++P M/GH0R\7#Z5Y8YGU1/8!$?5B&KL'\70)#QTY4.<(R2(HDE'._EYR4>5\P'Q7, MKW+FBR@X2J9BWO3UMBO<6WQX+9M@9C5O=HRDBV=,_##5/LTT@+._X3+*JLG-$-/(G"P!/5_6YY27R/5T&YS#M`E'7!6T+( M(^&VU`)W3,%4.N6.@7CV2O(C4EUO^[)/PQCZD8/:0*\,=N4I8W4B+JL5`2/Y M9B43G+-TCE.?A+N\7"9_R$.WYUL*[-.]^0$_9Y\C?4QWXCD=4ZTQ!6FDI'R7IGO`+@:+&X1UK\A2<)6F6EC51BW2Z%I,V&*NE^M3C"*-2NGH82FM5 MK<<@6U,O]W-KO=S)#, M=Z-?[TF*\=;RQF3KB;)2HD#2 M7C94%77MCH6SS!SB@TZ/FH?::&+<3';9KU@];N;6Q$U$Z$]^W_AXU/#AIU;= M`>1;:BC=_!>/-3U^C'G:E<)%?'N$0&+$SUBWI&8]:*( M#KP5-!=OQ<-:FR*UL= M8<[.I:Q]NK3)J(_E'U5"58RU60&V@1U4C%)I#T_%V:IOV MH]5-K_E^_YA2U02WY:G4?3,5,(2UU'"W"V.5_KLF@-;:\9H35[^W+V`1!YZ_ M+>^8U#NJ3_X&!_L(3M7BZ=`])D^AC]4MB9<1HX6E8XJVA+_C@*CNU`"NZ/M5DUNS#M`PIM'*[]<@!/$!=&^W\2#N_M9E;%F(^%BO+WPV* M*;726:!R7@`L9\X?(;"YT;<'Z"?@FHVK95!,EF51:>>%]YZ&UVNB)VQ]3T$TF;>>F& MU263TH?R1I]'TAOT0`U)"B^6;50(F(Y;C06I.C%'!B2?P2F;T7A;\P5O'S'1 M"-<(TL$+PBI3QA>$',S)"T*9M,Z7:N@;!Y_FVJ'W1>$T/,VG5[_@&!,O@O=9 MP3:,0WC^"9FH)IIE"&M'MSHQ)FN7$:`M_>I`7&TU"EC^&JX";5_'+/$U8_$I M2O)7;XN7SZ&VRGMEB*624@HR*]6CI+_/_CB^/GF]9A+]%X(QZ!N,LGG(4<>I MROS^]/-!?79D_^^!T@=O_@7+Y\G6"X]OAJ>=RM)!:$*Q58Y&$\PSNT),QX3F MW:@B0"S/!D62&@(5[#\(9F6V6M)5/K5%;15Q7!RH12KV$[)`VSO#$'O_I09C&9@-E()S1GITP<;(>9.470E*!Z#IP$"9$B`9NW3#F( MRRP[^7ZC<15PV`5*2+@.8VH`R@XYEI+Z9N$-[1@FB\EYYWB%"<'!@_>\3%.< MI5^QKI:9>JBE4B0-9%?JBRC&62L:HJ5%62DP$,-1YCTCCP',7PC$G.1\*&3D M(3YX`<467+C*&BE-`2+NM-Q82,5QHG+YW$D M^?EP1S=?DEV'<5-P;_II?PP]UHES2I4^GO/%:[>:H5D5?0&Q($X%`C*LQV/' MD6PIU\:([%2362KG-:GH*K7`)IEI=GV>DHUZY:[1-;>BMM9#L^,($YBYRO!6 MMS^//LM+5M6:L,;7T6**%ZJ<1_1/KI7H&U-'-N68C\A%/IPN\TR$CC45Z'MA ML!#?[<=D$>KM!CYOU+T/0>KU80TMR7JI@'G9)K&3 M#"8SB0M4B+6O,0E;,,XG" M%>MK>\`>L?!F>VY!S.'LP?POT,,309&;?99F]#`?QNN[)(HN$P)_''N_:IGL MA?ER1J(;Q8%KG.G%>6T&W+R0VA.S2F"X#2O*5$@3HV\P-1)SO\2HG>"*1773 MJUCYA&:J25ZFQ5*+:DQ+59WAI5HH%1?UMP![>!Y?W(>FQ37#^J5=,W3A>DQK MQ"<$=Y1/R=XE@$"I45KA$!I+U6S[R[%+$A/+.*#N8LC;\$UMJ@SF?9G6RUB@ M8QJTUDG'M7$?N9K'>`W/4Z>T<8:,M9J]0I^A_CU@I`J?$#AQAN0%&L&^8AG3 M+DHTL'M6B8K26/[`AC$/7RQY].+B&1,_3/$M7%K9^NS--/V@!M7D0\QJ;)L( M>JG.Y@A,ZP.``@;E0(A!20VK_W<9[QZBG-VP+U#+U[-H^2$"QR<[TD8 MKSG%W!&0"V[F!&M]W!Z(+-G8WBQ7#&-G+-;R^?#B/$)3D4QT MR;)`?-8?PJ);.)8;S_[BK?_<1VW#J7^0G6*6(_3_BHW%AB1_K'W(<@RBLCLY M&VG(JY95.GH<"SAMK+3?#87=SYQ&?0T[?15E:U7XIV)O MH=)F/9]#RADH;1MTL-E[46,5`S-`&\4+NK!4UBPP@9JY5($Y2>I=`WVN[QJO M!?P;ZX4)AG*G*D(P&W?M%0D&?SRN_'+U@5Y5!SHI?EXH(:^1?9F0\Y!@GV)- M5<9.-L/F4A@VBS,F90QAM=B?(5.X8*R&TV]NV?*"*V6!]U5"4#$=:GSBE&41JF MAQRS#6:+THL//Z4:J8YI^R\\$M,C8$H/WXP;`W>O%<2"539DHS"Q+>/GM9=& MQ-0?\0LH*6[BC$/7CR.JLJ'/^_V%T1[T!O*`KY/4"H^M9F;@9]M1EE*`LUA` M:AEG80"R#I_P/?9%UX.+9S_:!]1"4OT"6[3G,KA9'7.\W";[6%P:)&$GU6CKNT+"\1GL=F!^`G'>RSJ1U]6.VXE]U0S'[@NU%7]TQ MD(U=^QH>4(=>$S:XVJ4X/DLBBC#AF>O+-<%L;N5"-`6R$#HP9J4('K1"S!L^ M,"2GMH@8'*H`H@)RVHO4MOC!"V2I-5PPC">_PI.70UJ,'73V\ZY;VD@,0?A" M?/N:"`;Y]]?6^D`,)74T/_]ZDL8.52V-@^O09U<'N=:E!E'R[CAL-._MR6C9 MR;"ZV++'?7Z39!Y MB3%_J`K_N,/A]G%/4C:;BE<#(`NVQ)B5PGBT0LQK+0S)J:V97"\H8/Z:E_V[ M`FO%%`SE:"4X*J^SI^:H5<^'LJ1EA_[+Q]3+"-`^#C"1'>XG7+FG=Z`;N'"7 M--Y9;93=I.8C8E5YRV*([=3D"AGZ]%PBG%4INV._H[S31125FF,M`]F0"S%L MQ,WLB(#E-B%9^#M3966E*U,@"YN9,2O%9M8*,>]F9DA.Z_)`,J3F7?HL>UE_ MAIYPE.R8B=]-1W[KQC7X@^16QY,_".?(O19D15M&NDN?15Z:AJN0_^(JO@QC M+_9#+[JGTA*1\%[=QGI/XM0KT8&B`@-$)YU81I,8JBG(-G\?\"(Z5:4M[PF+ MJB%3UDP;F0BGM&]B4;=HYTPRGG)SML'="$^+YZ\^Y(2@3%X0IP-*%CG\E/C> MBW`JO"_16#K]BK,VUZ,-RI(U,V.F,#_=N)AN_;>2W2L,[<)6?K7=>2$!>F[( M>9CNDM2+;E;72;R^AJC2,DTQ%-6&Q,TP7E_1DT*\#N&6C/WA-HE"_\#_/T2J M/U-*?],LR4EFLK.,)Q1:OO1GD-;4V^LT4JKE&12S0)(<8#]AZ!%',^L^.3_' M\#J0SZ/D?H&*V5`Y7?%'/A?Z)OX+DR(VZYBWTDO?)WL/NH3D&SALZ:Z:BGHO'A[/7>P(`"0@K@;(!Y.\$^61"\EL# M91WI?]A@A-,LW'J\KYGWR!NN`C^K/=38/68+%#S_59I$-J-GU*@D6PPOW/A# MD3@+XSVU,3<[+.H!ZWP``T!+6[HQ2\4.W9F7P8LP2S(OTFZW)AS4:BGB#$7P M4I$]R?$+()044//NH'V8X$#H-8"]R1\7%9R4H&B9921\W&D1WK!^]9IOTAN<,["*?'ZPL*D!V,U&T0?A>T<@0!J95W M1,G,J>/#Y*$R!2'7)*9"@83=#7,P+K\*JR%/(-F-HK$3G67AN!%1FX_6XG/!2/00@/F.;LCYY"?K`1R_?`_`G#=3QV#!(NWU.@X, MKRN:W6S]ANAX3\PN:/L@H?1Q!IRT`'VE\*.Y`(,L@]'F[Z2=4`N%"8''!G\A MR7[7EJW2&8NE],Q^S.:Z/I#+R99Y=[9J&5?J]>O$+5.5B2(FK68:?DL]DCTO M3=1TI305S:GWKP5_][7D5;E:=FX!^ M-_5NZ?M0@PX\\9ML@\D=>VX'L5\X=9[M":F_=NT(:ZEH41?&7=P_W'Q%U+]BM^T^QD$J'E0"^*P:U9>+'(X%)!@DDD!9]&*!!+CM M4.:#]RS>OG[&,5Z%.L71CK89JK<@"6/[%-UQPXF*YBE-_V4UJ3B"8F52<990HT=VGD'EKGDK3)HHAUC=,`>L5D<1HZ:-P?- MQ0_P="+?/$QNAGH@=>!>J+H;4=D+C"]'TX^$,$3--=Q/'9H8QO6Q+I0K6U1& MLWC;.YB9(8HML+X(E3Y+TBR]6?V2)$%ZGT3'M;5&P>B\2NN$T$.EV[AW2*45 M7->?S:=9Y9T;/+QW5:L-^.FNU0PIB("A18#W1>AU2VG''HB!SL M#BCO<.$H-7H\J\Q9GRKBPIZTA&V$2<5RT&HK@U#.>2*?!+:9E# M<[)U=6S-36*>-%!F"GS%RIKMPW':J(([DB#*(KD#$B8K$ ME!(Y)*/8J<([C4@*%LND\H?92O=,P>2G:NP?Y]U]S9RDL%H#'FL,GL:C! M5%Y+H-?J*^DW"S;(6Z\).UT"E+?EH@SVXC;;WZ<9M:`DA2I'?A3BO-?\FIV, MZ`^I*,5&D7D9VGA/&#UB'"/1=P=F)*Q4"MP,P81Q0K:4`:>`G;L'MMEDV$DP?\]R(V%DS;4#U8',MYLB# MB7(^X825U$8TW'V$E#.-9:;Y';(W'=-C6O(^7$]GT=D=7PZ16W0F86J!O>#) MHQ:"V7#?VX5T:/@[1>*SD!>SX=_#*()+:O$]`OJ+;,.0[>CW8.W5*>Z0^M6" MA<3W66JKS_<0E)%PO<:$70K0DWJV8%\T1^MO/+*&7NUK+XS3#.&\YSA,`]D# MXC8\QR[VB_(*T3_XL,6'*Y9B@`E'7]W+?(^0`Q,BXY_1)>KM>6DNFT=D^XJ7/!^J^;=54TF]-_Z).&1<+X$?=8(HI]* MMTC`+:VN4]45(PJ42UT=/A7%Z\4R) M3@C=\CURN,KP-H6MG4)2^4>\^0ZF7ZZY`L5$,[I0.'<2(9H7TAY->H-5<6!/ MC2$R.U;2ZZ(,MT./]^<5@>+A?CFE['K4GNUCUME1FABQF1>H.C?*)W\1Q_Y? MX[Q&%@X^\RO#>[@Q[)G1.^)DS@<&>HBN1Z1@@,P<"AUTDU4MX,ANMX5349R9 MG3QV^(VAZ!AO!WM:F4@UR%C MRJ?>69LH/EY2^9!/LZI#%PIK[\C=V&E^P3&E*UK&P3+8AG$(!&7A$VXN!=$* M96>-&S*3K_2.7$R]WMNI/UY3`H+YA%X%QDZMAF$<5&'LEUNH:;>IJ7?&Q+>: M]GF='Q5]:M?&RNHU(:]NQ4>\B/DLGLE0_8'F1]3/NJ7\Y1GL!GMY+E1ZDU197CH-90X8%?&09CSOWG`[Q.]^.P!J044)Q<)9L0?WY MQ1$AE"M^N?/Y4(ZY]0[PN^5WC]#C$`O%_$)'9NE5?,M*^O\5A^M-AH,E%;:W MIKLD)GZ8XEL2^CK':U8*[.QB%H0,!L;"])-8J`;%M<9B3?-S$"1@4`Z$&!3K M_\PGCX`>R30@F0CT>$#R0$$(8I0LA:HY5,X5O<=RMBO5MC/6`S*.`K:$Y=#-=U-&6^LX-Z5XREO"7JQ:%J8 MG+4P8+A$E-$@ECB,8>,R;J/P?56VE,"VC\E*FG_QPE@J.L^"O!KV!O1I&#*+ M0[H]7%B-6C^>E.:U!X/$8FHI8)+C!@;\2D)K.`R:&5BS):/*C,F&.AJL<1,5 M1U[LV9ZM$77A[K"?K&.60WYS M#`!)$`O$8,KBFP:-Z.8(OW?FK:A]KF#2)17YLH^R1C@['&-.)P M18$,&-7K4P<.9U2O9I:,M"U'<2+J-;$*83*B!9(Z2+JKC=U$4`LQ"E[\)0$9PW`9HW)F].D>;A7MX%3SAZ%-H%]1B' MM]<"^(W@SF)%O0&\E(E[>'.R0%DZK5Y\E#+0!QN[H1AM-%T<10AE MX\5!Z&9NOC@"K;J,X&[O&N8R>ZU=&">4B".O/=K[+TXA`[7M9V4@2^E()37H M+E!(QW03F"\PK/`U&FV!H!&DG"-.!J3STTH.;R0(N M9N0K>K(PJ/S"H("#Y5E"3J*)&2;ZH,D8[(!ZC1'PU[@/].`E'I$0R5IT>E&B M+-D]#EX+KL28`BD^EK:2&MM2^=Q(B9D=)I:W$4-ZB6_D80[9MP)'NU# M3BSTM`YC1M8E;CMDJD3?$Y&5@CT#6)9J]?3`,G>9GMXD*FY#."XD(4,4FZWS M1'MAG@EXSR3>5WB:2KRM-FX.SJ8Z!VF,T"6=.O9#+UH&3V&:D$,_$]0+C04# M-(#=POSTP#&O\>E-8'WGS3&A')7+AF<*OKV<;VM&9VJN9C8X[%+O@7AQ2HT? M19X_Q>MA='JCLG4KWY_MZD5]=SQSOU893JOFYCLKT4W[T-3LXGL&[OKHYPRI M&2-S+J$K:RS,>S>6=R?Z"YP';U9]3['*"/MHN&WZH:)+%\*.;527J==,YZF4AZ#6QB!Z.HS*6KLTFYK+2,8T'J:`M7%2-@7IC MMZA+H`L/]!__'U!+`P04````"`!$7VA!_T3&DM,C`Q,C`Y,S!?<')E+GAM;%54"0`#G^2;4)_DFU!U>`L``00E#@`` M!#D!``#M75ESXSB2?M^(_0]$"^('E8&`'P+6>5M;]O76!?!]X'EA9C_9\#K#XBC4Z.6+_&WWZ^-_6 M.5JN,)P_!]8OYW]-]3H\C+]Q9A-*D_;C'QL?C9*_?*?#G$'^QR_6:'3\\7A\ M,AI;G[^C__D2)6)15GWP]>`Z"Y9?CXY\_?QZ]/F'O".$Y M[7AR>BP:'D0MO[P2F&K]\U2T'1W_^_O-@_,,%O8A])EPG'4O1B:OW^CSY\_' M_*^T*8%?".]_@QP[X,(O')CHU?B'E`96-:O&'G@ M'LPL/H`OP6I)-4G@8NFQ@?/?/6,P^WHP#U[A(9/CR>?3$];_+Q>Q?B>^>^D' M,%A=^S.$%WS4!Q:C^^/^.AD^Z^\[1PY:'+,_':M[']<=W)GM,>$_/`,0D.+1 M9)HW^_D[&U->$`'=LK.99,W]H#>PCH5&1R)]/9=`DPE[>&@&3]&AW0N4V> MKSSTL^1X-KK55UQ(H`\(H;"D"PRDU.\P(/0[FK`NZE]?7L\4$7SM.T>+)?") MM@9E'1L`.X$.9?@">B%=YV]!<(,(N0.8?U('\.K^M0=XCCS/?D(1:.F';J!# M^0>3.08<0\5#+*;0,O+ND`<="'26,DTZ+2'QT7[R=(:I[MVR-"]`8$.//(+7 M(-1:DDM1:TFR\6>JBC;IWN[P1C7'-VI[@..:`QRW/4!M5.I1:7EY+SV52E%K M?>DG9<=?FF!M%BX@<1`UD?T0N&5,-EF_E@:DO3P5=&]W>!K+4U'_=@>H#40] M*BT-5G>75_>.![?:/ MMN]:46=KLSX2(SL-[^IAC=Y(@&VG4`0HHL,\")*FOV. M2PTQEB#W%Q#@',W1R[$+('>5L!_X\`]/1K&WX"_T5[]%'[\'<\B^Z0>W]@)D MQBMOE@QO4]T3G!ZJC1U!D/Z8TO6V=R-N<;SD9^1#YQEZ"4QF&"U*22\>!5*Q M@+`+\->#]R='=!D("1T;6C(J;*(M,428]OEZ,-J=*LXI6]CVKND$>?T'6$EU ML=5N@,K8XF&MC7'7VA!EI)M1VP7E)\K#7SL6O-G(<8I\`C MWS3D30>E%SD;:[5\ZEHM$3=7T`/XG(YMCK#AAU;\/&5C9: M+)#_$"#G=^Z0(],PX)?\T,_;UW4Z#5!+:H;62M.RNWX]SCHXFG9[9&ZOTWZ. MT8AY.I+[4OKS.:*4?18]$7>TXIZ5,3:SR1-73T@.Y[:]C(`&O("(WV01%__Z MMV1Q-)03IH/N(7@)\0`;QM8PMA77W&NZF66K?:=JG=?#ANZW%K MT+$ZQWG>K@&KD\6+T#V!_>?RCQ"^V!Z[MYD$YS;&*[K"_]/VPJQ56+)O]^J6 MH'53ZYJ\Q"@X-6Q2_QUX[B/Z;@V_4/;H(8OR*E%MNLD@ M5)D>MH M>H@ZS=?>I[K:"U!@>WW1W1U&2X"#U9UG1XX7:E@NVJ#EU"H"S.)3"0N3A'IWGW;P-6O#CSW]DK=N#7\W%D&_=$X25< M'%D.A'H-=&3AD`Y]2TAR#-B:5:FTMG>C5_8:=^-L ML'N+?$>I6%6'GBBX](:LXDFHW;1#,PLI@0%_(<;NW/BCF#GPH[>X^5>-JAY# M5;V2*7'??&*8%5[Z6-;7@U@=S6LO"B)$[&[K7_KF]A-2RV!"`S/C6Z#@MP(R!@6LS(/7M=ZP/WTL8^ MW;<(/9&$B]!CV:TNP`PZ4+:@ZW0<#@1TN!$0,.WDO2TI[3U\2"K.&[U0:>U# M=J].9$4V347/^7`-M6+.!!!J!Y[T"@C"ARB"+=;A4D0[2JR@;_0==;[3IY09)+NQ423]Q0CS?<4UB\I0G_=OZ]H_EA%)3S%?*0N M/WZLL\85G;3D/8=XU:G%6'(R,\R_LO5<:Q(&SW1(?ZXGOQP'VST&KO]MAA*] M&W;)N<7T-2&AOLY%:R/T+9A)=)V7H<,D7>]2Q^.\9ZF-JKY] M>TR6;SACBXWE;UO7%"PTL]8TK%]^^';H0KH]=F*17?N429",KL`(D[;NQOWU M`OP0%+ULW6[6Y5PKD'?:KY4=>!(T:-9B&L\&?QX)AV7@E%T_Y[4 M3.3EO1BLZX*?TV^1C](ZJ\^4"4*F<@B=TS;)/]%V`%;(`[H>.RY^`V M7#P!/)UM&>X%FB]/9B"(*,]8$A+8&Z1($OUFDIPK.0,"!58 M%0BH_6BR9VO%>K^[HN*-PN)"*K;MHV_N^5#=<2#K@0XKR7G,*%L@S7E^SG1J M%$UGC_;K)`@P?`H#=A_WB.[!$F%F]%[RO&5:(*E%?Y!8JL5Q8G[VY+);LN6D MZE+$CHR\K26_79=JE7F5DBTB?\CB^?S11\,.=KEHU0#T&9@A#**&%-:2M:`Q MZ@-9"1KC-]EZ/AW5/XKV#'()F['7Y`SX8"8-9I2V'@@DI.-/5#S.S>VMI>#/ MD8)],&<7\/U2L,JVRN`=D,M7*D`J$>C;>'5-IE#^/N]D"0-6L!DE+ M7QP4T%J20>+7;&(]ZI4YG'4598Z(FAZRK5Y=@J;(VZ?RE&TQDKQ9-TKK94QV M*IJ,5%1!7XU0'@IZ&F%VG16A^D;89TM'M237P58I>L-$5"D6$QR-\H.$!PRD MY'(Y-B*+@B(4[0=BS2@X$(DHWQ75Q*D?"K[KB!<"J#!9FN0+\`(\Q).[Q0*X M?'6\D#NWG3]"B%EJL#N,'$#(.9+:Q;4H=HF40L"G(VEJ<)D\`S=KQ?A&CYG8 M]JA()NX"^KRR8`!?"J(T"GL-!A.%G(@7):;O%+H[Q(!TFS-VL2=\K&U"]NJ8 MDFM1,U_2;`8<:E;G_KV,+[:8UD#LA8K<;?A9WYWF^O;+VQ.Y3KDN0IE9K84K M#_WHZ#&LFK4JA'KR!D&JO4Q47FG^#*T'-+#0R^H0+X[*-,U(G[C_%Y(H M/Q5SO%.Q<2<\BPN@FY4#>>V,M1P>43.+1_N?'3X`VY>1J'34F_#"ADQ60(?O M0*YQ^K,'N.KI,6S!(EW^5%JH6ET[36NPHPF;LFRUI&)H#25Q)P7<<[1@AST5 M?F2-WQIB9'+H7?$E2739!:2`IXTOXD$I5*_1_JUH7T,4AI9PH@+$@,+]`D3_ MW1!9G"^N^-VK-H&W`J/--R01^3H)!B++F>-QX#<3D]L0?GEM73!H<>,9-0H\=Q_2(, M0X%3IMQ(Z8TFZ6<22+:8$W@PW[C=KDQ2!A);70U#Q19_C97VZ!DP]/V^0 M3'#HEN&VL;(@O0HFD$B`&6FDBCE80,,*.5_"557TPSHS>68)8\FQ5NH&(L MK.:ET:^':XK&7)#M3Q(F&RL"TW;L@K#GIJ)4V0WS3-$--I()6!\`ID\>G.>F MVZI#:+AHJ,-U`@_#,FELS@P^$Z:<+W+Y"K`#B30]@4:_X0*E!),"%V_$]YLC MP-JVAPE(*<.M@(Q9OE_&/C_ED6>V@K[8'EME[P`=EYN]1I%`IAR)(1FJY3@3 M<=LG;P`@$SIO,%[1*:*L**S7=_B0V&(IB>&OBX4E!QL=)0[>#")^&QN("<:4 M0$7MYTH1*B[]WMBC+,YT[O/*0=.9"-#)S_^IU^6M1=.JI9%L+6:=8JX72QOB M:*9=4QW[<_CD@2B0B]I@,``>?)&>9;1[OS4L:0M&P,JP5!>Y3_J_V=#?R$>V M1,3V)*__:Z2PK?.5MP;3Q@6H>N<]L&P-9R&!/B#L`H[E-"/3V=T&[42:<=H& M.@^L0XL)R4,DQ(#^0Q"P;)\5!*8D6-:&%)$NDM#@N>W'3Q//D4^0!UT[?K:X M.;:-@H3KM!-%J MSCSY!4++W^PT9U"3*$OE%VI79CM+9K"#;#.Y+TVW\LV,3\;9A8OW/.1=K=0C MQ=X\,IYX_).10L\]FQ`X@]$O$M>AQKI%B33^@:ZLK4A[_&HNX>(>>&SC9,GT MR)K/)*RI8'FJ3;6+!:@-E>;;3;5$8]`ZDTGX2HU49CRN:\UGEYO3+3N)$>!& M4DS"HC0L1L2B5*+5J(NEI_G"?!T.OFBR*]H/)3VQ@H4D`XL:]S\ZX%`D^\V(B5D*%=++9VQX@L`7.BB6HERU>Q?U MZ*9"?2+>%S#!V/;G7*9K'13-QE(4.MMF];25+EM?@B^3]DBE+T&<0[(S]UT5 MGX+UBR#722I(X]P+LL*>L2*XL%>R^:QN:M0!7A![]+$L`%E9(LCBO;R"@$R)@T-(V5LHQ!A'KI';M&3R.AH<5Y M+Z M[X&3NIY;1T9MW.1+7U>5)6,4TJJ+09E7:<"%^_(+G^IMG9I]C420)N\Q;$Q[ MQ!=?:VR$A//;CNGL&T*NS.%3U,E(G!0Q+0"27T!XP`O+-N/?0R^`2P]<>E%) MM/7]ECYBE#3>"("4,A!X^I!?2+@30$E<1CPG;NSOBLZLMR#0\`[I]3,*#"7X MWEW.T*YB-!]9UMRMV^#W^H&:UB\1B6Z*`>XC-C6$Y#P#-_38W!QL6.H':^YZY49XM"JUW]^%-PWHK^G7RT\;N9BH0]B0W MDALAX2+Z'5^V]+'`H";D92AM_EY8MI4R::8XG=UJ\I(+4OX;:&SK'1V M%F[0=8S@!0ALZ/$M)&3LI6W##]4B!6.B5DQU'S"X@X#!?/7&&I#P4X6`>@EX%EP`<1`LI\YQ=@"4B,!"9?B,+,C>,1*=;%T"HCOAU5(@. M;[V+-I/HE]<^L;TKA.\P4D?SDDK*V7:7D:4"7*I9B%7X:J@JC*UN> M>X&YK]B%+HM:DE<`JDW-,!#HL-R_*,$!9=\9YL)1@4E3HP%%+JI'^S7B^Q;( M+-Z\IL/6OXPCH6S3G!&;F7,O(,_<'_!WYD*26A4UI#V'"P0M]E0>JLI7@P'` MF8O!KFZ&X@/[]O&_Q-503&-_-_1F[H84E4E;^M9;<%HV*C#-O&DFP/%L=4\/ M\SB@ZR.8O$+9;M;^9SO-;]OF'&\3K]MB5`;/=XS=9GA>T'IT(4IK[U^09\@.D) MRGZ5&U\Q:9.4&G.- M2ZU^V=H8Q%Y;URX/X6)AXY4L1B2>E*I[\[(4AK_*;4V^Y`ZFK"R2DH]FK7&Q M!(&K%(-DZ=+MW)FGM=J4V5QG=%EL"AZ;#M8>Q>''GM)1CKMU*]RJT-]JC?8> MU]YZ7/-Y6+\[.EOE!]!>V1#STD(;0;.4X>\@>$8N\M!\51"AMI,O&^R-W87X M3(W5;U)V;$MPZ(;Q3^11,A[EZY[J;Q>@EWVYTP/![M:3UF:#3*ZF^D\:%=X] M)+]?80"N?6K:`!+L:C+D?W<_%=J0JJD.("Z7IV+1/95915A$WT@U`UKZX%N% M?DOB3()U#7AOHSSSC7/.?.5C;*SQ_LQGW)DO?I$V#0,2V#Y+UG6//!;6S/[8 M]"9?\+']R:ZLQ/:'N2)QW8:*F\(6OC/(+5IK$6@)ST)PC3V*Z&&!\P;%]2\` MY\_4A)G0*6O/P>4KP`XDX`Y#I_$S6;FO=UYD?8CH+Q)H8RDQ#9P5WVA#EF0T M]T5I6Q_9([R*U(SV+M20$U7!#/"''^Q(3(^G,,Y,V3*J-;Z[!WI#@DQ>=5?& M?F[A'"H3>"'(K2*:^D]C,Y;LS'\O^G%E+=#&>/]?V&48GRDO?1$3WU\NR MQW[#XA3SH7;FA>'-!U(@0R&I*A:YXEZEM0&8/3.ZD*B8'+DON8=L:]>58]K! MU<9VT>0(S)X8G8@TGAGO1 MO+EL+7>>[=_:"U5FE723-_%P-LUR\FRMA_JKOB7S_WNDXV-)EF-^E?E*VOE4 MEWC*`W\S]HZ*XS[G%1'9$U-Y];,<$F5RB'(D>FTXUY@[>2DI]21B:N[:?:*( M_NYWK26*R"VZUGC.A]SA:I1(T.QH=(8'/1&(PWAOUJ124!`I#$2:@BN$+R`& M#J5*\A9G127.UK[27?J',K.G`#?U1+"S["$[*,YC$^BPO&+0"ZD<;D%P@PBA M,Y++K1X99Z8H$4I6HRD16E&;J%^^(`N;>Q#?YZP6I#/0-Z\D>4@ M2UYC3RCLTNEN4"#=9'H6`+W3(=5OP%`G+Y&I6,8*G` MV?(3BG)"6_)0>6Q+^K1KTKL M%[PX"&;'I$W31.5CKTJL,R>ZG@[U*JZK6>RQVYOY;J:SC3$K_-^2MEW:`?40 MO*E;"7-]]E%N\D47X%LZK/5O'NE/A.*8W38KW92EJ72I;R5<4QMV6:[:4;3$ M'+]>4L&E-U"QP^7J2K=3EZJIB,;$4M=@S]042J57L2+G;QV"9BSG=22@3.[; M>`73(C-:XZA>GL:@E"QWVI9GO']+B`07,2M7`$0OE]@_[@%MH6MUE MT&I7LQ9CX&-_)KAD^71BLN3SP M.`"R1,3VOF$4+F5/'"I3Z<0V3XWEVF=7@M"?YX]]K2\V#\[HL'Z7\UZ3;)=G M_(KZ3]G_M06@2EDYL'=3$JYE5:UUEX9NBUJ_U47B%@6Y@Z881PN0/-!9*U!# M!,U0-VG)J".'G:T<':)0O:+&/_CS2%PLPDX'?!6(=HRY)J>E%(L5Q))X.NJ6 M"$.![?7%U55%*.JBW5@PJ,*Y6DPI^KFNZVJFT7GP8Z*;K[5$Z$: MPC_H7Z-L#L`]LSW;9\_?`*AZ0&SP8R:=%QL4BV:\[^Z.CY+[BLE\COEFR:M7 M36'D76$T1[LW>UCCLS2Y]&A.6`)ZGVJ7EA[JN3%X!O@6 M^4Z(F7(W)-G`"5)!VVR4-BRL!*7CH];-L=XB=>(XF/Z[483FT=PC4T-("2)' M1^V?$/H,2?90D=S9*\5+KSH$]V`LDE""Q).C#Z9!<4(("&K9EK4HO0WP51*- M2+_;D^L&652E/DMW&"QM*.+$V;F0&R21<'*#+QNC;3;,&A:6*'IAV$I70D#7 M_@M5*L*K^MOM!BFS05A/-@)S/3I]U%_PA"%Q#QP`7Y@M<0MRHXWKTS0;6PT) M*:GF8Z`9%W,LUO(UYRP$_#PZ\,L,-[V^9D.LI##64/I\^K$W6)(L6>P10&2! MXJINS%S[K!FZ9N.J04$EQ]!/1[4A5W`HZ/C"5)J@Z-VX]+5IETF)!G%Y*K=S M3)5"?"HEOPY;33V'"@#N#Q1R1?;-ACZ+F(W$$4THOM=M-ST#,X1! M%''T:+^660#K?&5X$&M:K[KO_LEJ9HS<5\@07A5 M#0V5R`P,"Y5X%(\<^HX#?CC?R&$FG-D5L%"9U,#P4)E/X>SXV/[JT-7!DVIU]:%6"1"UGV3KL!>D,^E-;C?&>Q^'4#9+D?;<.+ M5ALQ=2D.&3-U>1,WZ>;`+H/_X?4$L#!!0````(`$1?:$'5 M$5M8N@@``*-0```1`!P`9W1X:2TR,#$R,#DS,"YX'\,(/$(BF2/U*D9*6GOSR' MG#R"TDR*LYYW-.P1$+X,F)B?]2+=I]IGK/?+SW__V^D_^GWR^^>["?D5!"AJ M("!/S"S/$\59QOD]DG*<#Q@0ALJ?$CI.1/? M2LCM\!1M68O?H4^T\3Y]^C1PHSUBJ)J#^4I#T$OJPYI\;IZ9$]\&3J3AY^. MAZE<.U1.!QQ"$.92JO`"9C3BYJSW9T2Y\V6/4&,4FT8&-@@BD2/)'!28]5QY M7]&]=01IR-.O_[0ZQ][*9/`:(C"_2X-C!I8O@$2]9$* M%//7?-5,"0,&!R&G5`AIJ,&8=M_MD^62B9E,ON(#B\:)DAP>D)W8#[_=7>WS MLAT:7##M2V&8B""X6=KH1]GZ@4XYZ!YAP5FOE&(];3IQ`#,FF%-P^''X@?2) MY>=21PJ2+ZDPDDDC/\3R?CP=;$O9GB#"%+L1/[O/2P4:H\/)F."#A#LA*>/T M*?!UH;D`0QG7#_!L,,C+(-JB+(7JI^&'46VL$L$DD=R! M5AH]IX="AD*&`GR_RQ M""X8Q^XJ^`IF(K6^!76_H`KVU:!&'!49=+R-F!-.J`A((IZ@?&(G(#@#<5-T M=>EP0.M`6)5F!X'6091!Y!SBMI#G,ER"T$[=C;I43E*153L-GI/6CS>M>7E= M8=H'S[GDG$YE7"PP2R;,1X?!>*[`[5'W=N9-F2H@_+@-X89\EVO)#"2;HEL8 M2Q?&2#,!6B,X=L'2-[/;G+U[*UT3C@I`=WKY5+C#THDGI5K:H=:XR2\E9SY+#V/JDE;BMR'PQ(O%=YA5S?C1C5R;5299 ME?K=\ZSG[]$YD+C^7(K`KE(V(9P8$LOI?%[@\UNLP,(LP#`_>Z]1.%Z!AE<3 M#=Q7YL6^6^/UOX#.VG]8'K;?!A:,E:,R*LZ13)ZM'/GWM+$&@7,0-!A4X#- M.=6+2RZ?]D"3#94C$#OK:18NN;VL MYYXM%,S.>A:L?GJ/[@\T]^@YY"F)E5]R_<^AN^VA9.)4!%7^CI2=2X$H1&(: M&09ZD"J?"L`^P+)O'+#9>?0_">6HZ>#5C$?/-S5^"ZPWLOT\F^6-3,=-2U/3 MD07X&QH]L?+?R%S,S:;F;J;S&]E\L9YDK^&G@_PE3ORV>T;,.4AV;J)#YH)D**=_+5-BY-UM+ MBVTNJ\,GJX/WTXMTR%_X;::'%%\/5"5_77E.Z7+CMG*!$DZ!O8P#X$:G3_J9 MJ'JZ.+D:_*.Y?,148[5UV>:Q'UXV.SS[B\;3KYG+_W2 M6)/R.^R'1X63=9A?=J[?UUPN4@:;&!\WYDM^+.`Z4%L8_B@[PQA/M5'4QWFM M?N7G'1DM33Z=]8R*<(F+*Y/[^<4)CC`QO\).U?9N:$^$Q,Q$5L*O2D;+E!#[ MU1"G9?9,T9:'6%0\AI6$R>#!B0TBE1S(%!FX<2YY!X\@K*38H/UC>85#*.Q:;S3/>OY"K!/+[9DZ^[9?\#^W`:"\2/NPN:`:^$4U,W,'9'KU,)F M/!M0N6?O"M4%4^`;J;`7`*4VWQ6L8["4YGM!%\"T#+E;NHIW>N*<+IFA?`)8 MQ1&62R:L@.#+GQ%;6I*;*6?S=`__)LXPY;819.(Z635RNQ$34(6QJI1==%]@!5 M@[(%F!6\$(XO&&T7N)K$;:YP^RY0%EC;G*]EAE\M,?0VK4AUOP9;V5)+:Q!N MA&H@0\K$^\9I%(:X!"2U>"<&DT5D)V`;265B)[A&W_V>[FD7*K*ZY1]PO< M+CV`"J_$(VCC3"@H4"\0T(*ZE>*6[$K&(:K-_HK+K!.T;HBK"?,(IS._;X6R M9W\S9H,36X8+6$K-S#4UD<)-Y*8YM4B_,,\.@TN0Z$EKJE`NF M,?@H=Y/&=F"@[?U])5IO#YWT'?B`:PVJ\Q6R4Y,7R_E.#JI8H!O8A9N$)67I M3L@NPRX:QEI#5MM>3UYK_;7OCT3L;WEJ$K>L\:G<48R#P+WCH?S0/4F)A)8Y MH_SR7H']#9E:9K++PB0K,8-E:->O@O:L'FT+.K$D_="53LL[X+;'?I`E?_1E MU]@7R6B!$^*E-5>V#W+#2Z6TP!$8I+$5-RIG!W:J]:O7NN*]CJQV5KOQ')?L M.8+[;\HCN)D=:N`Z=%Y-7DO;S7-4U2[EMCUFPNEZ"54K158V#V)N9^C$[S48 MUKG@D6FI5O7]#V'__MXX'<2ON?'C?P%0 M2P$"'@,4````"`!$7VA!AMN'2E=<``!7#@0`$0`8```````!````I($````` M9W1X:2TR,#$R,#DS,"YX;6Q55`4``Y_DFU!U>`L``00E#@``!#D!``!02P$" M'@,4````"`!$7VA!P7082U4,``#YG0``%0`8```````!````I(&B7```9W1X M:2TR,#$R,#DS,%]C86PN>&UL550%``.?Y)M0=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`1%]H03VN^9EI!@```U<``!4`&````````0```*2!1FD``&=T M>&DM,C`Q,C`Y,S!?9&5F+GAM;%54!0`#G^2;4'5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`$1?:$%QG:$(U3$``!"9`@`5`!@```````$```"D@?YO``!G M='AI+3(P,3(P.3,P7VQA8BYX;6Q55`4``Y_DFU!U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!$7VA!_T3&UL550%``.?Y)M0=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`1%]H0=416UBZ"```HU```!$`&````````0```*2!]KT` M`&=T>&DM,C`Q,C`Y,S`N>'-D550%``.?Y)M0=7@+``$$)0X```0Y`0``4$L% 3!@`````&``8`&@(``/O&```````` ` end

Condensed Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 38,731	$ 63,745
Short-term investments	8,555	10,695
Accounts receivable, net	1,152	981
FARESTON sale proceeds receivable	21,671
Inventory		161
Prepaid expenses and other current assets	1,233	1,266
Total current assets	71,342	76,848
Property and equipment, net	640	1,096
Intangible and other assets, net	186	240
Total assets	72,168	78,184
Current liabilities:
Accounts payable	1,214	1,219
Accrued expenses and other current liabilities	10,263	4,142
Total current liabilities	11,477	5,361
Other long-term liabilities	786	949
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value: 120,000,000 shares authorized at both September 30, 2012 and December 31, 2011; 62,816,924 and 62,790,223 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	63	63
Additional paid-in capital	460,073	457,985
Accumulated deficit	(400,231)	(386,174)
Total stockholders' equity	59,905	71,874
Total liabilities and stockholders' equity	$ 72,168	$ 78,184

Discontinued Operations (Details Textual) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Discontinued Operations (Textual) [Abstract]
Proceeds from the sale of FARESTON		$ 21,671
Gain on sale of FARESTON	(18,831)	(18,831)
Contract termination fee	1,000	1,000
Financial advisory fee	1,712	1,712
Other transaction expenses	$ 128	$ 128

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Condensed Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	62,816,924	62,790,223
Common stock, shares outstanding	62,816,924	62,790,223

Share-Based Compensation (Details 2) (USD $)	9 Months Ended
Share-Based Compensation (Details 2) (USD $)	Sep. 30, 2012
Summary of Stock Option Transactions
Number of Shares Options outstanding at December 31, 2011	4,945,565
Weighted Average Exercise Price Per Share Options outstanding at December 31, 2011	$ 9.12
Number of Shares Options granted	1,129,250
Weighted Average Exercise Price Per Share Options granted	$ 3.34
Number of Shares, Options forfeited or expired	(669,754)
Weighted Average Exercise Price Per Share Options forfeited or expired	$ 8.86
Number of Shares Options exercised	(26,701)
Weighted Average Exercise Price Per Share Options exercised	$ 3.07
Number of Shares Options outstanding at September 30, 2012	5,378,360
Weighted Average Exercise Price Per Share Options outstanding at September 30, 2012	$ 7.97

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Nov. 05, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	GTX INC /DE/
Entity Central Index Key	0001260990
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		62,816,924

Share-Based Compensation (Details Textual) (Deferred Compensation Arrangements [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Deferred Compensation Arrangements [Member]
Share-Based Compensation (Textual) [Abstract]
Share-based compensation charge related to deferred compensation arrangements for non-employee directors	$ 40	$ 45	$ 128	$ 141

Business and Basis of Presentation (Policies)	9 Months Ended
Business and Basis of Presentation (Policies)	Sep. 30, 2012
Business and Basis of Presentation [Abstract]
Business	*Business* GTx, Inc. (“GTx” or the “Company”), a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The Company is developing selective androgen receptor modulators (“SARMs”), including enobosarm (also known as Ostarine^® or GTx-024). SARMs are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is enrolling two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. Additionally, the Company is developing Capesaris^® (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase II clinical trial to evaluate the safety and efficacy of three lower doses of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer. Effective September 30, 2012, the Company sold its rights and certain assets related to FARESTON ^® to Strakan International S.á r.l., an affiliate of ProStrakan Group plc (“ProStrakan”) for $21,671 in cash. Through September 30, 2012, the Company sold FARESTON^® (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note 4, Discontinued Operations, for further discussion.
Basis of Presentation	*Basis of Presentation* The accompanying unaudited condensed financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of GTx’s financial position, results of operations and cash flows for each period presented in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted from the accompanying condensed financial statements. These interim condensed financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year ending December 31, 2012.
Use of Estimates	*Use of Estimates* The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.
Discontinued Operations	*Discontinued Operations* On September 28, 2012, the Company entered into an asset purchase agreement (the “FARESTON ^® Purchase Agreement”) with ProStrakan pursuant to which the Company agreed to transfer, sell and assign to ProStrakan all of the Company’s rights and certain assets related to FARESTON^®. Effective September 30, 2012, the Company completed the sale of FARESTON^® pursuant to the FARESTON ^® Purchase Agreement for a total cash purchase price of $21,671, including payment for purchased inventory. The Company has accounted for FARESTON^® as a discontinued operation. As a result, revenue, cost of goods sold, and operating expenses relating to FARESTON^® have been excluded from their respective captions in the condensed statements of operations and have been included in discontinued operations for the three and nine months ended September 30, 2012. The Company has also applied retroactive adjustments to the condensed statements of operations for the three and nine months ended September 30, 2011 to reflect the effects of the discontinued operations. The Company has set forth the assets and liabilities relating to the FARESTON^® discontinued operations in Note 4, Discontinued Operations. See Note 4, Discontinued Operations, for further discussion.
FARESTON Revenue Recognition	*FARESTON^® Revenue Recognition* Revenue from product sales of FARESTON^®, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON^® effective September 30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON ^® by the Company prior to September 30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At September 30, 2012 and December 31, 2011, the Company’s accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $528 and $715 have been included in “Other long-term liabilities” in the condensed balance sheets at September 30, 2012 and December 31, 2011, respectively, and represents the portion of the Company’s product returns accrual estimated to be payable after one year. See Note 4, Discontinued Operations, for further discussion.
Collaboration Revenue Recognition	*Collaboration Revenue Recognition* Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company’s former collaboration and license agreements. Revenues from the Company’s prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note 5, Collaboration and License Agreements, for further discussion.
Research and Development Expenses	*Research and Development Expenses* Research and development expenses include, but are not limited to, the Company’s expenses for personnel, supplies, and facilities associated with research activities, screening and identification of product candidates, formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies, clinical trials, regulatory and medical affairs activities, quality assurance activities and license fees. The Company expenses these costs in the period in which they are incurred. The Company estimates its liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon the Company’s estimate of services received and degree of completion of the services in accordance with the specific third party contract.
Cash, Cash Equivalents and Short-term Investments	*Cash, Cash Equivalents and Short-term Investments* The Company considers highly liquid investments with initial maturities of three months or less to be cash equivalents. At September 30, 2012 and December 31, 2011, short-term investments consisted of Federal Deposit Insurance Corporation insured certificates of deposit with original maturities of greater than three months and less than one year. As the Company has the positive intent and ability to hold the certificates of deposit until maturity, these investments have been classified as held to maturity investments and are stated at cost, which approximates fair value. The Company considers these to be Level 2 investments as the fair values of these investments are determined using third-party pricing sources, which generally utilize observable inputs, such as interest rates and maturities of similar assets.
Impairment of Long-Lived Assets	*Impairment of Long-Lived Assets* The Company reviews long-lived assets for impairment whenever events or changes in facts and circumstances are present, both internally and externally, that may indicate impairment of long-lived assets held for use. An impairment loss is recognized when estimated future cash flows are less than the carrying amount. The cash flow estimates are based on management’s best estimates, using appropriate and customary assumptions and projections at the time. Based upon the Company’s decision to discontinue toremifene 80 mg development and after analyzing future cash flows and estimates of fair market value from a market participant perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and recorded an impairment charge of $1,598 during the nine months ended September 30, 2011. The impaired intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion Corporation (“Orion”) related to the Company’s former toremifene 80 mg program. This license fee was paid under the former amended and restated license and supply agreement for the Company’s exclusive license from Orion to develop and commercialize toremifene-based products. The impairment charge was included in research and development expenses in the condensed statement of operations for the nine months ended September 30, 2011.
Income Taxes	*Income Taxes* The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, at September 30, 2012 and December 31, 2011, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income taxes are described more fully in Note 9 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. The Company has recognized the tax effect of discontinued operations in the condensed statements of operations in accordance with the intra-period accounting rules. An offsetting tax benefit is recorded in continuing operations in each period.
Other (Expense) Income, net	*Other (Expense) Income, net* Other (expense) income, net consists of foreign currency transaction gains and losses, interest earned on the Company’s cash, cash equivalents and short-term investments, interest expense, and other non-operating income or expense.
Reclassification	*Reclassification* Certain prior period results have been reclassified to conform with the discontinued operations presentation. See Note 4, Discontinued Operations, for further discussion.
Subsequent Events	*Subsequent Events* The Company has evaluated all events or transactions that occurred after September 30, 2012 up through the date the condensed financial statements were issued. There were no material recognizable or nonrecognizable subsequent events during the period evaluated.

Collaboration and License Agreements (Details Textual) In Thousands, unless otherwise specified	9 Months Ended		1 Months Ended	3 Months Ended
	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2006 Ipsen Collaboration Agreement [Member] EUR (€)	Mar. 31, 2011 Ipsen Collaboration Agreement [Member] USD ($)	Sep. 30, 2006 Ipsen Collaboration Agreement [Member] USD ($)
Collaboration and License Agreements (Textual) [Abstract]
License fee and expense reimbursement			€ 23,000
Deferred revenue related to upfront license fee					29,330
Collaboration revenue	8,066			8,066
Development period			10 years
Collaboration and License Agreements (Additional Textual) [Abstract]
Contract termination fee		$ 1,000

Basic and Diluted Net Loss Per Share (Details Textual)	3 Months Ended		9 Months Ended
Basic and Diluted Net Loss Per Share (Details Textual)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Basic and Diluted Net Loss Per Share (Textual) [Abstract]
Weighted average options outstanding to purchase shares of common stock	5,408,065	5,113,943	5,639,672	5,455,700

Business and Basis of Presentation (Details Textual) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Business and Basis of Presentation (Textual) [Abstract]
Proceeds from the sale of FARESTON	$ 21,671
Certificates of deposit, original maturities	greater than three months and less than one year
Accrual for product returns	1,189		1,114
Accrual for product returns included in other long term liabilities	528		715
Impairment of intangible assets		1,598
Net deferred tax assets	$ 0		$ 0

Share-Based Compensation (Details 1)	3 Months Ended		9 Months Ended
Share-Based Compensation (Details 1)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Fair Value of Options Granted
Expected price volatility	73.80%	65.30%	69.60%	64.90%
Risk-free interest rate	1.10%	2.30%	1.20%	2.50%
Weighted average expected life in years	6 years 6 months	6 years 6 months	6 years 6 months	6 years 6 months

Discontinued Operations (Details 1) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Assets and Liabilities Related to Discontinued Operations
Accounts receivable, net	$ 1,152	$ 981
FARESTON sale proceeds receivable	21,671
Inventory		161
Prepaid expenses and other assets	279	178
Total assets	23,102	1,320
Accounts payable	35	116
Accrued expenses and other current liabilities	4,209	919
Other long-term liabilities	528	715
Total liabilities	4,772	1,750
Net assets (liabilities)	$ 18,330	$ (430)